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Abstract 
 
Trophoblasts of the placenta are the frontline cells involved in 
communication and exchange of materials between the mother and fetus. Within 
trophoblasts, Ca
2+
-signalling proteins, such as Ca
2+
 channels, Ca
2+
 pumps and Ca
2+
 
binding proteins are richly expressed. Intracellular free calcium ions are a key second 
messenger, participating in regulation of various cellular activities.  In the placenta, 
transcellular Ca
2+
 transport through trophoblasts is also essential in formation of the 
fetal skeleton.  Ryanodine receptors (RyRs) are high conductance cation channels 
that mediate Ca
2+
 release from intracellular Ca
2+
 stores such as the sarcoplasmic and 
endoplasmic reticulum to the cytoplasm. To date, the roles of RyRs in trophoblasts 
have not been reported. By use of reverse transcription PCR and western blotting, the 
current study revealed that RyRs are expressed in both model trophoblast cell lines 
(BeWo and JEG-3) and in human tissue from first trimester and term placental villi. 
Immunohistochemistry of human tissue sections posed that both syncytiotrophoblast 
and cytotrophoblast cell layers were positively stained by antibodies recognising 
RyRs; likewise, expression of multiple RyR isoforms was also revealed in BeWo and 
JEG-3 cells by immunofluorescence microscopy. RyRs in BeWo and JEG-3 cells 
were further demonstrated to be actively involved in [Ca
2+
]i regulation. Changes in 
[Ca
2+
]i were observed in both BeWo and JEG-3 cells upon application of various 
RyR agonists and antagonists, using fura-2 fluorescent videomicroscopy. In addition, 
endogenous placental peptide hormones, namely angiotensin II, arginine vasopressin 
and endothelin 1, were demonstrated to increase [Ca
2+
]i in BeWo cells, and such 
increases of [Ca
2+
]i were suppressed by RyR antagonists, in addition to blockers of 
corresponding peptide hormone receptors. These findings indicate that human 
trophoblasts of the placenta express multiple RyR subtypes; BeWo and JEG-3 cells 
were functionally responsive to direct pharmacological activation of RyR agonists 
and antagonists; the suppression effect of RyR antagonists upon the rise in [Ca
2+
]i 
that was evoked by hormones implies that RyRs mediate Ca
2+
 release from ER in 
response to the indirect stimulation by these endogenous peptides. These 
 19 
observations suggest that RyR contributes to trophoblastic cellular Ca
2+
 homeostasis, 
and such RyR-mediated Ca
2+
 release is linked to endogenous placental peptide (e.g 
AGII, AVP and ET1) induced signalling pathways. The current study provides new 
insights on maternal-fetal Ca
2+
 mobilisation; characterisation of the involvement of 
RyRs and/or RyR accessory proteins in connection with signal transduction through 
external stimuli may provide better understanding of pregnancy-related pathological 
complications. 
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NAADP Nicotinic acid adenine dinucleotide phosphate 
NCX Na
+
/Ca
2+
 exchanger  
NO Nitric oxide  
NOS Nitric oxide synthase/NO synthase  
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NSCC Non-selective cation channels  
PBS Phosphate buffer saline 
PKA cAMP-dependent protein kinase 
PKC Ca
2+
-dependent protein kinase 
PKG cGMP-dependent protein kinase 
PLC phospholipase C 
PLD phospholipase D 
PLN phsopholamban  
PMCA Plasma membrane Ca
2+
-ATPase 
PTHrP Parathyroid hormone-related peptide  
PI3K Phosphoinositde-3-kinase  
ROS Reactive oxygen species  
RyR Ryanodine receptor 
SCT Syncytiotrophoblast  
SERCA Sarcoplasmic and endoplasmic reticulum calcium ATPase 
SOCC Store-operated Ca
2+
 channels 
SOD Superoxide dismutase  
TPC Two-pore channel 
TRD Triadin 
TRPC 
‘Transient receptor potential canonical’; Transient receptor 
potential related Ca
2+
 channels  
TRPV 
‘Transient receptor potential vanilloid’; Transient receptor 
potential related Ca
2+
 channels  
V1 Arginine vasopressin receptor 1 
V2 Arginine vasopressin receptor 2 
VDCC Voltage dependent Ca
2+
 channels  
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Chapter I.  Introduction 
 
 
The intracellular free calcium ion (Ca
2+
) is a well-established second 
messenger that plays an important role in the regulation of cellular activity in all cell 
types (McPherson & Campbell,1993). Cellular events that rely on Ca
2+
 include 
muscle contraction, synaptic transmission, hormone secretion, fertilization, nuclear 
pore regulation, gene transcription, cell death and cell proliferation (Berridge et 
al.,2003). Under physiological conditions, the extracellular Ca
2+
 concentration 
([Ca
2+
]) is within millimolar range, whereas the internal [Ca
2+
] is in the micromolar 
range. However, the cytosolic/intracellular free Ca
2+
 concentration ([Ca
2+
]i) in most 
resting cells is approximately 100 nM (Fill & Copello,2002), which is far less than 
the [Ca
2+
] reported in the extracellular space and the internal Ca
2+
 store. The [Ca
2+
] 
difference between internal store, extracellular space and cytosolic space implicates 
that both internal and external Ca
2+
 sources can be involved in the generation of Ca
2+
 
transients in response to extracellular cues, which trigger signalling pathways within 
the cell. Maintenance of such steep [Ca
2+
] gradients across the cell membranes 
involves a wide range of Ca
2+
-regulating proteins, such as Ca
2+
 transporters and Ca
2+
 
channels. The internal Ca
2+
 store of the endoplasmic and sarcoplasmic reticulum 
(ER/SR) in the cell provides a faster and more precise pathway for Ca
2+
 signalling 
generation relative to Ca
2+
 influx across the plasma membrane (Fill & Copello,2002). 
For instance, large global intracellular Ca
2+
 increase are required for muscle 
contraction, while localised Ca
2+
 sparks activate Ca
2+
-dependent K
+
 channels in 
plasma membrane that result in relaxation of smooth muscle cells (Nelson et 
al.,1995). The high ER/SR [Ca
2+
] is particularly maintained by the ER/SR Ca
2+
 
ATPase (SERCA) pumps. One class of the Ca
2+
 channel that mediate Ca
2+
 release 
from the ER/SR is the ryanodine receptor (RyR) family. These ryanodine-sensitive 
Ca
2+
 channels can be activated by allosteric coupling to plasmalemmal voltage-
dependent Ca
2+
 channels (VDCCs), or activated by sensing changes in cytosolic 
[Ca
2+
]i, as reviewed previously (Coronado et al.,1994; Mackrill,1999). The opening 
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of RyR channels mediates Ca
2+
 release from the internal stores; the generation of 
these intracellular Ca
2+
 spikes and Ca
2+
 waves subsequently triggers downstream 
cellular signalling pathways (Berridge,1997). Since changes in [Ca
2+
]i are involved 
in the regulation of various cell functions, dysregulated cytosolic [Ca
2+
] can result in 
pathological conditions.  
The placenta is a unique organ that provides an interface for communication 
and nutrient transport between the mother and the fetus. Trophoblasts in the placenta 
are the front line cells involved in such delivery and disposal activities, among which, 
Ca
2+
 transport through trophoblasts is essential in the process of skeletal 
development in fetus (Belkacemi et al.,2005). The abundance of Ca
2+
 channels, Ca
2+
 
pumps and Ca
2+
 binding proteins expressed in trophoblasts is likely to fulfil the role 
of mineralisation (Moreau et al.,2003b). However, characterisation of these Ca
2+
 
channels and relevant functional accessory proteins in trophoblasts has not been 
established completely; and the exact mechanism of Ca
2+
 delivery from the maternal 
circulation to the fetus is not fully understood. The current project examined the 
expression of RyRs in both human placental trophoblast and human model 
trophoblast cell lines (BeWo, JAR, JEG-3 and SGHPL-4); the functional properties 
of RyRs in cell lines were studied using fura-2 calcium imaging. 
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1.1 Overview of RyRs 
 
RyRs are expressed widely in many tissues, including skeletal, cardiac and 
smooth muscles; neurons of both the central and peripheral nervous system; in 
organs of liver, lung, kidney, pancreas, testis and ovary; in osteocytes, neutrophils 
and macrophages; and in epithelial, endothelial and adrenal chromaffin cells (Sutko 
& Airey,1996; Franzini-Armstrong & Protasi,1997). RyRs are primarily expressed in 
the SR of muscle cells and the ER of non-muscle cells; the inner membrane of 
mitochondria was also reported to express RyRs (Beutner et al.,2001).  
RyRs are large homotetrameric complexes with molecular weights of more 
than 2 million daltons (Takeshima et al.,1989). Each RyR protein complex consists 
of four identical subunits; of which, each subunit has molecular weight over 560 kDa 
(Jayaraman et al.,1992). Figure 1.1 illustrates the “triad foot” component of the 
cytoplasmic N-terminal region of the RyR subunit that represents over 80% of the 
monomer (McCarthy & Mackrill,2004). The 4-TM arrangement, indicated in Figure 
1.1 as M1- M4 was adapted from the Takeshima model (Takeshima et al.,1989) for 
simplicity; a putative filter pore sequence of human RyRs (GVRAGGGIGD) is also 
indicated in the loop between M3 and M4 for later discussion. There are three genes 
(RYR1, RYR2 and RYR3) in humans encoding three RyR isoforms. These three 
receptor isoforms share about 70% amino acid sequence identity (Sorrentino & 
Volpe,1993). In mammalian striated muscles, the expression of RyR isoforms is 
tissue-specific. RyR1 and RyR2 are the predominant receptor isoforms expressed in 
skeletal and cardiac muscle, respectively. RyR3 is also present in mammalian striated 
muscles, such as in diaphragm and smooth muscle, but at relatively low levels in 
comparison to RyR1 and RyR2. Although RyR3 was referred to as the brain RyR 
isoform, recent studies have shown that the neurons and brain tissue express all three 
RyR isoforms; in addition, low expression level of RyR3 is co-expressed with other 
RyR isoforms in a wide range of both excitable and non-excitable cells (Giannini et 
al.,1995).  
Isoform-specific knock-out transgenic mice models were generated to 
investigate specific physiological roles of each RyR isoform. Mice with RyR1 gene 
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deficiency die perinatally with gross abnormalities of the skeletal muscle; the 
contractile response to electrical stimulation under physiological conditions is 
completely lost in RyR1-deficient muscle, which suggested the essential function of 
RyR1 in both muscular maturation and excitation-contraction coupling (E-C 
coupling) (Takeshima et al.,1994). Another study carried out by the same group 
reported mice lacking RyR2 developed large vacuolated SR, along with structurally 
abnormal mitochondria in the mutant cardiac myocytes; these animals died at around 
embryonic day 10 with morphological abnormalities in the heart tube; the authors 
proposed that RyR2 has a vital role in cellular Ca
2+
 homeostasis during the 
development of SR (Takeshima et al.,1998). These findings imply that RyR1 and 
RyR2 are essential for striated skeletal and cardiac muscle formation during embryo 
development. In contrast, RyR3-deficient mice were viable with no gross 
abnormalities (Takeshima et al.,1996). However, impairment in neonatal skeletal 
muscle contraction was observed at the first week after birth, suggesting RyR3 
contributes to E-C coupling in neonatal skeletal muscle contraction (Bertocchini et 
al.,1997).. Another independent study also reported increased locomotion activity of 
RyR3 (-/-) mice in the open-field test (Balschun et al.,1999). Such deletion of RyR3 
also resulted at specific changes in hippocampal synaptic plasticity without affecting 
hippocampal morphology, basal synaptic transmission or presynaptic function 
(Balschun et al.,1999). These findings reveal that RyR3 may be less important than 
RyR1 and RyR2 in striated muscle development but appears to be involved in spatial 
learning in the central nervous system, and the lack of RyR3-mediated Ca
2+
 
signalling results in abnormalities of certain neurons in the central nervous system 
(Takeshima et al.,1996). 
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Figure 1.1 RyR membrane topology (4-TM model) 
M4M1 M3M2
N
C
ER/ SR 
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Cytoplasm
‘Triad 
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GVRAGGGIGDPutative  filter pore:
 
  
Figure 1.1. Schematic illustration of RyR homotetrametric structure: the 4-TM 
arrangement (M1- M4) was adapted from the Takeshima model (Takeshima et al.,1989) for simplicity. 
The bulky amino-terminal portion forms the ‘triad foot’ structure. The region between transmembrane 
domains M3 and M4 that dips inside the lipid bilayer forms the putative pore. The sequence of the 
human RyR pore (GVRAGGGIGD) is indicated within this loop region. 
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1.2 Molecular Structure Overview of RyRs 
 
The human gene encoding RyR1 is located on chromosome 19q13.2 and 
contains 104 exons; the gene encoding RyR2 of human is located on chromosome 
1q43 and contains 102 exons; and the human RYR3 gene is found on chromosome 
15q13.3-14, with 103 exons (Lanner et al.,2010). Both RyR1 and RyR2 are well 
studied subtypes of RyR, due to the relatively high expression level and ease of 
protein purification process from skeletal and cardiac muscle, respectively. The 
primary structures of RyRs were elucidated by cDNA cloning.  
Although the protein sequences among mammalian RyRs (RyR1, RyR2 and 
RyR3) are well conserved, isoform specific functions are mainly governed by three 
divergent regions. Schematic diagram Figure 1.2A indicates the three divergent 
regions named D1, D2 and D3 within a subunit monomer. The D1 region (residues 
4254-4631 and residues 4210-4562 of RyR1 and RyR2, respectively) is found at the 
proximal location of the putative four transmembrane segments (M1-M4) of 
Takeshima model (Takeshima,1993). Both D2 (residues 1342-1403 and residues 
1353-1397 of RyR1 and RyR2, respectively), and D3 regions (residues 1872-1923 
and residues 1852-1890 of RyR1 and RyR2, respectively) are found in the 
cytoplasmic domain of the N-terminus (Ma et al.,2004) where sites respond to ligand 
and regulatory protein binding (Rossi & Sorrentino,2002). Figure 1.2B shows a 3-
dimensional reconstruction of human RyR2 protein with the views from the 
cytoplasm (left) and the ER/SR membrane (right). These 3D images were adapted 
from animation created by Dr. T. Wagenknecht (Jones et al.,2008), available for 
open-access (http://www.wadsworth.org/rvbc/animation.html). The corresponding 
D1, D2 and D3 regions are coloured in yellow, red and purple, respectively. The 
difference of D regions across RyR subtypes determines the isoform specificity. For 
example, the D3 region in RyR1 contains 38 net negative charges of 51 residues, but 
this D3 corresponding region in RyR2 only has 6 negative charges. In addition, the 
consecutive 17 glutamate residues of RyR1 D3 region are lacking in both RyR2 and 
RyR3 (Takeshima,1993). Furthermore, the corresponding D2 region is absent in 
RyR3 (Ma et al.,2004).  
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The membrane topology of RyR is not fully understood. However, it has been 
demonstrated by immunolocalisation studies that both N- and C- terminal domains of 
RyR1 are situated in the cytoplasm (Marty et al.,1994; Grunwald & Meissner,1995). 
This observation indicates an even number rather than an odd number of 
transmembrane (TM) domains in RyRs. Takeshima and colleagues first suggested 
the 4 TM model (M1-M4) of RyR1 (Takeshima et al.,1989). The amino acid 
sequence of these domains display high similarity to the pore region domains of IP3R 
(Ma et al.,2004), another receptor channel that also mediates Ca
2+
 release. Another 
model proposed by Zorzato and colleagues suggested a 10 TM model (M1-M10) 
(Zorzato et al.,1990). Figure 1.2A shows the RyR monomer as a schematric based on 
this 10 TM model, adapted and modified from (Zissimopoulos & Lai,2007). For 
simplicity, only M5, M6, M8 and M10 are indicated. TMs between M6 and M8 are 
shown as a TM hairpin (Zissimopoulos & Lai,2007). The four TM domains: M5, M6, 
M8 and M10 of this 10 TM model correspond to the M1, M2, M3 and M4 of the 
Takeshima model. Subsequently, Tunwell and colleagues proposed a 6 TM model, 
based on competitive enzyme-linked immunosorbent assay experiments using 
domain specific antibodies on intact and permeabilized SR microsomes (Tunwell et 
al.,1996). This model suggests similarity with the consensus selectivity filter of K
+
 
channels, in which the channel pore contains 6 TM domains and a P-loop between 
M5 and M6 that functions as the ion selectivity filter. A similar P-loop between M3 
and M4 of Takeshima model was also identified in RyR proteins, and the ion 
conducting pore has been revealed in the luminal-facing region of RyR (Zhao et 
al.,1999). Figure 1.2A indicates the putative Ca
2+
 filter domain sequence 
GVRAGGGIGD in the dashed rectangle in between M3 and M4 TM domains. This 
amino acid sequence of the pore structure is conserved in all RyR subtypes. For 
example, the protein sequence of human RyR1 that correspond to this putative filter 
segment is 4891-4900 (Zhao et al.,1999). The highly conserved motif GIG in RyR P-
loop is structurally related to the K
+
 channel filter GYG motif which contributes to 
this monovalent cation selective filter (Doyle et al.,1998). Mutations of the Ile to 
other hydrophobic amino acids such as Ala, Val and Leu, all resulted in a channel 
that lacked Ca
2+
 dependence, failed to bind ryanodine and displayed atypical Ca
2+
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release in response to caffeine, an RyR agonist, in a cell-based assay (Gao et 
al.,2000).  
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Figure 1.2 Schematic illusion of RyR monomer (A) and 3-dimentional 
constructs of RyR2 (B) 
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Figure 1.2A. A 6-TM model of RyR subunit (modified Takeshima model) adapted and 
modified from Zissimopoulos & Lai, 2007 (Zissimopoulos & Lai,2007). The isoform divergent 
regions are indicated as D1, D2, and D3 at the N-terminus. The amino acid sequence that involves 
pore formation is displayed in inset magnified from the dashed area between M8 and M10. 
Figure 1.2B. Three-dimensional constructs of RyR2, adapted from Jones et al., 2008 (Jones 
et al.,2008). The three-dimensional constructs are shown in two views: left, top view from the 
cytoplasmic surface; right, side view at the level of the ER/SR membrane. The corresponding 
locations of the three divergent regions are indicated, in which, D1, D2 and D3 are coloured yellow, 
orange and purple, respectively.  
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1.3 Ryanodine Receptor and Excitation-contraction Coupling  
 
RyRs were originally observed using transmission electron microscopy as 
electron-dense masses located within the SR terminal cisternae of skeletal muscle, 
the place where the SR is adjacent to the transverse-tubule (T-tubule) membranes 
(Franzini-Armstrong,1970). Based on their appearance, these proteins were initially 
named the “triad junctional foot proteins” (Franzini-Armstrong,1970) before they 
were characterised as ryanodine binding proteins (Pessah et al.,1985). The 
rectangular junctional feet fill up the gap between the SR and T-tubule; this 
architecture is crucial for subsequent excitation-contraction (E-C) coupling 
(Wagenknecht & Radermacher,1997). In skeletal muscle, RyRs in the SR membrane 
are in direct apposition to the dihydropyridine receptors (DHPRs) in the junctional T-
tubule membrane. The propagation of an action potential that activates depolarisation 
at the neuromusclular junction leads to a conformational change of the DHPRs that 
are physically in contact with the adjacent RyR in the SR membrane through a 
protein-protein interaction mechanism (McPherson & Campbell,1993; Mackrill,1999) 
between DHPR and RyR: the RyR is activated and the opening of RyR channel 
subsequently mediates Ca
2+
 release from the SR.  
Although the physical interaction between DHPRs and RyRs is one of the 
mechanisms for RyR activation, not all RyRs couple to DHPRs (Ikemoto & 
Yamamoto,2002). In skeletal muscle, only half of the RyR population are directly in 
contact with DHPRs; whereas the total number of RyRs are about 3 to 10 fold more 
abundant than the DHPR population in cardiac muscle, depending on species (Bers 
& Stiffel,1993). The remaining uncoupled RyRs in skeletal muscle are activated by 
the so-called Ca
2+
-induced Ca
2+
 release (CICR) mechanism, which adds to the Ca
2+
 
that is released from the nearby DHPR-coupled RyRs (Endo et al.,1970). In cardiac 
muscle tissue, the relative population of DHPRs is much lower than RyRs. The E-C 
coupling of cardiac RyRs relies more on the CICR mechanism than mechanical 
interaction with DHPRs. Therefore, cardiac muscle E-C coupling is initiated by 
membrane depolarisation which leads to activation and channel opening of the 
voltage-sensing DHPRs; a small amount of extracellular Ca
2+
 enters into the cell 
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through these DHPR channels and interacts with the Ca
2+
-sensing domain of the SR 
RyR; this subsequently induces SR RyR activation, resulting in further release of 
Ca
2+
 from SR through the opened RyR channels. Eventually, the increase of [Ca
2+
]i 
causes cardiac muscle contraction. 
 
 
1.4 Gating Properties and Activation of RyRs 
 
RyRs are the largest Ca
2+
 channels with Ca
2+
 conductance of about 100 pS, in 
comparison to about 20 pS for voltage-gated L-type Ca
2+
 channels (Cav1.1-1.4, i.e. 
DHPR) (Hess et al.,1989), as reviewed by (Zalk et al.,2007). Single channel 
electrophysiological studies on purified RyRs indicate that RyRs conduct both 
monovalent and divalent cations (Lindsay et al.,1991; Tinker & Williams,1992), as 
reviewed by (Fill & Copello,2002). The conductance of RyRs is over 500 pS in 
symmetrical monovalent cation containing solutions, containing about 200 mM K
+
, 
Na
+
, or Cs
+
 as the main permeant species (Lindsay et al.,1991); whereas for a 
divalent cation in asymmetric solutions, containing about 50 mM Ca
2+
, Ba
2+
, or Sr
2+
 
as the main permeant species, an RyR conductance of about 100 pS was measured 
(Tinker & Williams,1995). In addition, although RyRs show little selectivity for 
either monovalent or divalent cations as charge carrier, divalent cations are still more 
permeant than K
+
 under bi-ionic conditions. RyRs are relatively more selective for 
divalent cations, as the permeability ratio (PCa/PK: about 6) indicates that Ca
2+
 is six 
to seven times more permeable than K
+
 (Fill & Copello,2002). This PCa/PK value of 
RyRs is relatively low compared to DHPRs (PCa/PK > 20), as the latter display a 
much higher selectivity to Ca
2+
 in the cell plasma membrane. The feature of RyRs 
with high conductance and little ion selectivity may be explained by their specific 
location and environment. As RyRs are located in the SR/ER membranes, Ca
2+
 is the 
predominent cation that is conducted by activated RyR channels. The Ca
2+
 flows 
passively from ER/SR to cytosol through the opened RyR channel, as cations are 
driven by the ionic concentration gradient across the SR/ER membrane ([Ca
2+
]: 100 
µM within SR/ER; 100 nM within cytosol). Discrimination between ions, therefore, 
is not an essential requirement for RyR channels. However, selectivity is crucial for 
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ion channels (e.g. L-type Ca
2+
 channels) expressed in the cell plasma membrane, as 
proteins in this location are important for the regulation of electrochemical 
concentration gradient among different ions across the barrier. 
The neutral alkaloid ryanodine, a compound that was isolated from plant 
Ryania speciosa, binds to all RyR isoforms. It has been demonstrated that ryanodine 
binds to RyR via a negative allosteric mechanism, suggesting that each RyR channel 
protein contains one high-affinity ryanodine binding site per tetramer (Wang et 
al.,1993). The high-affinity binding site has been demonstrated to occur in 
association with the open state of the channel. This property governs ryanodine-
binding as an index of RyR channel activation (Chu et al.,1990a). The first ryanodine 
molecule binds and locks the channel in a subconductance state with high affinity; 
the binding of this first ryanodine on the other hand inhibits ryanodine binding on the 
other sites (Pessah & Zimanyi,1991). Therefore, ryanodine at low concentration 
(about 10 nM) appears to activate the channel by increasing the channel opening 
frequency to the full conductance level. Intermediate ryanodine doses (about 1 µM) 
encourage binding to the low-affinity site and slows the dissociation of ryanodine 
from the high-affinity site, which subsequently induces a long-duration open events 
and simultaneously reduces ion conductance through the pore (Buck et al.,1992). 
High concentrations of ryanodine (about 100 µM) can cause RyR inactivation to a 
closed conformation (Zimányi et al.,1992).  
Apart from ryanodine, 4-chloro-meta-cresol (CmC), caffeine and ruthenium 
red are also known as RyR pharmacological regulators (Endo et al.,1970; Ma,1993; 
Zorzato et al.,1993). In addition, ions such as Ca
2+
 and Mg
2+
, and physiological 
molecules such as ATP, also regulate the RyR complex. The threshold activating 
concentration of Ca
2+
 for both RyR1 and RyR3 is about 1 µM (Smith et al.,1986; 
Sharma et al.,2000); whereas RyR2 is much more sensitive to Ca
2+
 as it can be 
activated in 0.1 µM [Ca
2+
] (Ashley & Williams,1990). Evidence shows that the 
experimental Glu3987Ala mutation in RyR2 results in a mutant channel with 
decreased Ca
2+
 sensitivity (Li & Chen,2001); another study shows the mutant 
RyR1(Glu4032Ala) also presents reduced Ca
2+
 sensitivity (Fessenden et al.,2001). 
These findings suggest that the conserved residue Glu
3987
 forms part of the high-
affinity Ca
2+
-sensing device of both RyR1 and RyR2 (Ikemoto & Yamamoto,2002). 
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Additionally, an interesting study shows deletion of a highly acidic/negatively 
charged domain in the D3 region of RyR1 (Ile
1641
-Ala
2437
) caused about a 10-fold 
decrease in sensitivity to Ca
2+
 or Mg
2+
 inhibition (Bhat et al.,1997); this finding is 
consistent with the fact that RyR2 presents less inhibition sensitivity to Ca
2+
 or Mg
2+
, 
and contains a less acidic D3 region domain. This finding suggests that the structural 
difference in the acidic residues of the D3 region might result in a difference in the 
receptor sensitivity to Ca
2+
 or Mg
2+
 inhibition (Ikemoto & Yamamoto,2002). 
Cytosolic Mg
2+
 is a potent RyR channel inhibitor, whereas cytosolic ATP is a RyR 
activator; the concentrations of both free Mg
2+
 and ATP within the resting cell are 
about 1 mM and 300 µM, respectively.  
 
 
1.5 Endogenous Regulators of RyR 
 
The regulation of RyR gating involves a wide variety of ions and molecules. 
Both cytoplasmic and luminal Ca
2+
 ions are involved in channel activation. In 
addition to Ca
2+
, Mg
2+
 and ATP are also endogenous regulators of RyR. 
It has been demonstrated that cytosolic Ca
2+
 regulates skeletal muscle RyR1 
biphasically (Meissner et al.,1997). This RyR channel can be activated by Ca
2+
 as 
low as 100 nM and the peak channel activity activation can be observed at [Ca
2+
]i 
between 10-100 µM. However, Ca
2+
 alone is not sufficient to fully activate these 
receptor channels. Moreover, [Ca
2+
]i in the millimolar range almost completely 
inhibits the channel gating (Meissner et al.,1997). These results suggest that Ca
2+
 at 
low concentration favours binding at high affinity sites that activate the channel, 
while Ca
2+
 at high concentration also binds to low affinity inhibitory sites of the 
channel. In contrast, high [Ca
2+
]i has less inhibitory effect on RyR2 and RyR3; both 
RyR2 and RyR3 can almost be fully activated by cytosolic Ca
2+
 alone at 100 µM 
(Schiefer et al.,1995; Jeyakumar et al.,1998; Murayama et al.,1999). Studies on 
single-channel activity of rabbit skeletal muscle RyR and dog cardiac RyR indicated 
that both tissues contain heterogenous channel populations (Copello et al.,1997).  
Sulfhydryl (SH) oxidation by SH-oxidising agents resulted in increased activity of 
different native RyR channels incoporated in lipid bilayers, while reduction of 
cardiac RyRs caused their decreased in channel activity (Marengo et al.,1998).  
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Luminal Ca
2+
 also modulates RyR activity allosterically (Györke & 
Györke,1998). The luminal Ca
2+
 sensor of the RyR had been demonstrated to sense 
the change of internal store [Ca
2+
], and the receptor sensitivity to cytosolic Ca
2+
 is 
propotional to its luminal [Ca
2+
] (Sitsapesan & Williams,1994; Sitsapesan & 
Williams,1995; Ching et al.,2000). On the other hand, increased luminal Ca
2+
 
content also alleviates Mg
2+
 inhibition allosterically (Laver et al.,2004). Moreover, 
the channel inhibitory mechanism induced by high cytosolic Ca
2+
 can be reversed by 
luminal Ca
2+
 interaction (Györke et al.,1994; Györke & Györke,1998). Evidence 
shows that the luminal Ca
2+
 sensing ability of the receptor is granted by both an 
intrinsic Ca
2+
 binding domain and RyR accessory proteins, such as calsequestrin 
(CSQ), triadin and junctin that are expressed in the luminal region (Ching et al.,2000; 
Györke et al.,2004).   
Another element that also modulates the RyR channel is Mg
2+
. This divalent 
cation has a potent inhibitory effect on RyR channel. Experimental results provided 
by single channel recordings and ryanodine-binding assays have demonstrated that 
the Mg
2+
 inhihitory effect on RyR1 is concentration-dependent (Smith et al.,1986; 
Pessah et al.,1987). It has been demonstrated that Mg
2+
 is an RyR antagonist in the 
absence of Ca
2+
 (Laver et al.,2004). Mg
2+
 at a cytoplasmic concentraction of 1 mM 
was found to block the RyR1 (Copello et al.,2002), whereas RyR2 and RyR3 in 
contrast, are inhibited by Mg
2+
 at higher concentrations (Meissner & 
Henderson,1987; Chen et al.,1997). It has been suggested that Mg
2+
 inhibits the 
channel by competing with Ca
2+
 at its high-affinity activation site and also binding at 
the Ca
2+
 low-affinity inactivation site of the receptor (Laver et al.,2004).  
Adenine nucleotides such as ATP, ADP, AMP, cyclic-AMP, adenosine and 
adenine are also RyR activators. Among these molecules, ATP is the most potent.  
Experimental results on SR flux measurements, single channel recordings and 
ryanodine-binding assays have shown that ATP at millimolar concentration activates 
RyR1 in the presence of Ca
2+
 at nanomolar concentration; whereas, millimolar ATP 
produces persistent channel activation in the presence of Ca
2+
 at micromolar 
concentration (Meissner,1984; Smith et al.,1986; Meissner & Henderson,1987; 
Pessah et al.,1987). ATP has been demonstrated to increase the frequency and 
duration of channel opening of RyR2 in the presence of cytosolic Ca
2+
 (Kermode et 
 38 
al.,1998). RyR3 is also activated by 1 mM ATP at resting [Ca
2+
]i levels; interestingly, 
RyR3 resembles RyR2 more than RyR1 concerning high [Ca
2+
] (millimolar) 
inactivation and this high [Ca
2+
] inhibition is overiden by ATP stimulation (Chen et 
al.,1997; Manunta et al.,2000). It has been suggested that ATP increases the channel 
sensitivity to Ca
2+
 activation, while decreasing channel sensitivity to Ca
2+
 
inactivation (Meissner et al.,1997). 
 
 
1.6 Modulatory Proteins of RyRs 
 
The channel function of RyR macromolecular complexes is modulated by 
numerous proteins and molecules via direct or indirect interactions. Studies on 
skeletal muscle show that calmodulin and FKBP12 are accessory proteins that 
modulate RyR1 at the triad junction (Wagenknecht & Radermacher,1997). In 
addition, calreticulin and calsequestrins are high capacity, SR luminal Ca
2+
 storage 
proteins that help to maximise Ca
2+
 storage and to control cytosolic [Ca
2+
] at 
physiological levels; further studies proposed that the RyR, calsequestrin, and two 
SR/ER integral membrane proteins, triadin and junctin, form a quaternary complex 
that controls the accumulation and release of Ca
2+ 
from SR (Zhang et al.,1997). 
Calmodulin (CaM) is a 17 kDa Ca
2+
-sensing protein that binds to and 
modulates gating of RyRs. The high affinity Ca
2+
-binding property of CaM is 
governed by a pair of EF-hands: the helix-loop-helix structural motifs are situated on 
both N- and C-terminal globular domains; each EF-hand binds a Ca
2+
 ion (Moore et 
al.,1999). CaM binds to all types of mammalian RyRs with nanomolar affinity; each 
CaM molecule binds to an RyR subunit in a 1:1 stoichiometry, irrespective of 
whether CaM is Ca
2+
-free or Ca
2+
-bound. The primary binding site of both Ca
2+
-free 
and Ca
2+
-bound CaM is located at residues 3614-3643 of RyR1, 3583-3603 of RyR2 
and 3469-3489 of RyR3 (Takeshima et al.,1989; Yamaguchi et al.,2003; Yamaguchi 
et al.,2005). CaM modulates both RyR1 and RyR3 biphasically with a similar Ca
2+
-
dependent mechanism. At [Ca
2+
] in the nanomolar range, Ca
2+
-free CaM activates 
both RyR1 and RyR3, whereas under micromolar cytosolic [Ca
2+
], Ca
2+
-bound CaM 
undergoes a conformational change and inhibits the channel (Rodney et al.,2000; 
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Yamaguchi et al.,2005). CaM has been demonstrated to increase the channel opening 
frequency without affecting other channel properties, suggesting that CaM is 
involved in initiation of SR Ca
2+
 release via skeletal muscle RyRs (Rodney & 
Schneider,2003). In contrast, CaM suppresses SR Ca
2+
 release via RyR2 at low 
micromolar to submicromolar [Ca
2+
], and therefore, CaM facilitates the termination 
of SR Ca
2+
 release via cardiac muscle RyRs (Xu & Meissner,2004). 
The FK506-binding proteins (FKBPs) are a family of binding proteins for the 
immunosuppressant drugs FK506 and rapamycin (Fruman et al.,1995), as reviewed 
previously (Mackrill,1999). Both FKBP12 (calstabin1) and FKBP12.6 (calstabin2) 
are known as Ca
2+
 channel-stablising proteins; both are enzymes with peptidyl-
prolyl-cis-trans isomerase activity (Zalk et al.,2007). FKBP12 is the 12 kDa FKBP 
isoform that predominantly mediates the function of the immunosuppressant drugs. 
This small protein is mainly cytosolic, catalyses peptidylpropyl-cis-trans-
isomerization, which subsequently shapes target proteins by modifying the tertiary 
structure of protein folding. However, the isomerase activity is not required for 
interaction with RyR1 (Timerman et al.,1995). Subsequent mutation studies revealed 
that residues Q3, R18 and M49 of FKBP12 are required for the interaction with 
RyR1 (Lee et al.,2004). A high affinity (Kd ~ 1nM) binding of FKBP12 to RyR1 
requires channels to be in an open-state; such interaction was further enhanced by 
approximately 4 to 5 orders of magnitude in channels with a closed configuration 
(Jayaraman et al.,1992; Jones et al.,2005). Studies on isolated RyR1 or SR 
preparations with dissociated FKBP12 (by using FK506 or rapamycin) demonstrated 
that FKBP12-deficient channels display enhanced Ca
2+
 conductance and long-lasting 
subconductance states in their gating properties (Timerman et al.,1993; Ahern et 
al.,1997), in addition to increased sensitivity to Ca
2+
 or caffeine activation and 
reduced inhibition by millimolar Ca
2+
 or Mg
2+
 (Timerman et al.,1993; Mayrleitner et 
al.,1994). Restoration of FKBP12 to the FKBP12-deficient cells altered RyR channel 
gating from showing multiple subconductance states to predominantly fully open or 
closed state (Chen et al.,1994). This evidence suggests FKBP12 binding to RyR1 
stabilises the channel conductance and subsequently enhances E-C coupling. In vitro, 
RyR1 interacts with both FKBP12 and FKBP12.6, a distinct FKBP isoform; but 
RyR2 selectively binds to FKBP12.6 (Timerman et al.,1996). In cardiac muscle, 
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FKBP12.6 has similar effects on RyR2 to those of FKBP12 on RyR1. Removal of 
FKBP12.6 from RyR2 results in long-lasting subconductance states. However, 
restoration of this protein did not reverse the abnormal gating of RyR2 (Barg et 
al.,1997). On the other hand, enhanced contractility and cardiac output were 
observed in transgenic mice over-expressing FKBP12.6 (Huang et al.,2006). This 
observation implies that FKBP12.6 binding to RyR2 inhibits the channel activity and 
also promotes channel closure (Huang et al.,2006). Other studies also demonstrated 
that dissociation of FKBP12.6 from cardiac muscle RyRs due to 
hyperphosphorylation of residue S2814 is connected with heart failure and cardiac 
arrhythmias that were primarily caused by RyR2-mediated Ca
2+
 leak (Marx et 
al.,2000; Yano et al.,2000). These studies suggest that FKBPs association with RyRs 
is essential for stablisation of the RyR macromolecular complex in both skeletal and 
cardiac muscle. 
The roles of calreticulin (CRT) in Ca
2+
 storage and Ca
2+
 release channel 
modulation are controversial. However, both CRT and calsequestrin (CSQ) are 
structurally related high-capacity, moderate-affinity, non-EF-hand Ca
2+
 storage 
proteins (Mackrill,1999). Both CRT and CSQ are found in the lumen of ER/SR, of 
which CSQ is the major component and CRT is the minor component in skeletal and 
cardiac muscle SR (Michalak & Milner,1991). Both proteins bind up to 40 moles of 
Ca
2+
 per mole of protein. Evidence indicated that CRT may be expressed in parallel 
with inositol 1,4,5-trisphosphate receptor (IP3R), whereas CSQ is found in close 
association with RyRs (Ikemoto et al.,1989; Camacho & Lechleiter,1995). CRT is 
present in a variety of non-muscle tissues (Michalak & Milner,1991). It has been 
demonstrated that CRT acts as an ER molecular chaperone; in addition, CRT is also 
a modulator of both integrin function and transcription factors within the 
plasmalemma and nucleus, respectively (Meldolesi et al.,1996).  
The CSQs are rich in acidic residues, most of which are found in the C-
terminal region. Net surface charges provided by these acidic residues enable Ca
2+
 
binding to CSQ (Wang et al.,1998). CSQ buffers rises in SR Ca
2+
 by directly binding 
to the free cations and then undergoes conformational changes. At micromolar [Ca
2+
] 
(up to 10 µM), compaction of CSQ monomers occurs; while from 10 to 100 µM 
[Ca
2+
], dimerisation of CSQ begins; polymerisation of linear CSQ polymers occurs 
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at millimolar [Ca
2+
], the luminal free [Ca
2+
] under physiological conditions (Wang et 
al.,1998). Therefore, CSQs exist as stable polymers within ER/SR where the free 
[Ca
2+
] is at about 1 mM (Fryer & Stephenson,1996). Polymers of CSQ have been 
observed as electron-dense material in electron micrographs of junctional muscle 
preparations, indicating polymerisation of CSQ on Ca
2+
 binding (Wang et al.,1998; 
Franzini-Armstrong,1999).  
CSQ is highly abundant in the terminal cisternae, which suggests its role in 
Ca
2+
 recruitment for subsequent Ca
2+
 release. A transient increase in intraluminal 
free [Ca
2+
] is observed prior to RyR activation and subsequent decrease in luminal 
Ca
2+
; such transient increases in intraluminal free [Ca
2+
] are abolished in the absence 
of CSQ in the SR, and this can be reversed when CSQ are restored (Ikemoto et 
al.,1989). These observations imply that there is a reciprocal coupling between RyRs 
and CSQ (Gilchrist et al.,1992). It has been demonstrated that CSQ is anchored to 
the junctional face of the SR membrane through interactions with other SR integral 
proteins. During these interactions, junctin and triadin bind to the aspartate-rich 
region of the C-terminus (amino acids 354-367) of CSQ, the region that also 
responds to Ca
2+
 binding (Shin et al.,2000). It has been suggested that Ca
2+
 and 
triadin/junctin compete at the same binding site, and CSQ dissociates from Ca
2+
 upon 
change of [Ca
2+
] (Zhang et al.,1997). Therefore, by interacting with triadin/junctin, 
CSQ shuttles luminal Ca
2+
 to the Ca
2+
 release channel, RyR. Altered conformation 
and reduced affinity for Ca
2+
, triadin and junctin had been demonstrated in mutation 
at D307H of CSQ (Houle et al.,2004), which consequently results in reduced SR 
Ca
2+
 content and dysfunctional RyR2, characterised by decreased E-C coupling and 
Ca
2+
 spark frequency (Viatchenko-Karpinski et al.,2004). In contrast, enhanced E-C 
coupling and Ca
2+
 spark frequency were observed with overexpression of CSQ with 
a R33Q mutation, despite normal SR Ca
2+
 content (Terentyev et al.,2006).  In 
addition, R33Q mutant CSQ also enhanced RyR2 channel sensitivity to luminal Ca
2+
 
activation in single channel recordings (Terentyev et al.,2006). Both CSQ mutations 
lead to cardiac arrhythmias in human subjects.  
Triadin is a major integral membrane glycoprotein of the junctional SR of 
skeletal muscle triads (Mackrill,1999). All triadin isoforms contain a common N-
terminal cytoplasmic segment, a single TM domain and a variable luminal domain 
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with unique sequences at the C-terminus (Zissimopoulos & Lai,2007). Triadins 
interact with both RyR and CSQ, except Trisk 49 and 32 which do not bind RyR 
(Vassilopoulos et al.,2005). Fusion protein affinity chromatography shows the C-
terminal domain of triadin interacts with both CSQ and a luminal loop of RyR via the 
same KEKE motif (amino acids 210-224) (Guo et al.,1996; Kobayashi et al.,2000). 
The interaction between triadin C-terminus and CSQ is [Ca
2+
]-dependent and this 
interaction activity can be inhibited by increased [Ca
2+
]. In contrast, the binding of 
triadin to RyR is Ca
2+
-independent. It was suggested that triadin brings Ca
2+
-bound 
CSQ to the skeletal muscle Ca
2+
 release channel and such interaction between triadin 
and CSQ subsequently shuttles and concentrates the stored Ca
2+
 ions at positions 
closest to the Ca
2+
-release sites, as mentioned in previous paragraph.  
In heart junctional SR, the approximately 26 kDa junctin displays a high 
degree of sequence identity with triadin. Junctin from cardiac muscle interacts with 
calsequestrin, triadin and RyR. The interaction of junctin and calsequestrin is 
inhibited by Ca
2+
 at millimolar concentration. The binding between triadin and 
junctin is thought to be mediated by the ‘polar zippers’. It has been suggested that 
triadin and junctin directly interact in the junctional SR membrane and stablise the 
quaternary complex of RyR, CSQ, triadin and junction; and such coordination within 
the complex may be required for normal operation of SR Ca
2+
 release (Zhang et 
al.,1997). 
 
1.7 RyRs and Human Disease 
 
Several human diseases are associated with mutations of RYR1 and RYR2. 
Studies on malignant hyperthermia (MH), central core disease (CCD) multi-minicore 
disease (MmD), and atypical periodic paralyses (APP) have indicated that RyR1 
mutations are one cause of these diseases (MacLennan et al.,1990; Zhang et al.,1993; 
Ferreiro et al.,2002; Zhou et al.,2010). Mutations in RYR2 gene are linked to stress-
induced heart diseases such as catecholaminergic polymorphic ventricular 
tachycardia type 1 (CPVT1) and arrhythmogenic right ventricular dysplasia type 2 
(ARVD2). The pathophysiological consequences of these human diseases are due to 
the presence of abnormal RyR proteins that result in a dysregulated state of [Ca
2+
]i.  
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These disease-associated mutations in both RyR1 and RyR2 are found in three 
clusters: the N-terminus at position of amino acids 35 to 614 in RyR1 and 176-420 in 
RyR2; the central domain in the cytoplasmic region at position of amino acids 2162 
to 2458 in RyR1 and 2246-2504 in RyR2; the last cluster is located at the adjacent C-
terminal position of amino acids 4647–4914 in RyR1 and 3778-4950 in RyR2 
(Hamilton,2005).    
MH is an autosomal disease associated with a pharmacogenetic disorder of 
skeletal muscle. MH susceptible individuals are characterised by sustained muscle 
contactions, a rise in body temperature, skeletal muscle rigidity, and rhabdomyolysis. 
The trigger for these symptoms is the administration of certain inhalation anesthetics, 
such as halothane, and depolarising skeletal muscle relaxants, such as 
succinylcholine (Mickelson & Louis,1996), or when the patient is exposed to high 
ambient temperatures (above 37
o
C) (Jurkat-Rott et al.,2000). These triggers 
subsequently result in uncontrolled release of Ca
2+
 from the SR via the mutant RyR1 
that is hypersensitive to its agonists (such as Ca
2+
, cADPr, caffeine and halogenated 
anaesthetics) (López et al.,2000; Kobayashi et al.,2005).  
CCD is another RyR1-related disease that results at a loss of channel function 
(Zhang et al.,1993). CCD is a congenital myopathy inherited as an autosomal-
dominant disease. CCD is characterised by hypotonia, muscle weakness of lower 
extremities at birth and delayed motor development. CCD diagonosis is determined 
histologically by the presence of large amorphous areas (cores), which lacks 
mitochondria and oxidative enzyme activities, as reviewed by Zissimopoulos and Lai 
(Zissimopoulos & Lai,2007).  
The lack of oxidative enzyme activites is the common feature of both CCD 
and MmD, and clinically, patients with CCD and MmD share similar symptoms. 
MmD is an autosomal recessive congenital myopathy, in which multiple cores 
devoid of mitochondria and disorganised sarcomeric structure are present in skeletal 
muscles (Zissimopoulos & Lai,2007).  Patients with MmD are chacterised by 
hypotonia and weakness in axial and proximal limb muscles (Lanner et al.,2010). 
Disease states due to alteration of channel properties could be explained by 
the position of mutations within the receptor protein (Hamilton,2005). There are 
more than 150 MH-linked and 60 CCD-associated point mutations identified in 
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RYR1 (Vukcevic et al.,2010). These mutation spots have been found at three regions: 
the N-terminal, central and C-terminal domains, as reviewed by Hamilton 
(Hamilton,2005). The majority of MH mutations, however, are clustered in the RyR1 
cytoplasmic domains that are responsible for the increased sensitivity to 
pharmacological agents (eg. caffeine and halothane) (Treves et al.,1994); whereas 
most of the CCD-linked mutations are located at the pore-forming region which 
contributes to the enhanced Ca
2+
 leak from the store (Tilgen et al.,2001). 
Interestingly, some mutations are suggested to be the cause of both MH and CCD 
(Zissimopoulos & Lai,2007). In addition, patients with CCD are at risk of MH when 
general anaesthesia is given (Quinlivan et al.,2003), and the RyR1 and RyR3 
antagonist dantrolene is clinically used to reverse the symptoms of an MH episode. 
Mutations in RYR2 have been linked to two forms of stress-induced 
arrhythmogenic heart disease: CPVT1 and AVRD2. CPVT1 is an inherited disease, 
characterised by adrenergically mediated bidirectional or polymorphic ventricular 
tachycardia, which can cause heart failure and death (Francis et al.,2005; Kontula et 
al.,2005). Patients with CPVT are susceptible to ventricular tachycardia resulting 
from β–adrenergic receptor stimulation and can develop ventricular arrhythmias 
(Lanner et al.,2010). This complication is inducible during physical or emotional 
stress, and reproducible by catecholamine infusion (Zissimopoulos & Lai,2007). In 
contrast to the appearance of structurally normal hearts in patients with CPVT1, 
patients with ARVD2 are characterised by the replacement of myocytes with 
progressive fibro-fatty tissue in the right ventricular myocardium (Corrado et 
al.,2000). Despite the structural abnormality of ARVD2, both CPVT1 and ARVD2 
display similar phenotypes as stress-induced polymorphic ventricular tachycardia. At 
least one 2-residue insertion and over 60 point mutations have been identified in 
RyR2 within the C-terminal pore-forming domains, and the cytoplasimic N-terminal 
and central domains (Zissimopoulos & Lai,2007). These mutation regions are 
analogous to the mutations in RyR1 linked to MH and CCD (Lanner et al.,2010). 
Any of these RyR2 mutations at either N-terminal or central regions are suggested to 
‘unzip’ the stabilising domains and cause the diastolic Ca
2+
 leak from RyR2 channel 
(Oda et al.,2005). The SR Ca
2+
 leak probably triggers a net inward Na
+
 current that is 
generated by the activation of plasma membrane Na
+
/Ca
2+
 exchanger. Subsequently, 
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the net inward Na
+
 current causes membrane depolarisation of cardiomyocytes 
during diastole (Kannankeril et al.,2006), namely, delayed after-depolarisation, 
which triggers premature action potentials and initiation of arrhythmias 
(Zissimopoulos & Lai,2007). 
RyR3 is the least characterised RyR, and the functional roles of RyR3 are not 
fully understood. Several studies have demonstrated the connection between 
alterations in RyR-mediated Ca
2+
 release and the pathology of Alzheimer’s disease 
(Kelliher et al.,1999; Smith et al.,2005; Supnet et al.,2006; Stutzmann et al.,2007). 
One of these studies demonstrated upregulation of RyR3 in cultured cortical neurons 
from the TgCRND8 mouse model of Alzheimer’s disease (Supnet et al.,2006). 
Neuronal death of TgCRND8 neurons was observed after RyR3 knockdown by 
siRNA; Supnet et al. subsequently suggested RyR3 upregulation contributes to the 
neuroprotective compensatory response (Supnet et al.,2010). Another independent 
study also found increase of RyR3 mRNA level in late stage animal models of 
Alzheimer’s disease (Bruno et al.,2011). Although the exact mechanism of RyR3 
participation in the progression of Alzheimer’s disease is unclear; the discovery of an 
increase in RyR3 mRNA level at late stage of the disease may provide hints of 
finding novel therapeutic pathway (Bruno et al.,2011).   
 
 
 
1.8 G-Protein-coupled Receptor Activated Ca
2+
 Release 
 
The guanine nucleotide binding protein (G protein)-coupled receptors (GPCR) 
are seven α-helical transmembrane proteins that mediate cell signalling pathways via 
the activation of corresponding G proteins (Gether,2000). The activation of G 
proteins is triggered by a variety of extracellular stimuli that transmit through GPCRs 
and/or tyrosine kinase receptors (eg. epidermal growth factor receptors, insulin 
receptors, insulin-like growth factor receptors) (Kuemmerle & Murthy,2001; 
Kristiansen,2004). The activated GPCR acts on heterotrimeric G proteins via 
guanine-nucleotide exchange factors, inducing a conformational change in the 
associated G protein α-subunit; subsequently, the GDP is released from the α-subunit 
in exchange for GTP (Bourne et al.,1991). The resulting GTP-bound α-subunit 
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dissociates from the receptor complex and acts on proteins that the G protein subtype 
particularly targets. As reviewed by Kristiansen (Kristiansen,2004), the major G 
proteins are Gs, Gi/o, Gq, and G12/13; each one binds directly to its specific effector 
that conducts the corresponding downstream pathway.  
The Gs subfamily activates adenylyl cyclase (AC1 to AC9) through Gαs and 
results in cAMP augmentation that triggers various downstream siganalling pathways, 
as indicated in Figure 1.8 (pink zone).  Examples of Gαs-mediated GPCRs are cardiac 
subtype β-adrenergic recepor (βAR) and arginine vasopressin receptor 2 (V2). One 
of the well-established cAMP sensor proteins is cAMP-dependent protein kinase 
(PKA). In ventricular myocytes, it has been demonstrated that PKA signalling 
enhances contractility by phosphorylation of cardiac troponin I (cTnI), RyR, L-type 
calcium channel (LTCC) and phospholamban (PLN), as reviewed by Bers 
(Bers,2002). PKA also mediates phosphorylation of cAMP-response element binding 
protein (CREB) on Ser133, an essential step for the activation of gene transcription 
(Mayr & Montminy,2001). Another cAMP sensor that mediates downstream 
signalling pathways, independent of PKA, is the exchange protein directly activated 
by cAMP (EPAC). Increased EPAC activity has been shown to increase 
phosphorylation of cTnI, RyR, PLN and CaMKII in the heart (Pereira et al.,2007; 
Cazorla et al.,2009); EPAC has also been reported to activate phospholipase Cξ 
(PLC-ξ) which leads to Ca2+ release mediated via inositol 1,4,5-trisphosphate 
receptors (IP3R) and subsequent CICR in cardiac myocytes (Oestreich et al.,2007). 
Therefore, as cAMP rises in response to extracellular stimulation that activates Gs-
mediated GPCRs, PKA- and EPAC-mediated pathways can then be independently 
operated and lead to activation of their corresponding downstream effector proteins. 
The resulting Ca
2+
 mobilisation and/or activation of gene transcription can be the 
consequence of Gs-mediated GPCR activation, regardless whether the pathway is 
mediated by PKA or EPAC.  
Stimulation of Gq subfamily activates phospholipase C (PLCβ1-4) through 
Gαq and results in production of 1,2-diacylglycerol (DAG) and inositol 1,4,5-
trisphosphate (IP3) (Berridge,1993; Lee & Severson,1994). Examples of Gαq-
mediated GPCR are α-adrenergic recepor (αAR), angiotensin II type 1 receptor 
(AT1R), ETA type endothelin receptor (ETAR) and arginine vasopressin receoptor 1 
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(V1). As indicated in Figure 1.8 (blue zone), the production of DAG is essential for 
the activation of transient receptor potential (TRP) channel family TRPC1, TRPC3, 
TRPC6 and TRP7 channels, plasma membrane ion channels that mediate Ca
2+
 influx 
(Okada et al.,1999; Venkatachalam et al.,2001; Sydorenko et al.,2003). In addition, 
DAG production also results in activation of Ca
2+
-dependent protein kinase (PKC); 
which initiates serval mitogen-activated potein kinases (MAPKs) signalling cascades, 
such as the extracellular signal-regulated kinases 1/2 (ERK1/2) signaling in the heart 
(Garrington & Johnson,1999; Dorn & Force,2005). The consequence of ERK1/2 
signaling has been shown as gene expression in different cell types, as reviewed by 
Tohogo et al. and DeWire et al. (Tohgo et al.,2002; DeWire et al.,2008). The 
activation of IP3R, by IP3 is known to cause intracellular Ca
2+
 mobilisation 
(Berridge,1993). The formation of Ca
2+
/CaM complexes upon increased [Ca
2+
]i 
provides further opportunity for downstream protein interaction. In addition to PKC-
ERK1/2 signaling, PKC activation also results in calmodulin-dependent protein 
kinase II (CaMKII) activation (Shobe,2002). Various CaMKII isoforms (e.g. α, γ and 
δ) have been demonstrated to alter expression of different genes independent of PKC 
activity (MacNicol et al.,1990; Wegner et al.,1992; Matthews et al.,1994; Misra et 
al.,1994; Ramirez et al.,1997).  
RyR channel activity and the subsequent RyR-mediated Ca
2+
 current can be 
altered by phosphorylation on centain domains of the channel complex. Evidence 
from in vitro phosphorylation studies indicated that both skeletal and cardiac RyRs 
are substrates for serine (S)/threonine (T) protein kinases, such as PKA and CaMKII 
(Takasago et al.,1989; Chu et al.,1990b; Hohenegger & Suko,1993; Suko et 
al.,1993). CaMKII had been found tightly bound to the SR membranes and co-
purifies with RyR through a direct association (Chu et al.,1990b). Subsequent studies 
using site-directed mutagenesis of recombinant RyR2 indicated that CaMKII 
specifically phosphorylates S2815 at RyR2 and results in more active RyR2 channels 
that are sensitized to cytosolic Ca
2+
 (Wehrens et al.,2004; Kushnir et al.,2010). The 
activation of CaMKII requires Ca
2+
 elevation and the interaction with 
Ca
2+
/calmodulin. The elevated Ca
2+
 comes from either Ca
2+
 influx from extracellular 
space, or Ca
2+
 release from intracellular stores (such as the ER and lysosome-related 
acidic compartments). In contrast to CaMKII, PKA interacts with RyR through 
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indirect association via the A kinase anchoring protein (AKAP) (Marx et al.,2000), a 
protein that binds to the leucine/isoleucine zipper domains (3003-3039) of RyR2 
(Marx et al.,2001). The condition of PKA phosphorylation on RyRs is complicated, 
as conflicting results have been yielded by studies on identification of specific PKA 
phosphorylation sites on RyR. Both PKA and CaMKII were initially proposed to 
phosphorylate human RyR2 S2809 (Rodriguez et al.,2003). However, site-directed 
mutagenesis of recombinant RyR2 demonstrated that S2809 of RyR2 and the 
corresponding S2843 at RyR1 are the phosphorylation sites specifically for PKA 
(Witcher et al.,1991; Wehrens et al.,2006). The PKA phosphorylation on RyR2 had 
been demonstrated to activate the channel at least in part by increasing the receptor 
sensitivity to cytosolic Ca
2+
 (Marx et al.,2000). Controversially, while FKBP12.6 
dissociation and depletion in these PKA phosphorylated channels were reported 
(Marx et al.,2000; George et al.,2003), others presented the opposite case (Xiao et 
al.,2004); it has also been proposed that the enhanced channel activity of RyR2 due 
to PKA phosphorylation is independent of FKBP12.6 depletion (Wehrens et 
al.,2003). Moreover, although inhibition of channel activity by dephosphorylation of 
RyRs using protein phosphatase (PP) has been observed in the majority of studies, 
increased channel activity on PP-treated RyRs was also reported (Terentyev et 
al.,2003). Serval explanations have been given for these different observations. It has 
been suggested that the shift from a homeostatic phosphorylation level of RyR due to 
either further phosphorylation or dephosphorylation results in channel activation 
(Carter et al.,2006). In addition, nitrosylation and oxidation of RyR can affect 
FKBP12.6 binding to the channel (Aracena et al.,2005; Zissimopoulos et al.,2007). 
The molar ratio differences of RyR2 and FKBP12.6 also influence the available 
amount of FKBP12.6 bound to the PKA phosphorylated channels (Kushnir & 
Marks,2010). 
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Figure 1.8. Putative Gαs- and Gαq-mediated GPCR activation signalling 
pathways 
 
 
 
Figure 1.8. Putative GPCR-mediated Ca
2+
 release. Stimulation of Gαs-coupled receptors, 
such as βAR and V2, leads to the activation of AC. The subsequent elevation of cAMP results in 
various cellular events via different signalling pathways (left, pink zone): 1). Augmentation of cAMP 
causes PKA phosphorylation; in the regulation of AKAPs, PKA phosphorylates RyRs and leads to 
Ca
2+
 mobilisation; PKA can phosphorylate LTCC to induce Ca
2+
 influx; the increase of PKA activity 
also leads to gene transcription. 2). Independent of PKA activation, cAMP also activates EPAC. 
Cardiac muscle EPAC mediates CICR from RyR via EPAC-PLCξ-PKCξ-CaMKII phosphorylation 
pathway; another downstream effector of EPAC is PLN; phosphorylated PLN promotes SERCA 
activation and Ca
2+
 re-uptake. Signalling pathways initiated by activation of Gαq-coupled receptors, 
such as αAR, AT1R, ETAR and V1, are mediated through PLC activation (right, blue zone): the 
activation of PLC leads to the production of DAG and IP3. 1). IP3 activates IP3R channel and mediates 
Ca
2+
 mobilisation; Ca
2+
 can stimulate RyR channel directly through the CICR mechanism; 2). DAG 
can phosphorylate TRPC causing Ca
2+
 influx; DAG can also activate PKC; leading to CaMKII 
activation, which subsequently phosphorylates RyR in the presence of Ca
2+
; PKC also triggers 
ERK1/2 signalling cascade; the activation of both CaMKII and ERK1/2 leads to gene transcription.  
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1.9 Nitric Oxide-induced Ca
2+
 Mobilisation 
 
Nitric oxide (NO) has been recognised as a regulator of multiple functions in 
the placenta. For example, the endogenous production of NO by placenta is essential 
for vascular tone maintainance during pregnancy (Poston,1997; Lopez-Jaramillo et 
al.,2008); in extravillous trophoblasts (EVT), NO has been shown to participate in 
decidual and myometrial invasion (Lyall et al.,1999); NO has been demonstrated to 
influence the release of corticotrophin-releasing hormone (CRH) and human 
chorionic gonadotropin hormone (hCG) (Ni et al.,1997; Rossmanith et al.,1999); 
moreover, NO also stimulates glucose uptake in the placenta via an insulin-
independent mechanism (Acevedo et al.,2005). Decreased bioactivity and serum 
level of NO are thought to be associated with preeclampsia (PE), in which shallow 
trophoblast invasion of maternal spiral arteries in early gestation contributes to the 
development of a relatively hypoxic placenta in later gestation (Gilbert et al.,2008).  
The NO molecule is synthesized by the NO synthase (NOS) from the amino 
acid L-arginine. The NOS substrate L-arginine can be transported into the placenta 
by cationic amino acid transportors CAT1 and CAT4 (Ayuk et al.,2000). On the 
other hand, NOS also catalyses the production of the reactive oxygen species (ROS) 
superoxide (O2
-
) when substrate and/or cofactor (tetrahydrobiopterin (BH4)) levels 
are insufficient for NO synthesis. Superoxide can be metabolised by superoxide 
dismutase (SOD). However, the presence of NO results in the formation of a 
powerful oxidant peroxynitrite (ONO2
-
), as the two free radicals (NO + O2
-
 -> ONO2
-
) 
react. The resulting product peroxynitrite competes with superoxide for SOD 
detoxification. The formation of superoxide, therefore, depletes the available NO in 
the placenta, as reviewed by Myatt (Myatt,2010). The elevated levels of superoxide 
and peroxynitrite, hence, contribute to the decrease in NO bioactivity which is 
generally associated with endothelial dysfunction, vasoconstriction and reduced 
trophoblast invasion in PE (Gilbert et al.,2008).   
The activities of both endothelial (e) and inducible (i) NOS isoforms have 
been characterised in trophoblast populations (Eis et al.,1995; Lyall et al.,1998; 
Baylis et al.,1999; Schiessl et al.,2005). The Ca
2+
/CaM-dependent isoform eNOS is 
expressed in the syncytiotrophoblast (SCT) throughout pregnancy; and also 
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expressed in endothelium within the primitive villous capillaries during human early 
and mid gestation (Rossmanith et al.,1999); both eNOS and iNOS (the Ca
2+
/CaM-
independent isoform), are expressed in intermediate and EVT of human first 
trimester placenta (Ariel et al.,1998; Rossmanith et al.,1999). In addition, the iNOS 
activity increases throughout pregnancy and peaks at mid gestation, as reviewed by 
Krause et al. (Krause et al.,2011). The precise mechanism of placental eNOS 
activation is not fully established yet. However, study in eNOS knockout mice 
suggests that signalling molecules of MAPK and phosphoinositide-3-kinase (PI3K)-
Akt signaling system play a crucial role in the initial phosphorylation and activation 
of eNOS (Connelly et al.,2005). In addition, the eNOS trafficking inducer 
(NOSTRIN) which is involved in eNOS intracellular trafficking between cellular 
compartments, has been suggested to facilitate eNOS endocytosis in coordination 
with dynamin and neural Wiskott-Aldrich syndrome protein (N-WASP) (Icking et 
al.,2005). The N-WASP is involved in the formation of actin tails that propel 
pathogens and endogenous vesicles through the cytoplasm (Fehrenbacher et al.,2003). 
One of the immediate downstream effectors of NO in the NO-induced 
signalling pathway is guanylate cyclase (GC). In human placenta, the cytoplasmic 
soluble form of GC (sGC) has been identified in SCT and villous trophoblast and 
umbilical blood vessels, sites of where NO is produced (Bamberger et al.,2001). As 
Figure 1.9 illustrates: the activation of GC initiates the elevation of intracellular 
cyclic guanosine monophosphate (cGMP) concentration (Murad,1994). Studies in 
sea urchin eggs demonstrated that NO stimulates cGMP production via GC 
activation, followed by the activation of cGMP-dependent kinase (PKG); the 
activated PKG is then phosphorylated and activates ADP-ribosyl cyclase (ADPR 
cyclase), which in turn produces cyclic ADP-ribose (cADPR) and/or nicotinic acid 
adenine dinucleotide phosphate (NAADP) (Lee et al.,1989). Both cADPR and 
NAADP are Ca
2+
 mobilising nucleotides that release Ca
2+
 from internal stores in a 
wide variety of cells from protist and plant to human, as reviewed by Lee (Lee,1997; 
Lee,2000b). The cyclic nucleotide cADPR is derived from nicotinamide adenine 
dinucleotide (NAD), while NAADP is a metabolite of nicotinamide adenine 
dinucleotide phosphate (NADP) (Lee,1997). Despite the structural and functional 
difference between cADPR and NAADP, both products are synthesised by the same 
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class of enzymes. Among these enzymes, ADPR cyclase and its homolog CD38 
(cluster of differentiation 38) are the most well characterised. The CD38 is a 
mammalian antigen that can be found in a variety of tissues, present on membranes 
of both cell surfaces and intracellular organelles (Aarhus et al.,1995). The cyclisation 
of NAD by CD38 occurs optimally at physiological pH to produce cADPR, while the 
base-exchange reaction of the nicotinamide group in NADP with nicotinic acid by 
CD38 can only be achieved in acidic pH to produce NAADP, as reviewed by Lee 
(Lee,1997).  
Both cADPR and NAADP are known as the second messengers for 
intracellular Ca
2+
 mobilisation. The NAADP targets the two-pore channels (TPCs), 
the members of the superfamily of voltage-gated channels expressed in the 
lysosomes, the acidic stores often found in close proximity to the ER/SR (Ishibashi et 
al.,2000; Churchill et al.,2002; Kinnear et al.,2004; Calcraft et al.,2009). Direct 
NAADP-dependent current measurements indicate that TPC in the lysosomes are 
permeable to Ca
2+
; such Ca
2+
 permeability of TPC (TPC2) induced by NAADP is 
over 1000-fold more selective than K
+
 under acidic intralysosomal pH (Pitt et 
al.,2010); the TPC single channel Ca
2+
 conductance is ~15 pS, which is about 4 and 
8 times less than that measured in IP3R and RyR, respectively (Schieder et al.,2010). 
In addition, immunopurified TPC1 and TPC2 from urchin eggs have been 
demonstrated to mediate NAADP-induced Ca
2+
 release in transfected HEK293 cells; 
of which, activation of TPC2 is more tightly coupled to subsequent IP3R-mediated 
Ca
2+
 release; activation of TPC3, in contrast, suppresses NAADP-induced Ca
2+
 
release; increased expression of either type of TPC affects endolysosmal strutures 
and dynamics (Ruas et al.,2010). The authors proposed that NAADP regulates the 
endolysosomal Ca
2+
 store via TPCs and subsequently affect ER Ca
2+
 release that may 
have impacts on Ca
2+
 signalling in health and disease (Lloyd-Evans et al.,2008; Ruas 
et al.,2010).  
The ER Ca
2+
 channel RyR is generally accepted as the target for cADPR-
induced Ca
2+
 release. It has been demonstrated that cADPR in nanomolar 
concentration enhances the RyR-mediated CICR mechanism in sea urchin eggs 
(Galione et al.,1991). As the RyR protein possesses binding sites for adenine 
nucleotide, such as ATP and ADP diadenosine compounds (Smith et al.,1985), these 
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compounds therefore, potentially compete the same binding sites with cADPR. In 
addition, experimentation has shown that cADPR pharmacologically behaves as a 
partial agonist of RyR (Sitsapesan et al.,1994). The exact mechanism by which 
cADPR induces RyR-mediated Ca
2+
 release is still unclear. However, evidence has 
shown that the action of cADPR on RyR requires associate proteins such as FKBPs, 
CaM and CaMII, as reviewed by Lee (Lee,2011) and Venturi (Venturi et al.,2012). 
Apart from RyR, cADPR can also paradoxically induce Ca
2+
 influx via the plasma 
membrane channel TRPM2 in certain cells such as neutrophils and pancreatic β-cells 
(Partida-Sánchez et al.,2001; Togashi et al.,2006). This TRPM2 channel belongs to 
the M-family of TRPCs. In addition, the physiological consequence of cADPR-
dependent Ca
2+
 influx via TRPM2 has been revealed in several studies. For instance, 
cADPR-induced Ca
2+
 influx has been demonstrated to stimulate secretion of insulin 
and oxytocin from pancreatic islets and neuronal cells, respectively (Togashi et 
al.,2006; Jin et al.,2007); in human bone marrow mesenchymal stem cells, such 
cADPR-TRPM2 signals increase the frequency of Ca
2+
 oscillations and result in 
enhanced cell proliferation (Scarfì et al.,2008; Tao et al.,2011). 
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Figure 1.9 Putative NO-induced Ca
2+
 signalling pathways 
 
 
 
 
 
 
 
Figure 1.9. Possible signalling pathways trigger Ca
2+
 mobilisation initiated by nitric 
oxide synthesis. The substrate L-arginine enters the cell via cationic transporter CaT1 or CaT4. L-
arginine is then converted to nitric oxide (NO) by nitric oxide synthase (NOS); NO activates soluble 
guanylate cyclase (GC) and produces intracellular cyclic guanosine monophosphate (cGMP) 
(Murad,1994). Elevated cGMP activates cGMP-dependent kinase (PKG) and phosphorylates ADP-
ribosyl cyclase (ADPR cyclase); activated ADPR cyclase in turn produces cyclic ADP-ribose (cADPR) 
and/or nicotinic acid adenine dinucleotide phosphate (NAADP) (Lee et al.,1989). NAADP binds to 
the lysosmal two-pore channel (TPC) to release Ca
2+
, which subsequently results in CICR possibly via 
endoplasmic RyR and/or IP3R (Lee,1997). The cADPR activates on ER Ca
2+
 releasing channel RyR 
and M2 TRP (TRPM2) in certain cell types to induce Ca
2+
 release and Ca
2+
 influx, respectively, as 
reviewed by Lee (Lee,2011). 
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1.10 Ca
2+
 in Human Placenta  
 
Ionised intracellular free calcium is a universal signalling ion. Free [Ca
2+
]i in 
resting cells is about 100 nM; elevated cytosolic Ca
2+
 is a known trigger of various 
cellular events, such as gene transcription, cell proliferation, differentiation, 
apoptosis and necrosis (Berridge et al.,2000). The versatility of Ca
2+
 signalling is 
highly regulated; the control of [Ca
2+
]i is governed by a sophisticated functional 
coordination among a wide range of Ca
2+
-related proteins, which include Ca
2+
 pumps, 
Ca
2+
 channels, Ca
2+
 transporters/exchangers  and Ca
2+
 binding proteins.  
The elevated cytosolic Ca
2+
 level as a cellular signal is derived either from 
internal stores or from the external medium. The release of Ca
2+
 from the ER/SR via 
RyRs or IP3Rs is regulated by various endogenous factors, such as cADPR and IP3, 
respectively (Furuichi et al.,1989; Lee et al.,1989; Berridge,1993). In addition, Ca
2+
 
mobilisation has also been demonstrated from lysosome-related acidic compartments 
by NAADP (Churchill et al.,2002; Yamasaki et al.,2004), and such Ca
2+
 release is 
mediated by the TPCs that comprise a family of the NAADP receptors (Calcraft et 
al.,2009). Both RyR and IP3R respond to cellular signalling molecules that transduce 
extracellular stimuli via activation of different plasma membrane receptors/channels 
(Berridge et al.,2003). In the placenta, these Ca
2+
 signalling processes usually 
involve activation of different protein kinases and G-protein-coupled receptors 
(GPCR) (Baczyk et al.,2011). Figure 1.10.1 summarises the putative signalling 
pathways initiated by GPCR activation, indicating the possible movement of calcium 
ions. It has been demonstrated that elevated [Ca
2+
]i is a trigger of extravillous 
trophoblast (EVT) migration as a result of external stimulation by endothelin 1 (ET1) 
or prostaglandin E2 (PGE2) (Chakraborty et al.,2003; Nicola et al.,2005a). Both the 
prostaglandin E receptor 1 (EP1) and endothelin receptors (ETA and ETB) are GPCRs 
for PGE2 and ET1, respectively. The EP1 receptor is a Gq-coupled GPCR that is 
known to activate the phospholipase C (PLC) that causes accumulation of IP3 which 
subsequently activates IP3-sensitive receptors (IP3R) in the ER membrane. Opening 
of IP3 receptor channels leads to rise of [Ca
2+
]i. It has been demonstrated that such 
rise in intracellular Ca
2+
 has a crucial role in the migration of first trimester human 
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EVT (Nicola et al.,2005a). In the EVT cell line HTR8/svneo, stimulation of ETA and 
ETB by ET1 results in the activation of Gq-dependent but Gi-independent mitogen-
activated protein kinase (MAPK) cascades, also known as extracellular signal 
regulated protein kinases cascades (ERK1/2). These signalling events involve 
activation of PLC and the subsequent production of IP3 and DAG (Chakraborty et 
al.,2003). Both IP3 and DAG are important second messenger molecules. The former 
activates IP3R in the ER and causes the initial rise of [Ca
2+
]i; while the following 
sustained plateau is gained from the external entry via non-selective cation channels 
(NSCC) and store-operated Ca
2+
 channels (SOCC) (Chakraborty et al.,2003). On the 
other hand, DAG is involved in the activation of Ca
2+
-dependent protein kinase 
(PKC) activated MAPK signaling pathways (Gill et al.,1989). In BeWo cells, 
activation of MAPK signaling pathway (ERK1/2 and p38 MAPK) by forskolin 
stimulation is involved in cell fusion (Delidaki et al.,2011). In cultured primary 
human cytotrophoblasts (CT), spontaneous differentiation and fusion occurs; and the 
formation of syncytiotrophoblast (SCT) displays a positive correlation with Ca
2+
 
uptake and up-regulation of Ca
2+
 channel expression (Niger et al.,2004). In addition 
to cell migration and cell differentiation, intracellular Ca
2+
 signaling in trophoblasts 
also participates in cell proliferation, as reviewed by Baczyk et al. (Baczyk et 
al.,2011).  
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Figure 1.10.1 Putative signaling pathways in placental trophoblast initiated by 
GPCR activation 
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Figure 1.10.1. Two putative GPCR-initiated signalling pathways within placental 
trophoblast. As illustrated: (1) the cAMP-dependent Gs-mediated pathway; and (2) the Ca
2+
-
dependent Gq-mediated pathway. Green bold arrows indicate the movement of Ca
2+
: free Ca
2+
 from 
maternal circulation enters the brush border membrane (BBM) via various apical membrane 
receptor/channel proteins of placental trophoblastic cell, e.g. Ca
2+
 transporter proteins (CaT), voltage 
gated Ca
2+
 channels (VGCC) and transient receptor potential (TRP)-related /‘transient receptor 
potential vanilloid’ (TRPV) Ca
2+
 channels. Free Ca
2+
 entering the cytoplasm is speedily and actively 
compartmentalised and stored in organelles such as the ER by sarcoendoplasmic reticulum Ca
2+
-
ATPase pumps (SERCA); meanwhile, Ca
2+
 can also be buffered immediately by a variety of Ca
2+
 
binding proteins (CaBPs). Protein bound Ca
2+
 is divided in two groups depending on which CaBPs are 
bound. For example, CaBP67k, oncomodulin, and S100 bound Ca
2+
 leads to cell differentiation, 
proliferation and cell cycle regulation; while CaBP9k, CaBP28k and CaBP57k bound Ca
2+
 is shuttled 
for Ca
2+
 extrusion at the basal plasma membrane (BPM). Compartmentalised Ca
2+
 can also be 
released from the ER mediated by activation of IP3Rs or RyRs, which can be phosphorylated by 
CaMKII, PKC and/or PKA; internally released Ca
2+
 along with protein bound Ca
2+
 at positions close 
to the plasma membrane Ca
2+
-ATPase (PMCA) and/or Na
+
/Ca
2+
 exchanger (NCX) at the BPM can be 
extruded and transferred to the fetal circulation. 
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A functional placenta is crucial to successful pregnancy. During the 
formation of placenta, Ca
2+
 signalling plays a key role throughout blastocyst 
implantation and trophoblast cell differentiation (Baczyk et al.,2011). More 
importantly, Ca
2+
 and Ca
2+
 maternal-fetal transport are vital for fetal development 
(Lafond et al.,2001). The human placenta transfers up to 30 g of Ca
2+
 during 
pregnancy; particularly, from week 28 of pregnancy: the third trimester, the weight 
of the fetus triples and the Ca
2+
 transport quadruples to about 140 mg/kg/d for 
mineralization of the fetal skeleton (Salle et al.,1987). In the plasma, about 40% 
calcium is protein-bound (mainly albumin) form; approximately 10% forms 
complexes with other negatively charged molecules such as bicarbonate; the 
remaining calcium population is regarded as ionised free Ca
2+
 (Husain & 
Mughal,1992). Calcium in both ionised and ion complex forms are ultrafilterable: the 
forms of calcium that can be utilised by the body. The concentration of ultrafilterable 
calcium in the fetal circulation (2.65 ± 0.19 mM, ionised free Ca
2+
 1.41 ± 0.09 mM) 
is higher than in the maternal circulation (2.13 ± 0.15 mM, ionised free Ca
2+
 1.12 ± 
0.06 mM) (Schauberger & Pitkin,1979). Such hypercalcemic status of fetal calcium 
homeostasis is maintained by the parathyroid hormone-related peptide (PTHrP), an 
oncofetal hormone produced from early gestation until term (Senior et al.,1991). In 
contrast to plasma [Ca
2+
], cytosolic free [Ca
2+
] of SCT is maintained as low as 40 nM 
(Husain & Mughal,1992). These observations suggest the passive Ca
2+
 entry from 
maternal circulation via microvillous membrane of SCT is speedily buffered and 
compartmentalised without causing unwanted [Ca
2+
]i fluctuations in placental 
trophoblast.  
The delivery of Ca
2+
 ions from maternal circulation into the fetal circulation 
is initially facilitated by a variety of active Ca
2+
 transporters expressed in the brush 
border membrane (BBM) of trophoblasts. Figure 1.10.2 summarises the putative 
transepithelial Ca
2+
 transport through trophoblast. As reviewed by Belkacemi et al., 
Ca
2+
 entry through the BBM of SCT involves activation of Ca
2+
 transporter proteins 
(CaT); voltage dependent Ca
2+
 channels (VDCC) eg. L-type, T-type VDCC, and 
transient receptor potential (TRP)-related Ca
2+
 channels/‘transient receptor potential 
vanilloid’ (TRPV), such as TRPV5 and TRPV6; Ca
2+
 entering via these protein 
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channels can be actively transported into the ER by sarcoendoplasmic reticulum 
Ca
2+
-ATPase pumps (SERCA), or can bind to Ca
2+
-binding proteins such as 
calbindins (CaBPs) CaBP9k, CaBP28k and CaBP57k (Belkacemi et al.,2002); Ca
2+
 
extrusion at the basal plasma membrane (BPM) is carried out by plasma membrane 
Ca
2+
-ATPase (PMCA) and likely in parallel with Na
+
/Ca
2+
 exchanger (NCX) 
(Kamath & Smith,1994; Belkacemi et al.,2005). At these extrusion venues, free Ca
2+
 
ions are delivered trans-trophoblasticaly into the fetal circulation.  
It has been demonstrated that SERCA in the ER functions together with NCX 
and PMCA in series for the removal of cytosolic free Ca
2+
 in isolated rabbit aortic 
endothelial cells (Wang et al.,2002). The same research group has also suggested that 
endothelial Ca
2+
 removal/transport is through serial actions of Ca
2+
 active uptake by 
SERCA, then release by RyR, and finally extrusion by NCX and PMCA (Liang et 
al.,2004). This study indicates close functional proximity of RyR and both NCX and 
PMCA; the authors also emphasised that only RyRs but not IP3Rs are involved in 
Ca
2+
 extrusion in these cells (Liang et al.,2004). These observations suggesting RyR 
plays a potential role in Ca
2+
 transcellular transport in trophosphoblasts. A more 
recent study by Haché and collegues reported that Ca
2+
 transport by SCT is disturbed 
in preeclampsia (PE), a condition in which high blood pressure and high level of 
protein in urine develop after week 20 of pregnancy (Haché et al.,2011). This study 
demonstated the expression of BPM plasma membrane PMCAs were downregulated 
together with both TRPV5 and TRPV6 Ca
2+
 channels in the BBM and cytosolic 
CaBPs CaBP9k and CaBP28k. These results suggest low efficiency of Ca
2+
 transport 
at both BBM and BPM. In contrast mRNA levels of SERCA were upregulated, while 
of RyRs and IP3Rs mRNAs were downregulated in this pathlogical condition (Haché 
et al.,2011). The authors proposed this alteration is an adaptation of avoiding Ca
2+
 
overload from internal stores. The entry of Ca
2+
 may be partially compartmentalised 
into the ER in addition to Ca
2+
 transport by CaBP buffering. As indicated in Figure 
1.10.2, it is possible that Ca
2+
 can be actively transported into the ER by SERCA and 
released via Ca
2+
 release channels, the RyRs or IP3Rs, in addition to Ca
2+
 transport 
by CaBP shuttling. 
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Figure 1.10.2 Putative Ca
2+
 trans-trophoblast transport pathways 
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Figure 1.10.2. Putative Ca
2+
 trans-trophoblast transport. Bold arrows indicate the 
possible pathways of Ca
2+
 movement in placental trophoblast, while the dotted arrow indicates the 
overall Ca
2+
 movement from maternal circulation to fetal circulation is against its concentration 
gradient. Free Ca
2+
 enters the brush border membrane (BBM) via various apical membrane 
receptor/channel proteins of placental trophoblastic cell, eg. transient receptor potential (TRP)-related 
Ca
2+
 channels/‘transient receptor potential vanilloid’ (TRPV) and the voltage gated Ca
2+
 channels 
(VGCC: eg. L-type, T-type). Free Ca
2+
 is speedily and actively compartmentalised and stored in 
organelles such as the ER by sarcoendoplasmic reticulum Ca
2+
-ATPase pumps (SERCA); Ca
2+
 can 
also be buffered immediately by a variety of Ca
2+
 binding proteins (CaBPs). CaBP67k, oncomodulin, 
and S100 bound Ca
2+
 is involved in cell differentiation, proliferation and cell cycle regulation; while 
CaBP9k, CaBP28k and CaBP57k bound Ca
2+
 is shuttled for Ca
2+
 extrusion at the basal plasma 
membrane (BPM). Compartmentalised Ca
2+
 could also be released from ER via RyRs or IP3Rs that 
are in close apposition to plasma membrane Ca
2+
-ATPase (PMCA) and/or Na
+
/Ca
2+
 exchanger (NCX) 
at the BPM, where protein bound Ca
2+
 is released and extruded. Therefore, the transfer of Ca
2+
 is 
completed actively from the maternal to the fetal circulation. 
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1.11 Formation of Placenta 
 
Trophoblasts are epithelial cells forming the peripheral part of the human 
conceptus. These cells are derived from the blastocyst cytotrophoblast layer of the 
embryo and regarded as the precursor cells of the human placenta. Trophoblasts 
initially present as an outer layer of cells of the blastocyst, which can be found as 
early as from the third day of fertilization. The formation of a functional human 
placenta relies on trophoblast proliferation and differentiation. The sequential 
regulation of placental trophoblast development is crucial for successful pregnancy. 
A fully developed human placenta is an haemochorial villous organ (Gude et 
al.,2004), in which maternal blood is intimately in contact with the placental 
trophoblast, delivering nutrients and essential elements from the maternal side, 
meanwhile removing waste products from the blood circulation of fetus. The 
placenta is also a barrier that protects the fetus from immune attack from the 
maternal side. Apart from these protection and transportation functions, the placenta 
also generates hormones that are essential for the fetal development (Knobil & 
Neill,1998). 
The ovum is fertilized within the fallopian tube. After three days 
development, the germ cell forms a blastocyst that arrives at the uterus cavity (Figure 
1.11.1.A). The blastocyst is composed of two groups of cells: the inner cell mass 
which will develop into the fetus, and the outer trophoblasts which are a determinant 
for the process of blastocyst implantation and the subsequent development of the 
human placenta (Knobil & Neill,1998), as Figure 1.11.1.B illustrates trophoblast 
invasion starts by pentrating the uterine epithelium. Trophoblasts start generating 
human chorionic gonadotropin (hCG) after fertilization. The release of this signalling 
hormone increases the receptivity of uterus to the implanting embryo. Blastocyst 
implantation is a complicated process relying on communication between embryo 
and uterus. The trophoblasts are naturally invasive; but the uterine wall is usually 
covered by a thick layer of mucin and transmembrane glycoproteins which prevent 
blastocyst attachment and trophoblast invasion. However, the receptivity of 
endometrial surface to trophoblast invasion can be altered in a restricted period 
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termed the “window of receptivity” (Lunghi et al.,2007). In this particular period of 
the menstrual cycle (usually days 20-24) (Salamonsen et al.,2003), the endometrial 
surface is modified by estrogen and progesterone to prepare for blastocyst 
implantation (Gude et al.,2004). These hormones regulate the secretion of locally 
acting factors such as growth factors, chemokines, cytokines and adhesion molecules 
of the endometrium (Hoover,2004). These locally acting factors provide a docking 
site for the embryo attachment, and also limit the trophoblast invasion to a specific 
area rather than to anywhere over the uterus. Secretion of hCG together with the 
endometrial surface modification therefore, facilitate the docking of the floating 
blastocyst into the uterus.  
The zona pellucida, as illustrated in Figure 1.11.1.A, the ‘red coat’ 
surrounding the cell complex, disappears before the blastocyst attaches to the 
endometrial epithelium (Gude et al.,2004; Sadler,2006a). Once the embryo 
successfully docks into the endometrium, the trophoblasts of the blastocyst 
proliferate rapidly and differentiate into an inner mononuclear cytotrophoblast and an 
outer multinucleated syncytiotrophoblastic mass which continuously invades into the 
endometrial epithelium and connective tissues. Twelve days after fertilization, as 
illustrated in Figure 1.11.2.A, these invasive trophoblasts penetrate the maternal 
blood vessels and start forming new branches of vessels in terms of 
‘intertrophoblastic maternal blood filled sinuses’(maternal sinusoids, Figure 1.11.2.A) 
to support the growth of fetus and placenta (Knobil & Neill,1998; Sadler,2006b). 
Therefore, a primitive uteroplacental circulation is formed by the end of second week 
of fertilization. Meanwhile, cytotrophoblastic cell columns are formed as the non-
vascular primary chorionic villi that penetrate into the syncytium (Sadler,2006b). 
Three weeks after fertilization, the embryo starts generating its own circulatory 
system. This process begins with migration of mesodermal cells to the primary villi 
core towards the decidua. Mesodermal cells in the core of the villus are then 
differentiated into hematopoietic cells and small blood vessels to form the villous 
carpillary system, the intraembryonic circulatory system that connecting the placenta 
and embryo (Doetschman et al.,1985). The longitudinal villus section in Figure 
1.11.2.B shows the formation of capillaries within the mesoderm core of chorionic 
villi, the tertiary villus. There vessels are part of the intraembryonic circulatory 
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system that connecting the placenta and the fetus; the development of these villous 
capillary system is essential for future delivery of nutrients and gas exchange in the 
placenta (Sadler,2006c). The embryonic tissue and maternal blood are separated by a 
layer of cytotrophoblasts and syncytiotrophoblasts. At week 4, the basic structure of 
the placenta is formed; the chorionic villi adjacent to the maternal blood supply 
continuously expanding into a mass of chorionic tissue as the placenta matures; the 
villi gradually degenerating to form the chorionic layer of the external membranes 
(Knobil & Neill,1998). At about week 20, the amnion-chorion membrane reaches the 
opposite side of the uterus and fuses with the decidualized maternal endometrium, 
and the full external membrane (consisting of amnion, chorion and decidua layers) is 
formed. 
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Figure 1.11.1 Development of germ cell and implantation of blastocyst. 
 
 
Figure 1.11.1. Schematic representation of the development of germ cell and 
implantation of blastocyst. These figures are adapted from Sadler (Sadler,2006a). A. The fertilized 
ovum (germ cell) travels from the fallopian tube to the uterus cavity; meanwhile it has gone through a 
series of cleavages. As from Day 4, the germ cell develops into the morula stage and undergoes 
compaction to form a blastocyst. The blastocyst is composed of inner cell mass and outer trophoblast 
cell layer. The zona pellucida (the ‘red coat’) surrounding the blastocyst disappears at about Day 5. 
On about Day 6, the blastocyst docks into the uterine endometrium and starts implantation 
(Sadler,2006a). B. Schematic illustration of trophoblast invasion. Ourter trophoblast cells of blastocyst 
are penetrating the uterine epithelium. This marks the initiation of blastocyst implantation. 
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Figure 1.11.2 Post-implantation development of blastocyst and formation of 
chorionic villi. 
 
 
 
 
 
 
Figure 1.11.2. Post-implantation development of blastocyst. These figures are adapted 
from Sadler. A (Sadler,2006b; Sadler,2006c). A. Illustration of human blastocyst on about Day 12. 
Invading trophoblasts penetrate the maternal blood vessels and form maternal sinusoids; this marks 
the formation of uteroplacental circulation that maternal blood is delivered for placenta development 
and fetus growth (Sadler,2006b). B. Illustration of longitudinal section of villus at the end of the third 
week development. Villous capillary system is surrounded by maternal vessels that penetrate the 
cytotrophoblastic shell and fill in the intervillous spaces. These capillary vessels are connecting to the 
connecting stalk in the chorionic plate, which in turn are connected to intraembryonic vessels 
(Sadler,2006c).  
 
A. 
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B. 
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1.12 Differentiation of Trophoblasts 
 
Once implantation is successful and placentation is initiated, trophoblasts 
undergo rapid proliferation and differentiation (Gude et al.,2004). Primary blastocyst 
trophoblasts sequentially differentiate into the villous and extravillous trophoblasts 
during blastocyst implantation (Lunghi et al.,2007). Around day 13 of pregnancy, the 
cytotrophoblast cells form columns of extravillous cytrophoblast cells by penetrating 
the syncytiotrophoblast layer that surrounding the conceptus. The extravillous 
trophoblast column shell forms the interface of the feto-maternal compartments 
(Boyd & Hamilton,1970; Aplin,1991). These extravillous trophoblast cells can 
invade into the decidua and modify the uterine arteries. Uterine artery modification 
results in dilated and compliant uterine arterioles, which subsequently lead to 
increased placental blood supply from the maternal blood (Gude et al.,2004). On the 
other hand, extravillous cytotrophoblast cells also invade interstitially. These 
interstitial trophoblasts facilitate the placental expansion in size and also promote 
recruitment of maternal arterioles. By week 8 of pregnancy, the interstitial 
trophoblasts form a multinucleated placental bed of giant cells and invade deeper 
into the decidua (Boyd & Hamilton,1970; Aplin,1991). This morphology of the 
interstitial trophoblasts is thought to be the differentiation end-point of the 
extravillous cytotrophoblasts (Gude et al.,2004). 
Another differentiation pathway of cytotrophoblasts is towards to the 
formation of syncytiotrophoblasts. The non-migratory cytotrophoblasts proliferate, 
differentiate and fuse to form villous syncytiotrophoblasts, the barrier of cells that 
function as sites for material transport between fetus and maternal sides, which also 
act as endocrine secretion sites of the placenta. Villous syncytiotrophoblast cells 
generate most placental hormones. The best characterised of these is the hCG, the 
hormone that crucial to successful pregnancy. In addition, hCG is the diagnostic 
marker of pregnancy, as it is secreted and can be detected from the early conceptus 
(Knobil & Neill,1998). 
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1.13 Aims of Study 
 
The crucial roles of Ca
2+
 and Ca
2+
 signalling during placenta formation in 
process of blastocyst implantation and trophoblast differentiation, and during 
pregnancy in terms of fetal skeleton mineralisation have been reviewed (Husain & 
Mughal,1992; Baczyk et al.,2011). The association of Ca
2+
 transport disturbance has 
been proposed as a pathological condition of pregnancy-related disease such as PE 
(Haché et al.,2011). The discovery of channels for Ca
2+
 entry (L-type and CaT) and 
proteins for Ca
2+
 extrusion (PMCAs and NCXs) in human trophoblasts (Moreau et 
al.,2003b), in addition to the finding of multiple CaBPs in the placenta as reviewed 
by Belkacemi et al. (Belkacemi et al.,2002), lead to the proposal that placental Ca
2+
 
transepthelial transport can be achieved by the effect of trophoblastic CaBPs on Ca
2+
 
buffering and Ca
2+
 shuttling. However, placental Ca
2+
 signalling is not fully 
understood and the mechanism of Ca
2+
 trans-trophoblastic transport is still unclear. 
Particularly, the pathway of passive Ca
2+ 
entry that undergoes compartmentalisation 
into ER or mitochondria before delivery to fetal circulation has not been investigated. 
Although the expression of Ca
2+
 ATPase (Belkacemi et al.,2005), and only recently 
mRNA of Ca
2+
 release channels (RyRs and IP3Rs) of ER had been confirmed in 
human placenta (Haché et al.,2011), there is no direct information concerning how 
these Ca
2+
-related proteins of the ER membrane might be involved in placental Ca
2+
 
signalling and Ca
2+
 trans-trophoblastic transport.  
It is clear that the in vivo examination of human placental trophoblast is not a 
viable approach. Different trophoblastic cells have been isolated from placental 
tissue for in vitro studies. However, limits in cell mass and passages are often 
associated with these materials, especially when first trimester placentae are used 
(Huch et al.,1998). Choriocarcinomas are the malignant counterpart of the 
trophoblast which share a number of characteristics of early placental trophoblasts in 
terms of placental hormone production and the ability to differentiate into 
syncytiotrophoblast-like cells in vitro (Pattillo et al.,1971; Friedman & Skehan,1979). 
Since human choriocarcinoma cell lines possess many similarities to normal human 
trophoblasts, these cell lines are considered as models for research of early stages of 
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implantation in humans. For instance, BeWo cells originate from a malignant 
gestational choriocarcinoma of the foetal placenta; this cell line was also the first 
human trophoblastic endocrine cell type to be maintained in continuous culture. 
BeWo cells have been demonstrated to be heterogeneous, consisting of predominant 
(96 to 99%) proliferative mononucleate cytotrophoblast-like cells, and the non-
proliferative syncytiotrophoblast-like multinucleate giant cells as the remaining cell 
population (Friedman & Skehan,1979; Grümmer et al.,1990; Aplin,1991). JEG-3 
choriocarcinoma was derived from a cerebral metastasis of BeWo cells transplanted 
into the cheek pouch of the hamster (Pattillo & Gey,1968). JEG-3 cells form 
multinucleated syncytia in culture, similar to the syncytiotrophoblast in vivo 
(Babalola et al.,1990). Moreover, JEG-3 has the same DNA profile as BeWo; the 
former was established by serial cloning of the latter. Both BeWo and JEG-3 cells 
produce 17-β-estradiol and β-hCG; while JAR cells, another choriocarcinoma cell 
line, produces progesterone and β-hCG (Grümmer et al.,1994). In addition, JAR cells 
were also demonstrated to differentiate into syncytiotrophoblast-like cells (Grümmer 
et al.,1994). 
In human model trophoblast cell line BeWo, the presence of specific binding 
sites for fluorescent BODIPY-FLX-ryanodine was discovered, and the rise of [Ca
2+
]i 
in response to ryanodine in these cells was also observed (Mackrill, unpublished 
observations). These two novel findings lead to the proposal of the possible 
involvement of RyRs in Ca
2+
 trans-trophoblast transport, based on the demonstration 
of RyR involvement in vectorial Ca
2+
 transcellular transport in another epithelial cell 
type. As Liang and colleagues proposed, RyR in series mediates Ca
2+
 efflux from ER 
in close proximity to where NCX is located in the plasma membrane of isolated 
rabbit aortic endothelial cells; PMCA in addition, likely in parallel with NCX, could 
facilitate Ca
2+
 removal (Liang et al.,2004). As mentioned in Section 1.8, Ca
2+
 
‘removal’ from placental trophoblasts is crucial for both maternal-fetal Ca
2+
 delivery 
and placental function during pregnancy. Dysregulated Ca
2+
 signalling and/or 
disturbed Ca
2+
 homeostasis of trophoblastic cells is associated with pathological 
conditions such as intrauterine growth restriction (IUGR), maternal diabetes and fetal 
hypocalcaemia (Regnault et al.,2002; Strid et al.,2003). Therefore, investigation of 
trophoblastic Ca
2+
 signalling and Ca
2+
 transport has direct impacts in maternal and 
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fetal health research, leading to dentification of potential targets for therapeutic 
interventions for certain pregnancy-related diseases (Moreau et al.,2003b; Belkacemi 
et al.,2005). In this aspect, the roles of RyRs in Ca
2+
 homeostasis are drawn into 
attention; understanding how these Ca
2+
 channel proteins function in trophoblast 
could lead to the discovery of alternative therapeutic strategies in Ca
2+
-related 
pregnancy pathologies. Thereby, the objectives of this present study were to: (i) 
establish the expression of RyRs in human placental trophoblast and in model 
trophoblast cell lines; (ii) examine the expression of accessory proteins of RyR in 
both human cell lines and human tissues; (iii) investigate trophoblast RyR function 
by pharmacological stimulation and inhibition.  
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Chapter II.  Materials and Methods 
 
 
 
2.1 Materials 
 
Cell culture media and antibodies were obtained from Sigma-Aldrich, Poole, 
UK, unless stated elsewhere; animal sera were from Biowest Ltd., Ringmer, UK. 
General laboratory chemicals of analaytical reagent grade or better were obtained 
from Sigma or Calbiochem-Novabiochem Ltd., Nottingham, UK. The BeWo, JAR, 
and JEG-3 cell lines were obtained from European Collection of Animal Cell 
Cultures (ECACC) Salisbury, UK. SGHPL-4 cells were originally derived from 
primary extravillous trophoblasts, formerly known as MC4 (Choy & 
Manyonda,1998).  
All immunohistochemistry involving human placental tissues was performed 
at Maternal and Fetal Health Research Lab, St. Mary’s Hospital, Manchester under 
approval of the Central Manchester Local Ethics Committee. RNA and cDNA 
extracted from human term placental villous tissue of healthy individuals, cDNA 
from human first trimester villous tissue, and villous tissue homogenates of both 
human first and term placenta of healthy individuals were received as gifts from Prof. 
Aplin, Maternal and Fetal Health Research Group, University of Manchester, under 
approval of the Central Manchester Local Ethics Committee. Samples of small scale 
frozen human term placental villous tissues were obtained from Dr. Ball, Department 
of Biochemistry, University College Cork, as approved by the Clinical Research 
Ethics Committee of the Cork Teaching Hospitals. 
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2.2 Cell Culture 
 
Human BeWo trophoblast cells were maintained in Nutrient Mixture F12 
Ham medium, supplemented with 2 mM L-glutamate, 50 IU/ml of penicillin, 50 
µg/ml of streptomycin, and 10% (v/v) heat-inactivated fetal bovine serum (FBS). 
Human JAR and JEG-3 trophoblast cells were maintained in Dulbecco’s modified 
Eagles’s Medium (DMEM) containing 10% (v/v) heat-inactivated fetal bovine serum 
(FBS), 50 IU/ml of penicillin and 50 µg/ml of streptomycin. Human SGHPL-4 
trophoblast cells were grown in Nutrient Mixture F10 Ham medium containing 10% 
(v/v) heat-inactivated fetal bovine serum (FBS), 50 IU/ml of penicillin and 50 µg/ml 
of streptomycin. All cells were maintained in a humidified atmosphere of 95% air 
and 5% CO2 at 37 
o
C. 
 
 
2.3 Differentiation of C2C12 Cells 
 
C2C12 is a mouse myoblast cell line. The purpose of C2C12 differentiation 
in this study was to serve as a positive control, to compare and contrast with human 
trophoblast cell lines and human placental tissue examined for the expression of 
calsequestrins and RyR proteins. Differentiated C2C12 myotubes were used for both 
immunoblotting and immunofluorescence staining. 
  C2C12 cells were grown in normal growth medium (10% FBS (v/v), 50 
IU/ml penicillin and 50 µg/ml streptomycin, DMEM) to confluency in both 175 cm
2
 
and on cover slips that were placed in 12-well plates. To differentiate myoblasts, 
normal growth medium was removed and replaced by differentiation medium (0.5% 
FBS (v/v), 50 IU/ml penicillin and 50 µg/ml streptomycin, DMEM). During the 
differentiation period, differentiation medium was changed in every two days; and 
complete differentiation of cells from myoblasts to myotubes was observed within 6 
– 8 days of switching medium. 
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2.4 Preparation of Microsomes and Membrane Subfractionation 
 
All steps were performed at 0 to 4 
o
C, as described previously by Mackrill et 
al. (Mackrill et al.,1997). All buffers (wash buffer, Buffer I, Buffer II and Buffer A) 
contained freshly added protease inhibitors (2 mM benzamidine, 2 µg/ml aprotinin, 2 
µg/ml leupeptin, 2 µg/ml pepstatin A, and 0.5 mM PMSF). Crude microsomal 
membranes were prepared from 175 cm
2
 cell monolayers. Culture medium was 
removed from flasks and cell monolayers were briefly washed twice with wash 
buffer (0.02% EDTA, 0.9% NaCl, 10 mM Tris, pH7.4). After the second wash, same 
buffer was added to detach cells by 5 minutes incubation followed by gentle tapping 
of the flasks. Cells were harvested with 10 ml per 175 cm
2
 monolayer of wash buffer. 
Cell pellets were obtained by centrifugation at 500 x g for 5 minutes at 4
o
C (Rotor 
F34-6-38, Eppendorf Centrifuge 5810R; Eppendorf UK Ltd.). Resultant cell pellets 
were homogenized with 500 µl buffer I (0.5 mM MgCl2, 25 mM Tris pH 7.4) by 50 
strokes of a hand-held glass-Teflon homogeniser.  An equal volume of buffer II (0.3 
M KCl, 0.5 M sucrose, 25 mM Tris, pH 7.4) was added, followed by another 25 
strokes with the homogenizer. The homogenate was centrifuged at 500 x g for 5 
minutes at 4
o
C  (Rotor F34-6-38, Eppendorf Centrifuge 5810R; Eppendorf UK Ltd.), 
and the supernatant was centrifuged at 30,000 x g for 60 minutes at 4 
o
C (Beckman 
JA-25.50 rotor, Beckman Avanti
TM
 J-25 centrifuge, Beckman Coulter, Inc. U.S.A). 
The resultant microsomal pellets were resuspended in 50-100 µl buffer II by 10 
passes through a 21-gauge needle. Protein concentrations of microsomes were 
determined by Bradford protein assay using bovine serum albumin as a standard 
(Bradford, 1976). Microsomes were immediately flash-frozen in liquid nitrogen and 
stored at -80
o
C. Alternatively, microsomes were prepared and used immediately for 
SDS-PAGE and western blotting.  
Crude microsomal membranes from various rabbit or rat tissues (including 
rabbit skeletal muscle, rat brain, rat heart and rat skeletal muscle) were prepared by a 
differential centrifugation method. Frozen tissues were thawed in 10 volumes of (ie. 
1 g/10 ml) ice-cold buffer A (0.25 M sucrose, 10 mM Tris, pH 7.4), and cut into 
pieces of approximately 1 cm
3
. For fresh tissues, excess fat, major nerves and blood 
vessels were removed before diced and immersed into ice-cold buffer A.  Tissues 
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were then homogenized with buffer A for three 30 second bursts by using Ultra-
Turrax homogenizer (T-25 probe, maximum speed). Crude homogenates were 
centrifuged at 1,100 x g for 10 minutes at 4
o
C (Rotor F34-6-38, Eppendorf 
Centrifuge 5810R; Eppendorf UK Ltd.); supernatants were centrifuged at 7,700 x g 
for 20 minutes at 4
o
C (Rotor F34-6-38, Eppendorf Centrifuge 5810R; Eppendorf UK 
Ltd.); crude microsomal membranes were obtained by further 60 minutes 
centrifugation at 4
o
C (Beckman JA-25.50 rotor, Beckman Avanti
TM
 J-25 centrifuge, 
Beckman Coulter, Inc. U.S.A) at maximum speed (75,600 x g). Resultant membrane 
pellets were resuspended in buffer A to a protein concentration of 10-20 µg/µl by 10 
strokes of a loose-fitting glass-Teflon homogenizer. After the protein concentration 
was determined using the Bradford protein assay, membranes were immediately 
flash-frozen in liquid nitrogen and stored at -80
o
C until further use. 
Small scale frozen human term placental villous tissue homogenates were 
prepared in 1.5 ml Eppendorf tubes. Ice-cold buffer A (500 µl) was added and tissues 
were homogenised directly by using pellet pestles. Crude homogenates were 
centrifuged at 1,100 x g for 10 minutes at 4
o
C (Rotor F45-30-11, Eppendorf 
Centrifuge 5810R; Eppendorf UK Ltd.). Post-nuclear supernatants were obtained by 
further 20 minutes centrifugation of these supernatants at 7,700 x g at 4
o
C (Rotor 
F45-30-11, Eppendorf Centrifuge 5810R; Eppendorf UK Ltd.). Protein 
concentrations of homogenates were determined using the Bradford protein assay 
and samples were stored as described previously at the first paragraph of this section. 
 
 
2.5 SDS/PAGE and Western Blotting 
 
To denature proteins for SDS-PAGE, membrane extracts containing 80 to 100 
µg of protein were made up with 5x SDS-PAGE sample buffer (0.1% (w/v) 
bromophenol blue, 4% (w/v) SDS, 20% (v/v) glycerol, 125 mM Tris pH6.8) in 
addition to 50 mM dithiothreitol (DTT) in a total volume of 20 µl. Samples were 
incubated at 100
o
C for 5 minutes and briefly centrifuged at 12,000 x g before loading 
onto 7% SDS-PAGE gels, then electrophoresed at 20 mA constant current per mini 
gel for about 90 minutes. The components of resolving and stacking gels are shown 
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in Table 2.5.1 During electrophoresis, gel cassettes were immersed in running buffer 
containing 24.8 mM Tris Base, 191.8 mM glycine and 0.1% (w/v) SDS.  
 
 
Table 2.5. 1 Formulation of SDS-PAGE gels 
 
7% Resolving gel Formulation (10 ml) 5% Stacking gel Formulation (10 ml) 
30% acrylaminde 2.3 ml 30% acrylaminde 1.67 ml 
 deionised H2O 5.1 ml deionised H2O 5 ml 
Resolving Gel Buffer 
 (1.5 M Tris-Base, pH 8.8) 
3 ml 
Stacking Gel Buffer  
(1 M Tris-HCl, pH 6.8) 
2.5 ml 
10% w/v SDS 100 µl 10% w/v SDS 100 µl 
Glycerol - Glycerol 625 µl 
10% APS 100 µl 10% APS 100 µl 
TEMED 10 µl 
 
TEMED 10 µl 
 
Separated membrane proteins were transferred from SDS-PAGE gels to 
polyvinylidene difluoride (PVDF) membranes that were pre-wetted with 100% 
methanol and equilibrated with 1 x transfer buffer. Transfer was performed at 70 V 
constant voltage for 2 hours for ryanodine receptor proteins, or for 1 hour for all 
other lower molecular weight proteins. The transfer cassette was immersed in 
transfer buffer containing 20 mM Tris Base, 150 mM glycine and 0.037% (w/v) SDS. 
At the end of protein transfer, membranes were incubated with blocking buffer 
containing 5% Marvel dried skimmed milk powder in phosphate buffered saline 
(PBS, 0.8% (w/v) NaCl, 0.02% (w/v) KCl, 0.144% (w/v) Na2HPO4, 0.024% (w/v) 
KH2PO4, pH 7.4) for 45 minutes, prior to overnight 4
o
C incubation on a shaker at 
~60 rpm, with the same blocking buffer containing primary antibodies at desired 
concentrations (Table 2.5.2). At the end of incubation with the primary antibody, 
PVDF membranes were washed with PBS three times at 5 minutes intervals prior to 
incubation with secondary antibody. Membranes were incubated for 1 hour at room 
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temperature on the shaker with blocking buffer containing secondary antibodies at 
working dilution (Table 2.5.3).  
At the end of the secondary antibody incubation, membranes were washed 
with PBS for 20, 15, 10 and 10 minutes (a total of four washes). Immunoreactive 
protein bands were visualized using an enhanced chemiluminescence (ECL) kit 
(Pierce ECL Western Blotting Substrate (Product # 32106), Thermo Scientific, 
Fisher Scientific Ireland). ECL detection reagents 1 and 2 were freshly mixed at a 1:1 
ratio and were applied to the membrane. Chemiluminescence was detected using 
Kodak X-Omat LS film (Sigma, F1274-50 EA) using AGFA CP1000 developer in a 
dark room. 
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Table 2.5. 2 Primary antibodies for western blotting 
 
Primary Antibodies 
Source and Catalogue 
Number 
Working Dilution 
Polyclonal Rabbit Anti-RyRs 
(RS4) with amino acid 
sequence: 
SFPNNYWDKFVKRKV 
Rabbit polyclonal 
antiserum supplied by Dr. 
Richard Tunwell, 
University College London 
1:500 
Polyclonal Rabbit Anti-RyR1 Millipore, AB9078 1:1000 
Polyclonal Rabbit Anti-RyR2 Sigma, HPA016697 1:250 
Polyclonal Rabbit Anti-RyR3 Millipore, AB9082 1:1000 
Polyclonal Rabbit Anti-
Calsequestrin (CSQ) 
Pierce, PA1-913 1:250 
Monoclonal Mouse Anti-
Triadin (TRD) 
Pierce, MA3-927 (clone 
10: GE 4.90) 
1:100 
 
 
 
Table 2.5. 3 Secondary antibodies for western blotting 
 
Secondary Antibodies 
(horseradish peroxidase 
(HRP)) 
Source and Catalogue 
Number 
Working Dilution 
Goat Anti-Mouse IgG-
Peroxidase Antibody 
Sigma, A9917 1:1000 
Goat Anti-Rabbit IgG-
Peroxidase Antibody 
Sigma, A6154 1:2000 
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2.6 RNA Isolation 
 
The Absolutely RNA
®
 miniprep kit (Stratagene, Catalog #400800) was used 
for RNA isolation from human trophoblast cell lines, according to the manufacturer’s 
protocol. β-Mercaptoethanol (β-ME, 0.7% (v/v)) was added to the desired volume of 
lysis buffer before use. Cells were grown to approximately 90% confluence on 6-
well plates. β-ME-lysis buffer (400 µl per well) was added and cells were lysed by 
repeated pipetting.  The lysate was transferred into microcentrifuge tubes and the 
tubes were vortexed to further homogenize the cells.  
Cell lysates were then transferred into the prefilter spin cups which were 
placed on the 2 ml receptacle tube, and centrifuged at 16,300 x g for 5 minutes using 
the Labnet Spectrafuge 24D (Labnet, Labnet International inc.). Filtrates were mixed 
thoroughly with equal volume of 70% ethanol and the mixture was transferred into 
the RNA binding Spin Cups which were placed in the new 2 ml receptacle tubes. The 
filtrate of the mixture was discarded after 60 seconds centrifugation at 16,300 x g. 
The spin cup was then washed with 600 µl of 1 x Low-Salt Wash Buffer. Following 
a 60 second maximum speed centrifugation and an additional 2 minute centrifugation, 
the filtrate was discarded.  
DNase treatment of samples was done within the fiber matrix of the filter spin 
cup using a 15 minute incubation with the DNase solution in a 37
o
C air incubator. 
The DNase solution was made up freshly by gently mixing 50 µl of DNase Digestion 
Buffer with 5 µl of reconstituted RNase-Free DNase I, and the 55 µl of DNase 
solution was directly loaded onto the fiber matrix of spin cup. At the end of the 
incubation, 600 µl of 1 x High-Salt Wash Buffer was added and tubes were 
centrifuged at 16,300 x g for 60 seconds in the Spectrafuge. Spin cups were washed 
twice with Low-Salt Wash Buffer using volumes of 600 µl and 300 µl. The fiber 
matrix was dried by 2 minute 16,300 x g centrifugation after the second wash.  
RNA elution was achieved by 10 minute room temperature incubation with 
Elution Buffer, followed by centrifugation at 16,300 x g for 1 minute. The Elution 
Buffer was pre-warmed to 60 
o
C and 50 µl of this buffer was loaded directly onto the 
fiber matrix of the spin cup which was placed on a fresh 1.5 ml microcentrifuge tube. 
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The quality and concentration of eluted RNA was determined by an Eppendorf 
BioPhotometer (Eppendorf UK Ltd.), according to the manufacturer’s instruction. 
RNA from flash-frozen term placental villous tissue was isolated by using 
TRIzol
®
-Reagent (Invitrogen Cat.No. 15596-018, Bio Sciences, Dublin, Ireland). 
Tissue samples were directly homogenised with 1 ml TRIzol reagent using pellet 
pestles. The crude homogenates were obtained by centrifugation for 10 minutes at 
12,000 x g at 4
o
C (Rotor F45-30-11, Eppendorf Centrifuge 5810R; Eppendorf UK 
Ltd.). The supernatant was transferred into a fresh microcentrifuge and incubated at 
room temperature (RT, 18-22
o
C) for 5 minutes to allow the complete dissociation of 
nucleoprotein complexes. At the end of this incubation, 200 µl of chloroform was 
added and the tube was vortexed vigorously for 1 minute. The mixture was incubated 
at RT for 3 minutes before phase separation by centrifugation for 15 minutes at 
12,000 x g at 4
o
C. The resultant colourless upper aqueous phase was transferred into 
a fresh microtube, and the RNA was precipitated by mixing with 0.5 ml isopropyl 
alcohol, followed by 10 minute room temperature incubation. The RNA precipitate 
was obtained by centrifugation at 12,000 x g 4
o
C for 10 minute, and the gel-like 
pellet on the side and the bottom of tube was washed with 1 ml 75% ethanol by 
vortexing. The ethanol was removed using a 5 minute 7,500 x g centrifugation at 4
o
C. 
The RNA pellet was allowed to air-dry for 5 to 10 minutes. The resultant RNA pellet 
was redissolved in DNase/RNase-free H2O. The quality and concentration of RNA 
were determined by Eppendorf BioPhotometer as previously stated. All RNA 
samples were stored at -80
o
C until further use. 
 
 
2.7 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
 
cDNA was synthesized in a 20 µl reaction using the ImProm-II
TM
 Reverse 
Transcription System (Promega, Catalog #A3800). Total RNA (1–5 µg in a volume 
of 10 µl) was used as template, mixed with 0.5 µg (1 µl) Oligo (dT)15 primer and 
denatured at 70
o
C for 5 minutes.  The template and primer mix (11 µl) was chilled on 
ice for at least 5 minutes before proceeding to reverse transcription. The reaction 
mixture (9 µl) containing ImProm-II
TM
 5x Reaction Buffer, 2.5 mM MgCl2, 0.5 mM 
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each dNTP, 20 units of Recombinant RNasin Ribonuclease Inhibitor, and 1 unit of 
ImProm-II
TM
 Reverse Transcriptase, was subsequently combined and equilibrated 
with the pre-treated RNA/ Oligo (dT)15 mix to the final reverse transcription reaction 
mix (20 µl). The cDNA synthesis was performed on an Eppendorf Mastercycler 
Thermal Cycler for one hour at 42
o
C, and the Reverse Transcriptase was inactivated 
using 15 minute incubation at 70
o
C. The resultant cDNA was either stored on ice for 
immediate amplification, or stored at -20
o
C for future use. 
To determine whether the ryanodine receptor transcripts present in human 
trophoblast cell lines and human placental trophoblast villous tissues, cDNA 
synthesized from total RNA of cell lines and tissues was amplified using the PCR 
(GoTaq
®
 PCR Core System I, Catalog # M7650, Promega), using primers that 
selectively amplify specific region of RyR isoforms. The same downstream primer 
(5′-dCAGATGAAGCATTTGGTCTCCAT-3′) pairs to the upstream primers JBR1 
(5′-dGACATGGAAGGCTCAGCTGCT-3′), JBR2 (5′-
dAAGGAGCTCCCCACGAGAAGT-3′), and JBR3 (5′-
dGAGGAAGAAGCGATGGTGTT-3′) amplified products from RYR1, RYR2, and 
RYR3 at approximate sizes of 1112 bp, 1082 bp and 1013 bp, respectively (Sei et 
al.,1999). The 50 µl PCR reaction volume contained 5x Colourless GoTaq
®
 Flexi 
Buffer, 3 mM MgCl2, 300 µM of each PCR Nucleotides, 5 µg of each primer, 1.25 
units of GoTaq
®
 DNA Polymerase, and 5 µl of cDNA.  
Amplification was performed in a Eppendorf Mastercycler Thermal Cycler 
by ‘touchdown’ PCR method (Don et al.,1991). This protocol was modified from 
method of Sei et al. (Sei et al.,1999), optimised according to manufacturer’s 
instruction from Promega. Of which,  the reaction was started with a 4 minute initial 
denaturation at 95
o
C of target DNA templates, followed by 19 cycles of 1 minute 
denaturation at 95
o
C, 1 minute annealing from 65
o
C to a ‘touchdown’ at 55
o
C (0.5
o
C 
decrease every cycle), and 1 minute extension at 72
o
C. At cycle 20, the annealing 
temperature was expected to reach 55
o
C. The next 19 cycles were performed at this 
annealing temperature (55
o
C) under the same conditions. After the final 5 minute 
extension at 72
o
C, the entire PCR (total 40 cycles) was terminated. The quality and 
concentration of resultant products were determined by the Eppendorf 
BioPhotometer, according to the manufacturer’s instructions. PCR products (5 µl) 
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were then mixed with 1 µl 6x DNA loading dye (#R0611, supplied with GeneRuler 
100bp DNA Ladder (#SM0243), Fermentas Life Sciences, Germany), prepared for 
electrophoresis in agarose gel. The 1% agarose gel was made up with 1 g of agarose 
per 100 ml 1 x Tris-acetate-EDTA (TAE) buffer (40 mM Tris, 20 mM acetic acid 
and 1 mM EDTA) in a conical flask. The agarose was dissolved in the buffer by 
heating in a microwave oven for approximately 2 minute. The gel solution was 
swirled for mixing and kept inside the fume hood at room temperature for 
approximately 5 minutes; ethidium bromide was then added into the solution by 
gentle mixing to a final concentration of 0.8 µg/ml. This gel solution was then slowly 
poured into the gel tank. After the gel was set, the whole gel-tank assembly was 
immersed with 1 x TAE buffer; PCR product mixed with DNA loading dye was 
loaded into the wells of the gel and resolved by electrophoresis at constant voltage of 
180 V for approximately 45 minutes. DNA fragments were then visualised on a UV 
transilluminator.  
Examination of house-keeping gene (human β-ACTIN) as a loading control 
was performed using the same Thermal Cycler. Human β-ACTIN primers were from 
Stratagene (#302010). The sequences of sense and antisense primers were 5’-
TGACGGGGTCACCCACACTGTGCCCATCTA-3’ and 5’-
CTAGAAGCATTTGCGGTGGACGATGGAGGG-3’, respectively. Lyophilised 
primers were reconstituted in low-TE buffer (5 mM Tris-HCl and 0.1 mM EDTA). 
The 20 µl PCR reaction volume contained 5x Colourless GoTaq
®
 Flexi Buffer, 2 
mM MgCl2, 300 µM of each PCR Nucleotides, 1 µM of primer mix, 1 unit of 
GoTaq
®
 DNA Polymerase, and 2 µl of cDNA. The PCR cycles were setup according 
to manufacturer’s instruction: starting with a 5 minute initial denaturation at 94
o
C, 5 
minute annealing at 60
o
C and 1.5 minute extension at 72
o
C; the next 35 cycles were 
performed at 94
o
C for 45 seconds denaturation, followed by 45 seconds annealing at 
60
o
C, then 1.5 minute extension at 72
o
C; the duration for the final extension at 72
o
C 
was 10 minutes. The expected size of product is 661 bp. These PCR products were 
then examined by electrophoresis in agarose gels and visualised on a UV 
transilluminator. 
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2.8 DNA Purification from PCR Products 
 
To optimize the PCR product purity for sequencing, DNA of the expected 
size was isolated and extracted from agarose gels after electrophoresis using a 
StrataPrep DNA Gel Extraction Kit (Catalog # 400768, Agilent Technologies, 
Agilent Technologies Ireland Ltd, Ireland). The DNA was isolated from the gel by 
single-use sterile surgical blade and dissolved in 3 volumes of DNA extraction buffer 
(ie. 300 µl of buffer per 100 mg isolated agarose gel containing DNA). The mixtures 
were heated at 50
o
C for 10 minutes with occasional gentle flicking for mixing. When 
DNA gels were completely dissolved, mixtures were transferred into microspin cups 
which were placed in 2 ml receptacle tubes and centrifuged at 16,300 x g for 30 
seconds using the Labnet Spectrafuge 24D. The filtrates were discarded and the 
microspin cups were washed with 1 x wash buffer which was made up with equal 
volumes of 2 x wash buffer and 100% ethanol. The wash buffer was removed from 
the microspin cups by centrifugation twice for 30 seconds at 16,300 x g. DNA 
elution from the matrix of the microspin cups was achieved by a 10 minute room 
temperature incubation with 50 µl of DNase/RNase-free H2O, followed by 
centrifugation for 1 minute at 16,300 x g. The quality and concentration of DNA 
were determined using an Eppendorf BioPhotometer. The purified DNA was then 
analysed by electrophoresis on a 1% agarose gel containing 0.8 µg/ml ethidium 
bromide. 
In cases where the recovered product concentration was too low, the purified 
DNA was used as a template (1 µl in 50 µl reaction) for re-amplification using a 10 
cycle PCR with constant annealing temperature at 55
o
C at the same conditions as 
previously stated in Section 2.7. The resulting PCR products were examined by 
electrophoresis and purified by gel extraction, as described in the first paragraph of 
the current section, prior to sequencing.  
DNA samples for sequencing were prepared at a concentration of 10 ng/µl in 
duplicate, premixed with 15 pmol of either forward or reverse primer in a total 
volume of 20 µl DNase/RNase-free H2O. Samples were commercially sequenced by 
Eurofins MWG Operon Sequencing lab (Germany).  
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2.9 Indirect Immunofluorescence (IIF) Microscopy 
 
RT-PCR and western blotting experiments indicated (Chapter III, 3.1-2), 
there were a detectable levels of RyR transcripts and proteins in BeWo and JEG-3 
trophoblast cell lines. To visualize the subcellular distribution of RyRs and their 
accessory proteins, cultures of BeWo and JEG-3 cells were selected for analyses 
using indirect immunofluorescence microscopy.  
Cells were grown to approximately 80% confluency on 10 mm glass cover 
slips in 12-well plates. Cells were briefly washed twice with sterile-filtered PBS 
before 15 minute fixation with 100% methanol at -20
o
C. At the end of fixation, cells 
were washed twice with PBS, and then incubated with 50 mM ammonium chloride at 
room temperature for 15 minutes to quench autofluorescence. After two washes with 
PBS, cells were incubated with 10% v/v fetal bovine serum/phosphate buffer saline 
(FBS/PBS) at room temperature for one hour to block non-specific protein binding. 
At the end of this blocking step, cells were incubated with both mouse monoclonal 
and rabbit polyclonal primary antibodies in the same blocking solution (10% v/v 
FBS/PBS) at desired concentrations (Table 4.8.1) for one hour.  
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Table 2.9. Primary antibodies for indirect immunofluorescence microscopy 
 
Primary Antibodies Catalogue Number Working Dilution 
Polyclonal Rabbit Anti-
RyR1 
Millipore, AB9078 1:400 
Polyclonal Rabbit Anti-
RyR2 
Millipore, AB9080 1:400 
Polyclonal Rabbit Anti-
RyR3 
Millipore, AB9082 1:400 
Monoclonal Mouse Anti-
RyRs 
Pierce, MA3-916 (clone: 
C3-33) 
1:500 
Polyclonal Rabbit Anti-
CSQ 
Pierce, PA1-913 1:200 
Monoclonal Mouse Anti-
TRD 
Pierce, MA3-927 (clone: 
GE 4.90) 
1:200 
Monoclonal Mouse Anti-E 
Cadherin 
Abcam, ab1416 (clone: 
HECD-1) 
1:50 
Monoclonal Mouse Anti-
Pan Cadherin 
Sigma, C1821 (clone: 
CH-19) 
1:400 
 
At the end of incubation with primary antibodies, cells were washed twice 
with PBS and then were incubated for 40 minutes at room temperature with 
secondary antibodies in the same blocking solution. The secondary antibodies 
blocking solution cocktails contained Cy2-conjugated anti-rabbit IgG (Jackson 
ImmunoResearch, 711-225-152) 7.5 µg/ml, Cy3-conjugated anti-mouse IgG 
(Jackson ImmunoResearch, 715-165-150) 7 µg/ml, and 4, 6-diamidino-2-
phenylindole (DAPI, 1 ng/ml) (Catalog # D9542, Sigma) for staining of nuclei. From 
the secondary antibody addition on, all incubations and washes were performed in 
dark to avoid unnecessary photobleaching.  
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Cells were washed twice with PBS at the end of secondary antibody 
incubation. Cover slips were briefly rinsed with dH2O to remove the salt. Excessive 
water was absorbed in tissue before cover slips were mounted on microscopy slides 
with mowiol mounting medium (10.3% (w/v) Mowiol (575904, Mowiol 4-88, 
Calbiochem, Germany), 22.8% (v/v) glycerol, 0.1 M TrisHCl pH8.5). Slides were 
allowed to air dry in dark before further examination.  
Fluorescence microscopy was performed using a Leica DMI3000 B inverted 
microscope; cells were observed using HCX PL FLUOTAR 40x/0.75 numerical 
aperture (NA) PH2 objective lens. Immunostaining within the same observation area 
was visualized by switching fluorescent filter cubes to produce UV light (excitation 
filter BP340-380), blue light (excitation filter BP470/40) and green light (excitation 
filter BP545/30) that excited DAPI (blue), Cy2 (green) and Cy3 (red) emission, 
respectively. Images of each fluorochrome within the same observation area were 
captured using a Leica DFC340 FX digital camera fitted to the microscope. Images 
were managed and processed using Leica AF6000 E Fluorescence software, and then 
exported as jpeg files into a PC for further analysis. Contrast and intensity of images 
were adjusted to the same degree by Microsoft Office Picture Manager 2003 or 
Photoshop CS2; the images of DAPI (blue), Cy2 (green), and Cy3 (red) that were 
captured within the same observation area were superimposed to produce merged 
images. 
 
 
2.10 Immunohistochemistry (IHC) 
 
Immunohistochemistry involving use of human placental tissue was 
performed in the Maternal and Fetal Health Research Group, University of 
Manchester, under supervision of Prof. Aplin and members of his research group. All 
tissue samples used were obtained with the approval of the Local Ethics Committee, 
Manchester. Three representative samples of both first trimester and term placental 
villous tissue from healthy individuals were randomly selected for IHC analysis. 
Human placental villous tissue from healthy individuals was isolated and 
dissected before it underwent dehydration and embedding with paraffin by members 
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of Prof. Aplin’s research group (Forbes et al.,2008). Paraffin embedded samples 
were sectioned by Leica disposable blades using semi-automatic rotary microtome 
Leica RM2245 at a thickness of 5 µm. Tissue sections were mounted on the 
microscopy slides pre-coated with poly-L-lysine, allowed to dry overnight in the 
oven at 37
o
C and stored at room temperature until use. Slides mounted with tissue 
sections were arranged in slide racks and warmed to 60
o
C for 10 minutes before 
dewaxing and rehydration was performed in the fume hood. Sections were dewaxed 
in Histoclear series (i.e. Histoclear A, Histoclear B and Histoclear C) for 10 minutes 
each with agitation. Racks of slides were then transferred and rehydrated through an 
ethanol series (100% ethanol (A), 100% ethanol (B), 70% ethanol (A), 70% ethanol 
(B)) for 2 minutes at each step, with agitation. At the end of the last step with alcohol 
rehydration, sections were equilibrated with tap water for 10 minutes.  
Antigen retrieval was then performed by boiling the sections in 10 mM 
sodium citrate (pH 6.0) for 2 x 5 minutes. Buffer was allowed to cool at RT for 20 
minutes before sections were further cooled using running tap water. At the end of 
cooling, water was drained off from slides and sections were circled with 
hydrophobic pen. Tissue sections were equilibrated with TBS (5 mM Tris Base, 0.3 
M NaCl, pH 7.6) for 5 minutes before the 10 minute endogenous peroxidase 
quenching at room temperature with 3% hydrogen peroxide in H2O (v/v). At the end 
quenching, sections were washed with TBS (2 x 5 minutes) before 30 minute non-
immune block at room temperature with 2% human serum/10% normal goat serum 
in 0.1% Tween TBS (v/v). Sections were incubated with primary antibodies (Table 
2.9.1) diluted into the same blocking solution for at least 1 hour at room temperature. 
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Table 2.10. Primary antibodies for IHC 
 
Primary Antibodies Catalogue Number Working Dilution 
Polyclonal Rabbit Anti-
RyR1 
Millipore, AB9078 1:500 
Polyclonal Rabbit Anti-
RyR2 
Sigma, HPA016697 1:25 
Polyclonal Rabbit Anti-
RyR3 
Millipore, AB9082 1:500 
Monoclonal Mouse Anti-
TRD 
Pierce, MA3-927 (clone: 
GE 4.90) 
1:100 
Monoclonal Mouse Anti-
Human Cytokeratin 7 
Dako, M7018 (Clone OV-
TL 12/30)  
1:500 
 
At the end of primary antibody incubation, sections were washed with TBS 
for 5 minutes, followed by two 5 minute TBS-Tween (0.6% v/v) washes, and a 
further 5 minute TBS wash. Biotinylated goat anti-mouse IgG (E0433, 
DakoCytomation Ltd., Cambridgeshire, UK) and biotinylated swine anti-rabbit IgG 
(E0413, DakoCytomation Ltd., Cambridgeshire, UK) were applied as secondary 
antibodies diluted into TBS (1:200). Tissue sections were incubated with the 
corresponding biotinylated secondary antibodies for 30 minutes at RT and washed in 
the same way as before (5 minute TBS, 2 x 5 minute TBS-Tween (0.6%), 5 minute 
TBS).  
The tertiary step was applied by 30 minute RT incubation with 5 µg/ml 
avidin-peroxidase (Sigma, A3151) in TBS. Sections were then washed with TBS-
Tween (0.6%) for 2 x 5 minute and TBS for 5 minutes. Peroxidase activity was 
detected using 3, 3’-diaminobenzidine (DAB) peroxidase substrate (Sigma, D4168). 
One tablet of each DAB and urea hydrogen peroxide were dissolved together into 1 
ml ultrapure water. The DAB solution was then applied onto tissue sections; colour 
development was monitored using a light microscope with a 10x objective. Reactions 
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were terminated by rinsing off DAB solution on sections with ultrapure water. 
Sections were allowed to equilibrate with water for 5 minutes. Nuclei were 
counterstained with filtered Harris’s hematoxylin for 1 minute and rinsed with cold 
tap water. The differentiation of section stains was achieved using acid alcohol (1% 
HCl in 70% methanol, v/v) to wash off overstaining of hemotoxylin on sections and 
to define the nuclei staining with hematoxylin. Section slides were dipped into acid 
alcohol for 3 seconds to remove undesired overstaining, and then washed with 
running tap water.  
Sections were dehydrated through a fresh alcohol series (2 minutes in each of 
70% ethanol (A), 70% ethanol (B), 100% ethanol (A), and 100% ethanol (B)) with 
agitation in the fume hood. Excess ethanol was drained off before transfer into a 
fresh Histoclear series (2 minutes in Histoclear (A), 5 minutes in Histoclear (B), and 
30 minute Histoclear (C), with agitation at each step). Sections were then directly 
mounted with DPX mounting medium (Fluka, 44581) and allowed to dry overnight 
in the fume hood. Stained tissue sections were visualized by Leitz Dialux 22 
microscope, using Phaco 100x/1.20 NA water objective; images were captured using 
a QI Cam Fast 1394 camera and analyzed by Image Proplus 6.0 imaging system. 
Images were subsequently exported to a PC as .jpeg files; contrast and intensity were 
adjusted using Microsoft Office Picture Manager 2003. 
 
 
2.11 MTT Assay 
 
To determine whether direct pharmacological stimulation of RyRs by 
agonists affected the viability of human trophoblast cell lines, BeWo and JEG-3 cells 
were selected for MTT assay according to manufacturer’s instruction (Cat. # 
1465007, Roche, Roche Applied Science, Germany). MTT assay is a colourimetric 
assay that reveals metabolic activity of viable cells. In this method, the tetrazolium 
salt MTT is used; and MTT can only be converted to a coloured, water-insoluble 
formazan salt by viable cells; the formazan salt can be solubilised in a solubilisation 
solution and can be quantitated in a conventional ELISA plate reader. Therefore, 
MTT assay is used to quantitate cell proliferation and cytotoxicity (Mosmann,1983).  
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Cells (~3000 per well) were seeded and grown with normal growth medium 
overnight in the 96-well plates in the 37
o
C incubator before stimulation. The next 
day, normal growth medium was replaced by assay medium with addition of drugs: 
ryanodine (final concentrations: 0.1 µM, 0.2 µM, 0.5 µM, 1 µM, 2 µM, and 5 µM), 4-
CmC (final concentrations: 5 µM, 10 µM, 50 µM, 100 µM, 200 µM, and 500 µM), 
and etoposide (final concentrations: 10 µM, 25 µM, 50 µM, and 100 µM). Etoposide 
served as a positive control for cytotoxicity. Quadruplets of wells were assigned for 
each concentration. In addition, quadruplet blank wells without cells were used to 
determine the background absorbance of solutions; while quadruplet wells of cells 
without addition of drugs were used as viability controls. Cells were stimulated for 
24 hours at 37
o
C before labelling with 10 µl (0.5 mg/ml) MTT reagent. At the end of 
the 4 hour labeling period, medium was removed and replaced by 100 µl per well of 
solubilisation solution. After overnight solubilisation at 37
o
C in the cell-culture 
incubator, the absorbance of solution in each well was measured by a 
spectrophotometer at 595 nm.  
Values of absorbance in each well were normalised by subtracting the 
averaged background reading from blank wells. Percentages reflecting relative 
formazan production from MTT reduction in each reaction were deduced from the 
averaged normalised absorbance of control and stimulated wells. The percentage of 
relative formazan salt formation in control wells was regarded as 100% at their 
averaged normalized absorbance. This value was then divided by the averaged 
normalized absorbance from each experiment and expressed as percentage. The 
percentages of relative formazan formation were also regarded as an indicator of the 
percentage of viable cells in relation to controls. These values were plotted against 
drug concentration for analysis. 
 
 
2.12 Fura-2 Fluorescence Microscopy 
 
To determine the changes in intracellular [Ca
2+
] upon direct and indirect 
pharmacological stimulation of ryanodine receptors, BeWo and JEG-3 cells were 
loaded with fura-2 (Grynkiewicz et al.,1985), using a protocol modified from the 
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method of Ratto et al. (Ratto et al.,1988). Cells were grown on 35 mm γ–irradiated 
glass bottom dishes (MatTek) to approximately 80% confluency. Cells were washed 
twice with sterile-filtered modified Krebs-Henseleit bicarbonate (KHB) buffer (NaCl 
120 mM, KCl 4.8 mM, MgSO4 1.2 mM, KH2PO4 1.2 mM, NaHCO3 25 mM, CaCl2 2 
mM, glucose 10 mM, HEPES 5 mM, pH 7.2) before incubation with the ratiometric 
fluorophore. The fluorophore-loading solution was freshly prepared by making up 5 
µM fura-2 AM (F-1221, Invitrogen, Ireland) and 5 µM Pluronic F-127 (P3000MP, 
Invitrogen, Ireland) in KHB. Cells were incubated with the fluorescent dye for 30 to 
45 minutes in a 37
o
C incubator. At the end of the incubation, cells were washed 
twice with KHB and allowed to equilibrate with the buffer for 10 to 20 minutes 
before pharmacological stimulation. During experiments, cell dishes were placed on 
the microscope stage. The fluorescence of cells was monitored using an Olympus 
IX51 inverted fluorescent microscope (Olympus Optical Co. (UK) Ltd.) with 
Olympus UPlanFI100XOI3 oil-immersion 100x/1.3NA objective, using Andor iQ 
acquisition software (Andor Technology Ltd. Belfast, N. Ireland) which 
synchronized with a Hamamatsu ORCA-ER Digital Camera C4742-80. Non-
stimulated cell images were recorded for at least 1 minute to obtain a basal value, 
prior to addition of drugs. Pharmacological agents (5 µl) at 200x the desired 
concentration were added directly into the cell dish containing 995 µl KHB using a 
micropipette. Experiments were terminated when there was no further change 
observed. The duration of stimulation was between 5 to 15 minutes. All experiments 
were performed on the microscope stage within a humidified encapsulating incubator 
at 37
o
C.  
Microscope-equipped IX2-RFAC Reflected Fluorescence System (Olympus 
Optical Co. (UK) Ltd.) was used during experiment. The excitation light was 
generated by a 75W xenon lamp; the wavelengths of 340 nm and 380 nm lights were 
selected by the Cairn Optoscan monochromator. The combination of U-MWU2 
mirror unit and BP330-385 excitation filter controlled the wavelengths of emitted 
light reaching the camera. During experiments, cells were illuminated alternately 
with two wavelengths of 340 nm and 380 nm that specifically excited Ca
2+
-bound 
and Ca
2+
-free fura-2 within dye-loaded cell (Thomas & Delaville,1991). The light 
emitted at both excitation wavelengths (peak emission ~510 nm) was collected by the 
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Hamamatsu ORCA-ER Digital Camera (Hamamatsu Photonics (UK) Ltd.); the 
camera-synchronized widefield emission paired images of the fura2 (excited by 340 
nm and 380 nm wavelengths) was produced and processed by Andor iQ software. 
The acquisition control and data analysis of images (including generation of ratio 
images) were also achieved by using Andor iQ program.  
Images were collected and the intensity was recorded in the pixels of each 
frame. The paired images were presented in red and blue images represented light 
emitted at 340 nm and 380 nm excitation wavelengths, respectively. The exposure 
time of each excitation wavelength was set at 800 ms, and the interval in between 
was set at the fastest possible value. The image recording was initiated by clicking 
the ‘run’ button in the software control panel. At the end of experiment, recording 
was terminated by clicking the ‘stop’ button at the same place. The duration of 
pharmacological stimulation was various between 5 to 15 minutes. All original data 
images were saved as multi-dimensional .TIFF files. 
To process the fura-2 data, a stack of ratio images was created per stack of 
original paired fura-2 images. The background fluorescence of individual raw image 
was masked based on the Ca
2+
-sensitive 340 nm excited images; a stack of 
intermediate threshold paired images was then generated to remove ‘background’ 
fluorescence. The ratio images were generated from the original and threshold paired 
images.  
Cells of interest (at least four cells) were outlined by polygons, defining 
regions of interest. The mean fura-2 intensity ratios within the outlined regions were 
averaged in every ratio image for analysis. The average value of at least 30 frames of 
non-stimulated ratio images (~ 60 seconds) at the beginning of each experiment was 
taken as basal fluorescence ratio, and this value was then subtracted from values 
obtained during pharmacological stimulation to obtain the mathematical value of 
change in fura-2 ratio. Mean ratios of fura-2 intensity were plotted against time in 
seconds to display the changes of fura-2 ratio during experiment, using Microsoft 
Excel 2003. 
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2.13 Statistics 
 
Statistical analyses of numerical data were made by unpaired t test (two 
groups) or one-way ANOVA followed by Tukey's Multiple Comparison Test (more 
than two groups), using GraphPad Prism software version 4. All quantitative data 
represent mean values from at least four independent experiments. Significance of 
differences between these mean values was taken at P < 0.05. 
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Chapter III.  Expression of Ryanodine Receptors 
 
To establish the expression of RyRs in both human first trimester and term 
placental tissues, RNA/cDNA and protein extracts were used for RT-PCR and 
western blotting, respectively. The expression of RyR proteins was also investigated 
using indirect immunofluorescent microscopy in cell lines and 
immunohistochemistry in human tissue sections from first and term placenta of 
healthy individuals. 
 
3.1  Ryanodine Receptor Transcripts are Expressed in Human Trophoblast Cell 
Lines and Human Placental Villous Tissues. 
 
The expression of ryanodine receptors was examined in both human first 
trimester and term placental tissues, and in the human trophoblast cell lines BeWo, 
JAR, JEG-3 and SGHPL-4. The total RNA was extracted from cells and tissues, 
followed by RT-PCR as described in Chapter II 2.6 and 2.7. Figure 3.1.1 shows 
representative agarose gel images indicating the presence of RyR transcripts in 
samples, in which 5 µl of the original 50 µl reaction PCR products from each sample 
were loaded into the gel. Figure 3.1.1.A shows products amplified using RYR1 
primers. A549 cells are a human lung carcinoma cell line which served as a positive 
control, as they have been reported to express RyR1 (Xue et al.,2000), whereas 
Jurkat T cells were reported as RyR1/2-negative (Hosoi et al.,2001). Results show 
that the ~1112 bp PCR products amplified from RYR1 mRNA (Figure 3.1.1.A (n = 3)) 
were found in the trophoblast cell lines BeWo and JAR; a weaker RYR1 PCR product 
was also present in human first trimester placental villous sample. Sequencing of 
PCR products confirmed the presence of RyR1 transcripts. The nucleotide sequences 
of RYR1 PCR products from both BeWo and first trimester villous samples displayed 
99% mRNA identity to Homo sapiens RYR1 on both plus and minus strands; whereas 
JAR RYR1 PCR products were showed 100%/99% mRNA identity to Homo sapiens 
RYR1 on plus/minus strands (see Appendix I, III and VII). A single nucleotide 
polymorphism (SNP) exists in sequence of products in BeWo, JAR and human first 
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trimester samples. However, protein sequences of conceptual translation from these 
PCR products showed 100% identity to Homo sapiens RyR1 in these samples, i.e 
SNPs do not affect protein sequence in cells and tissue samples were examined.  
In Figure 3.1.1.B (n = 3), PCR product from an RNA extract of SH-SY5Y 
(Lane 3), a cell line which has been reported to express RyR2 protein (Mackrill et 
al.,1997), were used as an RYR2 positive control. Along with SH-SY5Y, the RYR2 
PCR product of ~ 1082 bp was also detected in BeWo, JAR and first trimester tissue 
samples. PCR product sequencing indicated 99% identity to Homo sapiens RYR2 on 
plus /minus strands of BeWo and JAR; 100%/99% mRNA identity to Homo sapiens 
RYR2 on plus/minus strands of first trimester villous sample. Sequences derived from 
conceptual protein translations based on these RYR2 PCR products showed 100% 
identity to Homo sapiens RyR2 protein in samples of both BeWo cells and first 
trimester tissues. 
Jurkat cells were used as an RYR3 positive control (Hakamata et al.,1994). 
However, no RYR3 products from Jurkat cells were amplified in current study 
(Figure 3.1.1.C.I. (n = 3)). A rabbit skeletal muscle cDNA library (Stratagene) was 
also used for RYR3 PCR control. As Figure 3.1.1.C.II shows, RYR3 PCR products of 
expected size (~1013 bp) were detected in BeWo, JAR, JEG-3 and SGHPL-4 cells, 
along with rabbit skeletal muscle cDNA. In addition, a weak signal at expected size 
found in human term placental samples indicates presence of RYR3 (Figure 3.1.1.C.I). 
Amplification of housekeeping gene β-ACTIN in both trophoblast cell lines and 
positive control samples indicated there was sufficient RNA of suitable quality in 
each sample, and that the amount of cDNA did not vary much between these samples 
(Figure 3.1.1.C.III). The PCR products of the expected size for RYR3 were isolated 
and purified for sequencing. The sequencing results indicated 92% mRNA identity to 
Homo sapiens RYR3 on plus/minus strands in PCR products from JEG-3 and 
SGHPL-4 cells. In addition, small amount of RYR3 PCR product were also produced 
from a term placental villous tissue sample. Sequencing results indicated 94% 
mRNA identity to Homo sapiens RYR3. 
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Figure 3.1.1 Selective RT-PCR products of RYR1, RYR2 and RYR3 from human 
cell lines and human placental villous tissues 
 
Figure 3.1.1.A Selective RT-PCR products of RYR1 from human cell lines and 
human placental villous tissues 
 
 
 
 
 
Figure 3.1.1.A. Reverse-transcription PCR of RYR1. PCR products were amplified from total 
cell RNA extracts of A549, BeWo and JAR, using selective RYR1 selective primers. A weaker 
product of RYR1 segment was also amplifed from human first trimester placental villous cDNA 
(sample Ep63). Lane 1. GeneRuler (0.5 µg/ lane, ~8 cm length gel); Lane 2. blank lane; Lane 3. A549; 
Lane 4. Jurkat; Lane 5. BeWo (1 of 2); Lane 6. BeWo (2 of 2); Lane 7. JAR; Lane 8. JEG-3 (1 of 2); 
Lane 9. JEG-3 (2 of 2); Lane 10. SGHPL-4; Lane 11. human first trimester placental villous tissue 
(Ep63); Lane 12. human term placental villous tissue (T1); Lane 13. blank lane; Lane 14. template-
free control (PCR without template). 
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RYR1 1000 
bp 
500 
bp 
200 
bp 
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Figure 3.1.1.B Selective RT-PCR products of RYR2 from human cell lines and 
human placental villous tissues 
 
 
 
 
 
 
 
 
Figure 3.1.1.B. Reverse-transcription PCR of RYR2. Sequence of RYR2 was amplified from 
total cell RNA extract of SH-SY5Y, BeWo and JAR; sequence of RYR2 was also amplified from 
human first trimester placental villous cDNA (sample E63). Lane 1. GeneRuler (0.5 µg/ lane, ~8 cm 
length gel); Lane 2. blank lane; Lane 3. SHSY-5Y; Lane 4. blank lane; Lane 5. BeWo (1 of 2); Lane 6. 
BeWo (2 of 2); Lane 7. JAR; Lane 8. JEG-3 (1 of 2); Lane 9. JEG-3 (2 of 2); Lane 10. SGHPL-4; 
Lane 11. human first trimester placental villous tissue (Ep63); Lane 12. human term placental villous 
tissue (T1); Lane 13. blank lane; Lane 14. template-free control (PCR without template). 
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Figure 3.1.1.C. Selective RT-PCR products of RYR3 from human cell lines and 
human placental villous tissues 
I. 
 
  
 
 
 
 
 
 
 
 
 
II. 
 
 
III. 
 
 
Figure 3.1.1.C. Reverse-transcription PCR of RYR3 (~1013 bp). Panel I. Product of RYR3 
was amplified from cell total RNA extract of JEG-3 and SGHPL-4; smaller amount of RYR3 product 
was also amplified from RNA extract of human term placental tissue (T1). Lane 1. GeneRuler (0.5 µg/ 
lane, ~8 cm length gel); Lane 2. blank; Lane 3. A549; Lane 4. Jurkat; Lane 5. BeWo (1 of 2); Lane 6. 
BeWo (2 of 2); Lane 7. JAR; Lane 8. JEG-3 (1 of 2); Lane 9. JEG-3 (2 of 2); Lane 10. SGHPL-4; 
Lane 11. human first trimester placental villous tissue (Ep63); Lane 12. human term placental villous 
tissue (T1); Lane 13. blank lane; Lane 14. template-free control (PCR without template). Panel II. 
PCR Products of RYR3 from cells. Lane 1. GeneRuler (0.5 µg/ lane, ~8 cm length gel); Lane 2. blank; 
Lane 3. rabbit skeletal muscle (cDNA); Lane 4. BeWo; Lane 5. JAR; Lane 6. JEG-3; Lane 7. SGHPL-
4; Lane 8. template-free control (PCR without template). Panel III. PCR product of β-ACTIN (~661 bp) 
from cells. Lane 1. GeneRuler (0.5 µg/ lane, ~8 cm length gel); Lane 2. rabbit skeletal muscle (cDNA); 
Lane 3. A549; Lane 4. Jurkat; Lane 5. BeWo; Lane 6. JAR; Lane 7. JEG-3; Lane 8. SGHPL-4; Lane 9. 
template-free control (PCR without template). 
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To determine whether RyR transcripts are present commonly in placental 
villous tissues, three more independent samples of human first trimester villous 
tissue were examined using RT-PCR. Products were visualized by UV illumination 
following agarose gel electrophoresis. As shown in Figure 3.1.2, products of the 
expected size of both RYR1 (Figure 3.1.2.A) and RYR2 (Figure 3.1.2.B) were found 
in samples of Ep64, Ep65, and Ep66, in addition to Ep63 which is presented in 
Figure 3.1.1.  
In contrast, no PCR products of RYR3 transcript were produced by selective 
primers in placental samples examined, while products of RYR1 and RYR2 were 
found in several samples. Amplification of housekeeping gene β-ACTIN in all 
samples indicated the presence of sufficient RNA of suitable quality in each sample, 
and that the amount of cDNA did not vary much between these samples (Figure 
3.1.4). These results indicated the RYR1 and RYR2 mRNA is commonly expressed in 
human first trimester villous placental tissue.  
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Figure 3.1.2 Selective RT-PCR products of RYR1, RYR2 and RYR3 from human 
first trimester placental villous tissue. 
 
Figure 3.1.2.A Selective RT-PCR products of RYR1 from human first trimester 
placental villous tissues 
 
 
 
 
Figure 3.1.2.A. Reverse-transcription PCR of RYR1. Sequence of RYR1 was amplifed from 
cDNA from human first trimester placental villous samples (Ep64, Ep65 and Ep66). Lane 1. 
GeneRuler (0.1 µg/ lane, ~8 cm length gel); Lane 2. blank lane; Lane 3. Ep64; Lane 4. Ep65; Lane 5. 
Ep66; Lane 6. template-free control (PCR without template). 
1 2 3 4 5 6 
RYR1 1000 bp 
500 bp 
100 bp 
 103 
Figure 3.1.2.B Selective RT-PCR products of RYR2 from human first trimester 
placental villous tissues 
 
 
 
Figure 3.1.2.B. Reverse-transcription PCR of RYR2. Sequence of RYR2 was amplified from 
cDNA of human first trimester placental villous samples (E64, Ep65 and Ep66). Lane 1. GeneRuler 
(0.1 µg/ lane, ~8 cm length gel);  Lane 2. blank lane; Lane 3. Ep64; Lane 4. Ep65; Lane 5. Ep66; Lane 
6. template-free control (PCR without template).  
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Figure 3.1.2.C Selective RT-PCR products of RYR3 from human first trimester 
placental villous tissues 
 
 
 
 
 
 
 
Figure 3.1.2.C. Reverse-transcription PCR of RYR3. Sequence of RYR3 was not amplified 
from available human first trimester placental villous samples. Lane 1. GeneRuler (0.5 µg/ lane, ~8 
cm length gel); Lane 2. blank lane; Lane 3. Ep64; Lane 4. Ep65; Lane 5. Ep66; Lane 6. template-free 
control (PCR without template).  
1 2 3 4 5 6 
RYR3 
1000 bp 
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500 bp 
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Similarly, three more independent samples of human term placental villous 
tissue were also examined by RT-PCR. Products were visualized using UV 
illumination following agarose gel electrophoresis. Figure 3.1.3. shows that RYR1 
(Figure 3.1.3. A) and RYR2 (Figure 3.1.3.B) PCR products were amplified from 
samples T3 and T410, respectively. However, no RYR1 and RYR2 PCR products 
were amplified from the other term samples examined. In contrast, RYR3 PCR 
products were detected in 4 out of 5 term placental tissue villous samples, together 
with observation presented in Figure 3.1.1.C. showing that, with the exception of 
sample T4, RYR3 DNA nucleotides were amplified from samples T2, T3 and T410. 
These results indicated that the RYR3 mRNA is detectable in some human term 
placental villous tissue.     
The presence of house-keeping gene human β-ACTIN was examined in 
samples from both human first trimester and term placental villi. Figure 3.1.4 shows 
the expected 661 bp products were detected in first trimester samples (Ep64, Ep65 
and Ep66) and term samples (T2, T3, T4 and T410). These results indicate each 
sample contains a substantial amount of cDNA required for amplification. Therefore, 
the relatively low yield of RYR PCR products was unlikely due to lack of templates.  
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Figure 3.1.3 Selective RT-PCR of RYR1, RYR2 and RYR3 from RNA extracts of 
human term placental villous tissue. 
 
Figure 3.1.3.A Selective RT-PCR of RYR1 from human term placental villous 
tissue 
 
 
 
 
Figure 3.1.3.A. Reverse-transcription PCR of RYR1. Sequence of RYR1 was amplifed from 
RNA extract of human term placental villous sample T3. Lane 1. GeneRuler (0.1 µg/ lane, ~8 cm 
length gel); Lane 2. T2; Lane 3. T3; Lane 4. T4; Lane 5. T410; Lane 6. template-free control (PCR 
without template). 
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Figure 3.1.3.B Selective RT-PCR of RYR2 from human term placental villous 
tissue 
 
 
 
 
 
Figure 3.1.3.B. Reverse-transcription PCR of RYR2. Sequence of RYR2 was amplified from 
RNA extract of human term placental villous sample T410. Lane 1. GeneRuler (0.1 µg/ lane, ~8 cm 
length gel); Lane 2. T2; Lane 3. T3; Lane 4. T4; Lane 5. T410.  
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Figure 3.1.3.C Selective RT-PCR of RYR3 from human term placental villous 
tissue 
 
 
 
 
Figure 3.1.3.C. Reverse-transcription PCR of RYR3. Sequence of RYR3 was amplified from 
RNA extracts from human term placental villous samples (T2, T3 and T410). Lane 1. GeneRuler (0.1 
µg/ lane, ~8 cm length gel); Lane 2. template-free control (PCR without template); Lane 3. T410; 
Lane 4. T4; Lane 5. T3; Lane 6. T2.  
 
6 5 4 3 2 1 
RYR3 1000 bp 
500 bp 
200 bp 
 109 
 
Figure 3.1.4. PCR of β-ACTIN in samples of human first trimester and term 
placental villous tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.4. PCR products of human β-ACTIN. Sequence of β-ACTIN (~661 bp) was 
amplified from samples of both human first and term placental villous samples Lane 1. GeneRuler 
(0.1 µg/ lane, ~8 cm length gel); Lane 2. Ep64; Lane 3. Ep65; Lane 4. Ep66; Lane 5. T2; Lane 6. T3; 
Lane 7, T4; Lane 8, T410; Lane 9. template-free control (PCR without template).  
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3.2 RyR Proteins are Expressed in Human Trophoblast Cell Lines and Tissues: 
Western Blotting   
 
The expression of RyR proteins was also examined by western blotting. 
Figure 3.2.1 shows representative blots probed with various antibodies that recognize 
RyRs. Proteins of approximately 560 kDa apparent molecular weight were detected 
by RS4, an antiserum that recognizes all RyR isoforms, in BeWo, JAR and JEG-3 
membrane fraction preparations, as indicated in Figure 3.2.1.A (n = 4).  
In other independent experiments under the same conditions, antibodies 
specifically recognizing RyR subtypes were used. Figure 3.2.1.B, C and D are the 
representative blots (all n = 4) that were probed with antisera against RyR1, RyR2, 
and RyR3, respectively, at working dilutions shown in Table 2.5.2. Expression of 
RyR1 was detected in JEG-3 and in BeWo cell membrane fraction preparations. The 
expression of RyR2 and RyR3 proteins was not detectable in these western blotting 
experiments. 
Although the expression of RyR subtypes was not detectable using RyR 
isoform seletective antibodies, the expression of RyR1, RyR2 and RyR3 was 
detected in rat skeletal muscle, heart muscle and brain tissue microsomes, 
respectively. Among these positive control samples, both RyR1 and RyR3 were 
detected in rat brain microsomal preparations.  
The expression of RyRs was also determined in human placental tissues 
homogenates. Figure 3.2.2 showed the representative blot (n = 3) incubated with pan-
RyR antiserum (RS4), which indicated both first trimester and term placental villous 
tissue expressing RyRs, along with samples of rat skeletal muscle, SH-SY5Y cells 
and BeWo cells.     
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Figure 3.2.1 Expression of RyRs in human trophoblast cell lines detected by 
western blotting. 
 
Figure 3.2.1.A RyR proteins in human trophoblast cell lines: western blot 
 
 
 
 
Figure 3.2.1.A. Representative blot (n = 4) using antiserum RS4 that recognizes all RyR 
isoforms: expression of RyRs was detected in microsomes from both rat brain and skeletal muscle, 
and membrane fraction preparation of BeWo, JAR and JEG-3. Higher molecular weight protein bands 
of RyR were recognized by this pan RyR antisera in BeWo and JAR samples. Samples were loaded 
with 80 µg of protein per well. Lane 1. rat brain microsomes; Lane 2. rat heart microsomes; Lane 3. 
rat skeletal muscle microsomes; Lane 4. BeWo membrane fraction; Lane 5. JAR membrane fraction; 
Lane 6. JEG-3 membrane fraction; Lane 7. SGHPL-4 membrane fraction.  
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7 
250 kDa 
160 kDa 
 112 
 
Figure 3.2.1.B RyR1 in human trophoblast cell lines: western blot 
 
 
 
 
 
Figure 3.2.1.B. Representative blot (n = 4) probed with an antiserum recognizes RyR1: 
expression of RyR1 was detected in microsomes of both rat brain and skeletal muscle, and membrane 
fraction preparations of BeWo and JEG-3. Samples were loaded with 80 µg of protein per well. Lane 
1. rat brain microsomes; Lane 2. rat heart microsomes; Lane 3. rat skeletal muscle microsomes; Lane 
4. BeWo membrane fraction; Lane 5. JAR membrane fraction; Lane 6. JEG-3 membrane fraction.  
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Figure 3.2.1.C RyR2 in human trophoblast cell lines: western blot 
 
 
 
 
 
Figure 3.2.1.C. Representative blot (n = 4) probed with an antiserum recognizes RyR2: 
expression of RyR2 was not detected in any human trophoblast cell lines (BeWo, JAR, JEG-3 and 
SGHPL-4). Samples were loaded with 80 µg of protein per well. Lane 1. rat brain microsomes; Lane 2. 
rat heart microsomes; Lane 3. rat skeletal muscle microsomes; Lane 4. BeWo membrane fraction; 
Lane 5. JAR membrane fraction; Lane 6. JEG-3 membrane fraction; Lane 7. SGHPL-4 membrane 
fraction.  
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Figure 3.2.1.D RyR3 in human trophoblast cell lines: western blot 
 
 
 
 
 
Figure 3.2.1.D. Representative blot (n = 4) probed with an antiserum recognizes RyR3: 
expression of RyR3 was not detected in human trophoblast cell lines (BeWo, JAR, JEG-3 and 
SGHPL-4). Samples were loaded approximately 80 µg of protein per well. Lane 1. rat brain 
microsomes; Lane 2. rat heart microsomes; Lane 3. rat skeletal muscle microsomes; Lane 4. BeWo 
membrane fraction; Lane 5. JAR membrane fraction; Lane 6. JEG-3 membrane fraction; Lane 7. 
SGHPL-4 membrane fraction.  
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Figure 3.2.2 RyRs in human placental tissues: western blot  
 
 
 
 
Figure 3.2.2. Representative blot (n = 3) using antiserum RS4 that recognizes all RyR 
isoforms: expression of RyRs was detected in microsomes of rat skeletal muscle, membrane fraction 
preparations of SH-SY5Y and BeWo cell-lines, and in homogenates of both human first trimester and 
term placental tissue. Samples were loaded approximately 80 µg of protein per well. Lane 1. rat 
skeletal muscle microsomes; Lane 2. SH-SY5Y membrane fraction; Lane 3. BeWo membrane fraction; 
Lane 4. JAR membrane fraction; Lane 5. JEG-3 membrane fraction; Lane 6. human first trimester 
placental homogenate; Lane 7. human term placental homogenate. 
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3.3 RyR Accessory Proteins, CSQ and TRD, are Expressed in Human Trophoblast 
Cell Lines and Tissues: Western Blotting.   
 
To determine whether RyR accessory proteins are expressed along with RyRs, 
the expression of CSQ and TRD was examined in both human trophoblast cell lines 
and human term placental villous tissues. High levels of CSQs were detected in rat 
heart and skeletal muscle microsomes (Lane 1 and Lane 2, respectively, Figure 3.3.1 
(n = 3)); along with these two positive control samples, CSQ was detected in the 
trophoblast cell lines BeWo and JEG-3.  The 55 kDa RyR accessory proteins were 
also detected in five independent human term placental villous tissue homogenates, 
as indicated in Figure 3.3.1. In addition to CSQ, the 97 kDa CSQ-like proteins 
(Zhang et al.,1997) were also found in BeWo, JEG-3 and differentiated C2C12 
myotubes. 
Expression of another accessory protein TRD was also determined. The 
trophoblast cell lines of BeWo, JAR, JEG-3 and SGHPL-4 were found to express 
TRD as indicated in blot image, Figure 3.3.2.A. In human samples, TRD was 
detected in sample Ep1 and Ep4 of first trimester villous homogenates, and sample 
T1 term placental villous homogenates (Figure 3.3.2.B (n = 3)). 
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Figure 3.3.1 CSQ in trophoblast cells and human tissues: western blot 
 
 
Figure 3.3.1. Representative blot (n = 3) using an antiserum recognizes all CSQ isoforms: 
expression of CSQs was detected in all samples examined from both cell lines and tissue. The 97 kDa 
CSQ-like proteins were also detected in human trophoblast cell lines (BeWo and JEG-3) and in 
differentiated C2C12 myoblasts. Samples were loaded with 80 µg of protein per well. Lane 1. rat heart 
microsomes; Lane 2. rat skeletal muscle microsomes; Lane 3. cell lysate of differentiated C2C12 
myotubes; Lane 4. BeWo membrane fraction; Lane 5. JEG-3 membrane fraction; Lane 6 to Lane 10. 
Samples (359, 364, 374, 387, 393) of human term placental homogenate. 
 
 
1 2 3 4 5 6 7 8 9 10 
100 kDa 
50 kDa 
CSQ-like 
proteins 
CSQs 
250 kDa 
 118 
 
Figure 3.3.2 Determination of TRD expression by western blotting. 
 
Figure 3.3.2.A TRD in trophoblast cells: western blot 
 
 
 
Figure 3.3.2.A. Determination of triadin (TRD) expression in human trophoblast cell lines 
by western blotting (n = 3). Each well was loaded with 60 µg of protein. The antiserum used 
recognizes all TRD isoforms. Expression of TRDs was detected in all samples examined (human 
trophoblast cell lines: BeWo, JAR, JEG-3 and SGHPL-4). Lane 1. BeWo membrane fraction; Lane 2. 
JAR memebrane fraction; Lane 3. JEG-3 membrane fraction; Lane 4. SGHPL-4 cell lysate. 
 
 
  
 
1 2 3 4 
100 kDa TRD 
250 kDa 
50 kDa 
 119 
 
Figure 3.3.2.B TRD in human placental tissues: western blot 
  
 
 
 
Figure 3.3.2.B. Determination of triadin (TRD) expression in human placental tissue by 
western blotting (n = 3). The antiserum used recognizes all TRD isoforms. Expression of TRDs was 
detected in human first trimester villous homogenate samples (first trimester sample Ep1 and Ep4, and 
human term placental villous sample T1). Lane 1. rat heart microsomes (70 µg protein); Lane 2. 
human first trimester villous homogenate (Ep1, 70 µg protein); Lane 3. human first trimester villous 
homogenate (Ep3, 50 µg protein); Lane 4. human first trimester villous homogenate (Ep4, 70 µg 
protein); Lane 5. human term placental villous homogenate (T1, 70 µg protein); Lane 6. human term 
placental villous homogenate (T2, 50 µg protein); Lane 7, human term placental villous homogenate 
(T3, 40 µg protein). 
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3.4 Expression of RyRs and TRD Revealed in Human Placental Villous Tissue 
Sections 
 
To determine whether RyRs and their accessory proteins are primarily 
expressed in human placental tissues rather than just being present in 
choriocarcinoma cell lines that originated from the trophoblasts of human placenta, 
paraffin embedded human trophoblast tissue sections were examined by IHC as 
described in Chapter II 2.10. Results of sections from both first trimester and term 
tissues supported the protein expression of RyR1, RyR3, and TRD in human 
trophoblast tissues.  
 
 
3.4.1 RyRs and TRD are expressed in human first trimester villous trophoblast 
 
Figure 3.4.1 shows representative IHC images of human first trimester villous 
sections (n = 3). The brown staining represents the DAB detection of peroxidase 
activity; the blue stain represents counterstaining with Harris’s haematoxylin. Both 
syncytiotrophoblasts (outer monolayer of the villi) and cytotrophoblasts (cell layer 
underneath the syncytiotrophoblasts) were stained positively as shown in panel A, C 
and D of Figure 3.4.1. This brown colour development in sections implies that RyR1 
(A), RyR3 (C) and TRD (D) are present in both syncytio- (* SCT) and cyto- (▲CT) 
trophoblast of human first trimester placental villous tissue. In contrast, panel B 
shows no detectable staining for RyR2. Panel E shows a positive control IHC image, 
stained using anti-cytokeratin 7, which outlined cells of interest including both 
syncytio- and cyto- trophoblast cell layers. Panel F presented the primary antibody-
free control IHC image, in which, these sections were stained in parallel with other 
sections but without adding primary antibody.  
 121 
Figure 3.4.1 RyRs and TRD in human first trimester villous tissues: IHC 
 
Figure 3.4.1. Determination of RyRs and TRD expression in human first trimester placental 
villous tissue section by IHC (n = 3). * SCT: Syncytiotrophoblast; ▲CT: cytotrophoblast. Panel A. 
Antiserum used recognizes RyR1; Panel B. Antiserum used recognizes RyR2; Panel C. Antiserum 
used recognizes RyR3; Panel D. Antiserum used recognizes all TRD isoforms; Panel E. Antiserum 
used recognizes cytokeatin 7; Panel F. no primary antiserum was applied.  
A. RyR1 B. RyR2 
C. RyR3 D. Triadin 
E. Cytokeratin 7 F. Null 
Scale: 10 µm 
* 
▲
▲
* 
* 
▲
▲
* 
* 
* 
▲
▲
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3.4.2 RyRs and TRD are expressed in human term placental villous trophoblast 
 
Figure 3.4.2 shows representative IHC images of human term placental 
villous sections (n = 3). Similar to IHC results in first trimester sections, both 
syncytio- (* SCT) and cyto- (▲CT) trophoblast of term placental villous sections 
were stained positively with primary antibodies recognising RyR1, RyR3 and TRD, 
as indicated by brown colour development in panel A, C and D of Figure 3.4.2, 
respectively; while sections stained with anti-RyR2 antibody showed no positive 
staining, as the corresponding representative IHC image in Panel B displayed no 
detectable difference in sections performed as primary antibody-free controls in 
Panel F.  
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Figure 3.4.2 RyRs and TRD in human term placental villous tissues: IHC 
 
 
Figure 3.4.2. Determination of RyRs and TRD expression in human term placental villous 
tissue section by IHC (n = 3). * SCT: Syncytiotrophoblast; ▲CT: cytotrophoblast. Panel A. 
Antiserum used recognizes RyR1; Panel B. Antiserum used recognizes RyR2; Panel C. Antiserum 
used recognizes RyR3; Panel D. Antiserum used recognizes all TRD isoforms; Panel E. Antiserum 
used recognizes cytokeratin 7; Panel F. no primary antiserum was applied.  
A. RyR1 B. RyR2 
C. RyR3 D. Triadin 
E. Cytokeratin 7 F. Null 
Scale: 10 µm 
* 
▲
* 
▲
* 
▲
* 
▲
* 
▲
* 
▲
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3.4.3 RyR2 is expressed in trophoblast of human first trimester decidua 
 
Representative IHC images from both human first trimester and term 
placental villous sections displayed negative staining for RyR2, as shown in Figure 
3.4.1.B and Figure 3.4.2.B shown. However, a preliminary result shows RyR2 
staining was positive in one sample from sections of human first trimester decidua 
(EP98DC). These sections contained invasive forms of trophoblast, the extravillous 
trophoblast. Cytokeratin 7 is a known specific marker for human trophoblast (Haighn 
et al.,1999); this protein marker is also expressed in extravillous trophoblast 
(Hallikas et al.,2006). In current study, cytokeratin 7 was used as marker of all types 
of trophoblast. Figure 3.4.3.C shows trophoblastic cells that were identified by 
antibodies recognising cytokeratin 7 (▲) localised as outer layer of cells in this 
tissue section. Another section from the same sample was treated with primary 
antibodies recognising RyR2. In this experiment, positive staining of cells 
morphologically remembling trophoblasts (▲) was obtained as shown in Figure 
3.4.3.A. This result indicates the anti-serum used to label RyR2 (HPA016697, Sigma) 
was workable in current IHC method; RyR2-positve section found in samples of 
placental decidua but not in villi, suggesting differential expression of RyR2 in 
different trophoblast populations.  
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Figure 3.4.3  RyR2 in human first trimester decidua bed (IHC) 
 
Figure 3.4.3 RyR2 expression detected using IHC in decidua bed of first trimester tissue 
sections (Sample: EP98DC). Panel A. The antiserum used recognizes RyR2 (HPA016697, Sigma).▲: 
trophoblast. Panel B. Negative control (no primary antibody used); Panel C. Cytokeratin 7 stain 
indicating trophoblastic cells within tissue section. 
A. RyR2 
B. -ve 
C. Cytokeratin 7 
▲ 
▲
Scale: 100 µm 
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3.5 Determination of RyRs, CSQs and TRDs in BeWo and JEG-3: 
immunofluorescence microscopy  
 
RT-PCR and western blotting data indicated that both RyR transcripts and 
proteins were detectable in BeWo and JEG-3 cell lines. Transcripts encoding RyR1 
and RyR2 and protein expression of RyR1 were detectable in BeWo, whereas mRNA 
transcripts of RyR3 and protein expression of RyR1 were found in JEG-3. In 
addition, RyR proteins in both BeWo and JEG-3 were recognising by RS4 anti-
panRyR serum. In other words, of all cell lines examined, BeWo and JEG-3 had the 
most extensive evidence of RyR expression. Therefore, both BeWo and JEG-3 were 
chosen for indirect immunofluorescence (IF) microscopy and Ca
2+
-imaging studies 
as described in the following sections. 
 
 
3.5.1 RyRs are distributed intracellularly in BeWo and JEG-3 cells 
 
Apart from ER/SR membrane-expressing RyRs, expression of RyRs has been 
revealed in other areas of cells, such as plasma membranes and mitochondira (Zaidi 
et al.,1995; Beutner et al.,2001). To determine whether RyRs are expressed on the 
ER membrane of trophoblastic cell lines, BeWo and JEG-3 cells were treated with 
rabbit anti-RyR isoform specific antisera together with either mouse anti-E-cadherin 
or mouse anti-pan-cadherin primary antibodies. Cells were then incubated with Cy2-
conjugated anti-rabbit and Cy3-conjugated anti-mouse secondary antibodies that 
recognized the corresponding primary antibodies. Cadherin is regarded as a plasma 
membrane marker that outlines cell membrane. E-cadherin is reported to be 
expressed in both BeWo and JEG-3 trophoblast (Coutifaris et al.,1991; Al-Nasiry et 
al.,2006; Pospechova et al.,2009).  
The IF images in Figure 3.5.1.A indicate the presence of RyR1, RyR2 and 
RyR3 by Cy2-conjugated IgG as green fluorescence (Figure 3.5.1.A, left column), 
with a recticular intracellular distribution in BeWo cells (n = 4). Detection of E-
cadherin by Cy3-conjugated IgG that presented in red fluorescence (Figure 3.5.1.A, 
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middle column), which was limited within cell plasma membrane. Merged images 
shown limited overlap of green and red fluorescence (Figure 3.5.1.A, right column), 
indicating that RyR1, RyR2 and RyR3 were localized within ER/ cytoplasm rather 
than being juxtaposed to the plasma membrane of BeWo cells.  
Similarly, detection of RyR1, RyR2 and RyR3 by IF in JEG-3 cells also 
revealed the reticular, intracellular distribution of all three RyR isoforms (Figure 
3.5.1.B). The green fluorescence was more intense in perinuclear regions (Figure 
3.5.1.B, left column), consistent with an ER localization of RyR expression. The 
primary antibodies of plasma membrane marker used in JEG-3 cells for IF detection 
recognized all types of cadherin protein, which resulted in a stronger intensity of red 
fluorescence (Figure 3.5.1.B, middle column) when coupled to Cy3-conjugated 
secondary antibodies. Although overlaps of green and red fluorescence appeared in 
intracellular space of JEG-3 cells in merged images (Figure 3.5.1.B, right column), 
areas of cell-cell contact still presented strong red fluorescence without extensive 
overlap with green fluorescence. 
In both BeWo and JEG-3 cells, there was no non-specific fluorescence 
detected in either green or red channels when cells were treated under the same 
experimental conditions but without adding primary antibodies (BeWo cells: Figure 
3.5.1.A, bottom row; JEG-3 cells: Figure 3.5.1.B, bottom row). These results 
indicated that the fluorescence that produced by secondary antibodies (Cy2-/Cy3-
conjugated) was dependent on the recognition of antigens by their primary antibodies. 
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Figure 3.5.1.A RyRs in BeWo cells: immunofluorescence microscopy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.1.A. Immunofluorescence microscopy of BeWo cells. ‘Green fluorescence’ 
images at the left column (panels A, D, G and J): Cy2-conjugated anti-rabbit secondary antibodies are 
used; ‘Red fluorescence’ images at the middle column (panels B, E, H and K): Cy3-conjugated anti-
mouse secondary antibodies are used; Merged images at the right column (panels C, F, I and L): Cy2- 
(green) and Cy3- (red) stained images merge with DAPI- (blue) stained images. Panels A, D and G: 
Cy2-conjugated anti-rabbit secondary antibodies (green fluorescence) recognize primary antiserum of 
RyR1, RyR2 and RyR3, respectively; Panels B, E and H: Cy3-conjugated anti-mouse secondary 
antibodies (red fluorescence) recognize primary antiserum of E cadherin. Bottom images (Panels C, F 
and I): no primary antiserum was applied.  
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Figure 3.5.1.B RyRs in JEG-3 cells: immunofluorescence microscopy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.1.B. Immunofluorescence microscopy of JEG-3 cells. ‘Green fluorescence’ 
images at the left column (panels A, D, G and J): Cy2-conjugated anti-rabbit secondary antibodies are 
used; ‘Red fluorescence’ images at the middle column (panels B, E, H and K): Cy3-conjugated anti-
mouse secondary antibodies are used; Merge images at the right column (panels C, F, I and L): Cy2- 
(green) and Cy3- (red) stained images merge with DAPI- (blue) stained images. Panels A, D and G: 
Cy2-conjugated anti-rabbit secondary antibodies (green fluorescence) recognize primary antiserum of 
RyR1, RyR2 and RyR3, respectively; Panels B, E and H: Cy3-conjugated anti-mouse secondary 
antibodies (red fluorescence) recognize primary antiserum of pan cadherin. Bottom images (Panels C, 
F and I): no primary antiserum was applied.  
Anti-pan Cadherin Merge 
Scale: 10 µm 
Anti-RyR 
RyR1 
RyR2 
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null 
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3.5.2 CSQs are Co-distributed with RyRs in BeWo and JEG-3 Cells 
 
Western blot analyses in the current study have shown that RyRs, CSQs and 
TRDs are detected in BeWo and JEG-3 cells. To find out whether these RyR 
accessory proteins are co-distributed with RyRs, BeWo and JEG-3 cells were stained 
with anti pan-CSQ (Cy2: green) and anti pan-RyR (Cy3: red) antibodies, respectively. 
Figure 3.5.2 shows that overlaps of green (Cy2) and red (Cy3) occurred in the 
intracellular structures surrounding the nucleus in both BeWo (Figure 3.5.2.J) and 
JEG-3 (Figure 3.5.2.K) cells. This observation indicated that CSQ and RyRs were 
co-distributed in a perinuclear domain in BeWo and JEG-3 cells.  
The Cy2-conjugated green fluorescence stain was also visualized in a 
perinuclear region in BeWo cells (Figure 3.5.2.G), which suggests that CSQ is 
present within the ER membrane that surrounds the nucleus. In contrast, the 
distribution of anti-RyR (Cy3: red) in JEG-3 cells (Figure 3.5.2.H) extended from 
nuclear membrane to the plasma membrane.  
Differentiated C2C12 mouse myotubes (Figure 3.5.2.C, F, I, and L) served as 
positive controls for expression of RyRs (Lorenzon et al.,2000) and CSQs (Shin et 
al.,2003). The extensively overlap of green and red fluorescence suggests that RyRs 
and CSQ were co-distributed in C2C12 mouse myotubes.  
 
 131 
 
Figure 3.5.2 CSQs and RyRs in BeWo and JEG-3 Cells: immunofluorescence 
microscopy 
 
Figure 3.5.2. Immunofluorescence microscopy of BeWo (left column), JEG-3 (middle 
column) and differentiated C2C12 (right column) cells. ‘Green fluorescence’ images (panels A, B and 
C): Cy2-conjugated anti-rabbit secondary antibodies are used, of which recognize primary antiserum 
of all types of CSQ; ‘Red fluorescence’ images (panels D, E and F): Cy3-conjugated anti-mouse 
secondary antibodies are used, of which recognize primary antiserum of all types of RyR. Merged 
images (panels G, H and I): Cy2- (green) merged with Cy3- (red) stained images. Merged images 
(panels J, K and L): Cy2- (green) and Cy3- (red) stained images merged with DAPI- (blue) stained 
images.  
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3.5.3 CSQs co-distribute with TRD in BeWo and JEG-3 cells 
 
Both CSQ (Figure 3.3.1) and TRD (3.3.2.A) were detected in BeWo and 
JEG-3 cells by western blotting. In order to determine whether CSQs and TRDs are 
co-distribute within the same region of cells, BeWo and JEG-3 cells were stained 
with anti-pan-CSQ and anti-TRD antibodies and visualized using IF microscopy. 
Figure 3.5.3 shows overlaps of CSQ and red TRD occurred in a perinuclear 
intracellular region in both BeWo (Figure 3.5.3.J) and JEG-3 (Figure 3.5.3.K) cells. 
This observation indicated that CSQ and TRD were co-distributed in the perinuclear 
region of BeWo and JEG-3 cells. In addition, the red fluorescence staining that 
represents TRD cellular distribution found in BeWo (Figure 3.5.3.D) and JEG-3 
(Figure 3.5.3.E) cells was similar to that observed in IF stain of RyRs (Figure 3.5.2.D, 
and E, for BeWo and JEG-3, respectively). Therefore, TRD was expected to also co-
distribute with RyRs.  
Differentiated C2C12 mouse myotubes (Figure 3.5.3.C, F, I, and L) served as 
positive controls for expression of both CSQ (Shin et al.,2003) and TRD (Fodor et 
al.,2008; Wang et al.,2009). The overlap of green and red fluorescence implies that 
CSQ and TRD were co-expressed, along with RyRs, in C2C12 mouse myotubes. 
. 
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Figure 3.5.3 CSQs and TRDs in BeWo and JEG-3 cells: immunofluorescence 
microscopy 
 
Figure 3.5.3. Immunofluorescence microscopy of BeWo (left column), JEG-3 (middle 
column) and differentiated C2C12 (right column) cells. ‘Green fluorescence’ images (panels A, B and 
C): Cy2-conjugated anti-rabbit secondary antibodies are used, which recognize primary antiserum of 
all types of CSQ; ‘Red fluorescence’ images (panels D, E and F): Cy3-conjugated anti-mouse 
secondary antibodies are used, which recognize primary antiserum of TRDs. Merged images (panels 
G, H and I): Cy2- (green) merge with Cy3- (red) stained images. Merged images (panels J, K and L): 
Cy2- (green) and Cy3- (red) stained images merged with DAPI- (blue) stained images.  
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Chapter IV. Functional Analysis of Ryanodine Receptors in 
Human Trophoblast Cell Lines 
  
By use of RT-PCR, immunoblotting and immunofluorescence microscopy, 
the previous results chapter indicated the expression of more than one isoform of 
RyR in both BeWo and JEG-3 cells. To find out whether the RyR proteins in 
trophoblasts are actively involved in [Ca
2+
]i homeostasis, BeWo and JEG-3 were 
treated with various agents, including RyR agonists and antagonists. Changes of 
[Ca
2+
]i were monitored by using ratiometric fluorescence dye fura-2, as described in 
Chapter II, 2.12. Data are expressed as mean ± S.E.M. and were analysed using 
GraphPad Prism version 4.0. Unpaired t tests were used to compare differences in 
changes in mean fura-2 ratio between two groups, while one-way ANOVA followed 
by Tukey’s test was used to analyse between more than two groups. A P-value < 
0.05 was considered statistically significant. 
 
4.1 CmC induces rapid increases in fura-2 ratio in BeWo and JEG-3 cells  
 
To examine whether the RyRs expressed in BeWo and JEG-3 trophoblast cell 
lines are functionally involved in [Ca
2+
]i regulation, RyR agonists were applied to 
cells and changes of [Ca
2+
]i were indicated by changes in fura-2 ratios. Figure 4.1.1 
shows a representative trace of mean fura-2 ratio over time during stimulation with 
500 µM CmC in BeWo cells. CmC is a RyR activator that has higher selectivity for 
RyR1 and RyR2 rather than for RyR3 (Zorzato et al.,1993; Herrmann-Frank et 
al.,1996; Matyash et al.,2002). As Figure 4.1.1.A shows, an increase in fura-2 ratio 
was observed in BeWo cells, with the maximal rise in mean fura-2 ratio of 0.41 ± 
0.06 (n = 7) over basal level (0.55 ± 0.06); the rise of fura-2 ratio was equivalent to 
increase over the basal as a percentage of 69 ± 19 %. A fast drop of mean fura-2 ratio 
followed the peak increase, and the fura-2 fluorescence at both 340 nm and 380 nm 
wavelength was completely lost within 3 minutes of the addition of CmC. The  
pseudocolour ratio images in Figure 4.1.1.B display high colour constrast between 
peak response to CmC (~175 s) and pre-stimulation ratios, indicating a large change 
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in fura-2 ratio and [Ca
2+
]i. The loss of fluorescence in cells might indicate that the 
fura-2 dye leaked out into the extracellular space. This unexpected outcome from 
CmC stimulation suggests that this molecule had effects on memebrane permeability 
that might not be dependent on RyR activation.   
Increases in mean fura-2 ratio were also observed in JEG-3 cells upon 
addition of 500 µM CmC. Two types of response were observed. Figure 4.1.2.A is 
representative of one type of response in JEG-3 cells, observed in 6 out of 16 
independent experiments, as representative trace shown in Figure 4.1.2.A. A plateau-
like rise in mean fura-2 ratio was detected after the initially rapid increase within 200 
seconds, as indicated in the pseudocolour images in Figure 4.1.2.B. Meanwhile, in 
the other 10 out of 16 experiments, a rapid rise of fura-2 ratio was followed by a 
slow decline, as shown in Figure 4.1.3. During the recording period, a less rapid 
decrease in ratio than in observed BeWo cells was detected after maximum increase 
was reached, as represented in Figure 4.1.3.A. Pseudocolour images shown in Figure 
4.1.3.B displayed a smaller change between peak response and resting ratios in JEG-
3 cells. Despite these were two different types of response following the peak, 
similar maximal increases in ratio were measured. The average peak change of mean 
fura-2 ratio was 0.23 ± 0.02 (n = 16) over basal ratio (0.49 ± 0.04), equivalent to 37 ± 
4 % increase above the resting value.  
Addition of ryanodine to BeWo and JEG-3 cells triggered distinct Ca
2+
 
responses from those caused by CmC. A representative trace in Figure 4.1.4.A 
indicates a gradual increase in fura-2 ratio in BeWo cells when 1 µM ryanodine was 
applied, and the elevated fura-2 ratio did not decrease with time; the change of mean 
fura-2 ratio was measured as 0.24 ± 0.03 (n = 11) over basal ratio (0.54 ± 0.02), 
equivalent to 44 ± 6 % increase of the basal. Addition of 1 µM ryanodine to JEG-3 
cells caused an initial rise in mean fura-2 ratio of 0.18 ± 0.02 (n = 9) over basal level 
(0.58 ± 0.03), equivalent to 25 ± 4 % increase of the resting value. This change fully 
recovered within approximately 4 minutes after addition of ryanodine. The 
representative trace in Figure 4.1.4.B displayed the mean fura-2 ratio against time 
during pharmacological stimulation with ryanodine in JEG-3 cells. As shown in the 
trace, the mean fura-2 ratio at the end of stimulation had returned to a steady level. 
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Figure 4.1.1 Changes in fura-2 ratio in BeWo cells in response to CmC. 
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Figure 4.1.1. BeWo cell calcium response to CmC. Panel A. Representative trace of mean 
fura-2 ratio in BeWo (n = 7) cells in response to CmC. The black bar at the top represents the 
stimulation period; light blue trace represents mean fura-2 ratio during addition of vehicle; dark blue 
trace represents mean fura-2 ratio during addition of 500 µM CmC. Panel B. Pseudocolour images of 
change in fura-2 ratio during CmC stimulation in BeWo cells at about 0, 100, 175, and 250 seconds. 
The look up table in the upper left indicates the fura-2 ratio from 0 to 1.2, as a pseudocolour scale. 
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Figure 4.1.2 Changes in fura-2 ratio in JEG-3 cells in response to CmC (type 1). 
A. 
   
B. 
 
Figure 4.1.2. JEG-3 cell calcium response to CmC (type 1). Panel A. Representative trace of 
mean fura-2 ratio in JEG-3 (n = 6) cells in response to CmC. The black bar at the top represents the 
stimulation period; light blue trace represents mean fura-2 ratio during addition of vehicle; dark blue 
trace represents mean fura-2 ratio during addition of 500 µM CmC. Panel B. Pseudocolour images of 
change in fura-2 ratio during CmC stimulation in JEG-3 cells at about 0, 150, 200, and 300 seconds. 
The look up table on the upper left indicates the fura-2 ratio from 0 to 1.2, as a pseudocolour scale. 
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Figure 4.1.3 Changes in fura-2 ratio in JEG-3 cells in response to CmC (type 2). 
A. 
  
B. 
 
Figure 4.1.3. JEG-3 cell calcium response to CmC (type 2). Panel A. Representative trace of 
mean fura-2 ratio in JEG-3 (n = 10) cells in response to CmC. The black bar at the top represents the 
stimulation period; light blue trace represents mean fura-2 ratio during addition of vehicle; dark blue 
trace represents mean fura-2 ratio during addition of 500 µM CmC. Panel B. Pseudocolour images of 
change in fura-2 ratio during CmC stimulation in JEG-3 cells at about 0, 150, 200, and 300 seconds. 
The look up table on upper left indicates the fura-2 ratio from 0 to 1.2, as a pseudocolour scale. 
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Figure 4.1.4 Changes in fura-2 ratio in BeWo and JEG-3 cells in response to 
ryanodine. 
 
A. BeWo  
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 50 100 150 200 250 300 350 400 450 500
Time (s)
M
ea
n
 F
u
ra
-2
 R
a
ti
o
 (
3
4
0
:3
8
0
 n
m
)
1µM Ryanodine
 
B. JEG-3 
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Figure 4.1.4. Representative traces of changes in fura-2 ratio in BeWo (panel A, n = 11) and 
JEG-3 (panel B, n = 9) cells in response to ryanodine. In both Panel A and B: the black bar at the top 
represents stimulation period; dark blue trace represents change in fura-2 ratio during addition of 1 
µM ryanodine. 
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4.2 Dantrolene decreases fura-2 ratio in BeWo and JEG-3 cells.  
           
To further examine the involvement of RyRs in the elevation of [Ca
2+
]i 
stimulated by CmC or ryanodine in BeWo and JEG-3 cells, the RyR subtype 
selective antagonist dantrolene was pre-incubated with cells before the application of 
these agonists. Dantrolene is a muscle relaxant that is clinically used for the 
treatment of malignant hyperthermia. The inhibitory effect of dantrolene on RyRs is 
by directly targeting RyR1 and RyR3 to reduce the Ca
2+
-sensitivity of the channel 
activation (Fruen et al.,1997), but not that of RyR2 (Zhao et al.,2001). Therefore, 
incompleted suppression or partial inhibition of [Ca
2+
]i elevation is expected on the 
co-application of dantrolene with CmC or ryanodine on cells that co-express RyR2 
with other RyR subtypes. 
Figure 4.2.1 panel A, shows a representative trace of mean fura-2 ratio 
against time during the co-application of dantrolene and CmC in BeWo cells. 
Dantrolene (50 µM) was added and cells were incubated with this drug for 3 to 4 
minutes before the addition of CmC. A decline followed by a slow incline of fura-2 
ratio was observed during dantrolene pre-incubation in BeWo cells. Subsequent 
addition CmC resulted in a smaller increase of mean fura-2 ratio than when CmC 
was added alone. This observation indicates that the increase of fura-2 ratio induced 
by CmC was partially suppressed by dantrolene. The maximum change in mean fura-
2 ratio was 0.24 ± 0.04 (n = 17) over basal level (0.46 ± 0.02), which was equivalent 
to 45 ± 7 % increase of the basal value. Despite the pre-incubation with dantrolene, 
the fura-2 signal was completely lost within 5 minutes after addition of CmC to 
BeWo cells. Similar partial inhibition in BeWo cells was also observed when 
dantrolene was co-applied with ryanodine. The application of ryanodine after 
dantrolene pre-incubation resulted in a smaller increase in mean fura-2 ratio than that 
induced by ryanodine alone. Figure 4.2.2 panel A shows a representative trace of 
mean fura-2 ratio during co-application of dantrolene and ryanodine; the change of 
mean fura-2 ratio was 0.09 ± 0.03 (n = 7), which was equivalent to 20 ± 4 % increase 
above the basal value (0.53 ± 0.02). 
Pre-incubation with dantrolene in JEG-3 cells, however, resulted in complete 
suppression in both CmC and ryanodine-induced [Ca
2+
]i elevation. Panels B of 
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Figure 4.2.1 and Figure 4.2.2 show representative traces of mean fura-2 ratio upon 
addition of CmC and ryanodine after dantrolene pre-treatment, respectively. Neither 
CmC nor ryanodine were able to induce rises in fura-2 ratio in JEG-3 cells pre-
incubated with dantrolene. In addition, the post-dantrolene fura-2 ratios were lower 
than that pre-dantrolene ratio in these cells, regardless of the addition of either CmC 
or ryanodine.  
Decreases in fura-2 ratios were observed in both BeWo and JEG-3 cells 
during the application of dantrolene, suggesting that this drug may interfere with 
intracellular Ca
2+
 homeostasis by blocking channels participating in either Ca
2+
 
release, Ca
2+
 influx, or both. There is also a possibility that dantrolene induces 
change in fura-2 ratios by a photochemical rather than a physiological mechanism. 
Published data indicates that dantrolene can enhance cellular autofluorescence at UV 
wavelengths, particularly at the 380 nm wavelength used to excite the calcium-free 
form of fura-2 (Nohmi et al.,1991). Therefore, it was essential to examine the effect 
of dantrolene on the fluorescence emitted at either 340 nm or 380 nm in the cells 
used in this study. Such examination was necessary to determine whether dantrolene 
can be used in combination with fura-2 AM in current study.  
Responses during dantrolene stimulation of BeWo and JEG-3 cells are shown 
in Figure 4.2.3. Traces of mean fura-2 ratio, along with mean fluorescence intensity 
(AU, arbitrary unit) at either 340 nm (F340) and 380 nm (F380) excitation wavelength 
are shown in the same graph. In both BeWo and JEG-3 cells, the appearance of 
steady red traces (F340) indicated little changes in [Ca
2+
]i. The ranges of these Ca
2+
-
sensitive traces were seemingly from 180 to 190 AU in BeWo cells, and from 160 to 
165 AU in JEG-3 cells, respectively, as shown in Figure 4.2.3. This result indicated 
that dantrolene has little effect on the intracellular Ca
2+
 balance in both BeWo 
(Figure 4.2.3.A) and JEG-3 cells (Figure 4.2.3.B). However, despite the presence of 
a stable Ca
2+
-sensitive F340 intensity, increased F380 was observed upon addition of 
dantrolene, as blue traces in Figure 4.2.3.A and B indicate. These blue traces (F380) 
represent the change in fluorescence intensity that is independent of [Ca
2+
]i. In these 
representative experiments, F380 in BeWo cells increased from 356 AU to 508 AU; 
whereas, in JEG-3 cells raised from 259 AU to 349 AU. As a result, increase in F380 
with little change in F340 caused declines in fura-2 ratios, as indicated by purple 
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traces. In BeWo cells, dantrolene induced a decrease (from 0.50 down to 0.37) 
followed by a slow increase in fura-2 ratio (up to 0.63); whereas, the recovery of 
decline in fura-2 ratio stimulated by dantrolene in JEG-3 cells was not seen, as ratios 
dropped from 0.49 to 0.39, and only increased to 0.41 by the end of the experiment. 
These values are similar to those observed when RyR-agonists (CmC and ryanodine) 
were added after dantrolene pre-incubation. Therefore, suppression of fura-2 ratios 
recorded during co-application of RyR-agonists and dantrolene, was due to rises in 
F380 unaccompanied by changes in F340 induced by dantrolene, rather than being due 
to genuine decreases in intracellular Ca
2+
 content of cells.  
To further examine whether dantrolene could enhance the autofluorescence of 
cells during excitation at 380 nm in the absence of fura-2, cells not loaded with the 
fluorescent calcium indicator were used to repeat these dantrolene experiments. The 
mean ratio and mean fluorescence intensity were plotted against time in seconds, as 
shown in Figure 4.2.4 (BeWo: Figure 4.2.4.A; JEG-3: Figure 4.2.4.B). A rise in F380 
was observed in both cell types, while F340 remained steady. For example, in one 
experiment following addition of dantrolene, a maximum F380 of 397 AU was 
recorded in BeWo cells from the initial value of 150 AU; whereas, in an experiment 
with JEG-3 cells a maximum F380 of 363 AU was increased from an initial F380 of 
140 AU. Although increases in F380 were observed, the ratios of fluorescence were 
relatively stable in comparison to fura-2-loaded experiments in both BeWo and JEG-
3 cells. These obervations suggest that the cellular free Ca
2+
 indicator fura-2 and 
dantrolene co-ordinately enhance the F380 fluorescence and suppress the F340/F380 
ratio in BeWo and JEG-3 cells. Hence, the RyR antagonist property of dantrolene 
would be hard to monitor in these fura-2 loaded cells, as unaccompanied rises in F380 
fluorescence were induced. Therefore, dantrolene is not a suitable antagonist for 
assessment of RyR function in BeWo and JEG-3 cells when fura-2 is used as the 
cellular free Ca
2+
 indicator. 
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Figure 4.2.1 Traces of changes in fura-2 ratio in BeWo and JEG-3 cells in 
response to dantrolene and CmC. 
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Figure 4.2.1. Representative traces of changes in fura-2 ratio in BeWo (panel A, n = 17) and 
JEG-3 (pancel B, n = 9) cells upon 500 µM CmC stimulation in presence of 50 µM dantrolene. On 
both Panel A and B: black bars at the top represent stimulation periods of dantrolene and CmC in cells; 
dark blue trace represents changes in fura-2 ratio during stimulation.  
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Figure 4.2.2 Traces of changes in fura-2 ratio in BeWo and JEG-3 cells in 
response to dantrolene and ryanodine. 
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Figure 4.2.2. Representative traces of changes in fura-2 ratio in BeWo (panel A, n = 7) and 
JEG-3 (pancel B, n = 7) cells upon 1 µM ryanodine stimulation in presence of 50 µM dantrolene. On 
both Panel A and B: black bars at the top represent stimulation periods of dantrolene and ryanodine in 
cells; dark blue trace represents changes in fura-2 ratio during stimulation. 
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Figure 4.2.3 Changes in fluorescence intensity and fura-2 ratio in response to 
dantrolene in fura-2-loaded BeWo (A) and JEG-3 (B) cells. 
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Figure 4.2.3. Representative traces showing fluorescence intensity and ratio alterations in 
fura-2-loaded BeWo (A) and JEG-3 (B) cells during dantrolene stimulation. Values shown on the left 
Y axis are mean fluorescence intensity (AU), and the values displayed on the right Y axis are mean 
fura-2 ratios. The red (F340: excited by 340 nm light) and blue (F380: excited by 380 nm light) traces 
representing the fluorescence intensities during the experiment. The purple trace represents changes in 
mean fura-2 ratios during stimulation. The black bars at the top on both Panel A and Panel B 
represent periods of stimulation with dantrolene. 
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Figure 4.2.4 Changes in fluorescence intensity and ratio in response to 
dantrolene in fura-2-free BeWo (A) and JEG-3 (B) cells. 
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Figure 4.2.4. Representative traces showing fluorescence intensity and ratio alternations in 
fura-2-free BeWo (A) and JEG-3 (B) cells during dantrolene stimulation. Values shown on the left Y 
axis are mean fluorescence intensity (AU), and the values displayed at the right Y axis are mean fura-2 
ratio. The red (F340: excited by 340 nm light) and blue (F380: excited by 380 nm light) traces 
representing the fluorescence intensity alterations during experiment. The purple trace represents 
changes in mean ratios during stimulation. The black bars at the top on both Panel A and Panel B 
represent periods of stimulation with dantrolene. 
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4.3 Tetracaine blocks the ryanodine-induced rise in fura-2 ratio in BeWo and 
JEG-3 cells  
           
Since dantrolene caused an artefactual increase in F380 autofluorescence in 
BeWo and JEG-3 cells, thereby affecting fura-2 ratios, an alternative RyR inhibitor 
was considered. Tetracaine is a local anaesthetic, which is reported to inhibit RyR-
mediated Ca
2+
 release in mammalian skeletal and cardiac muscles (Lukyanenko et 
al.,1996; Csernoch et al.,1999). Figure 4.3.1.A shows the effect of tetracaine (TET: 
100 µM) on the change in fura-2 ratio caused by ryanodine (RYD: 1 µM) in BeWo 
cells. A significant suppression of the ryanodine-induced fura-2 rise was observed in 
the presence of tetracaine (Panel B, Figure 4.3.1). The change in mean fura-2 ratio 
was 0.15 ± 0.03 (n = 8) over basal level (0.57 ± 0.03), which was equivalent to 30 ± 
7 % increase above the resting value. Despite the significant inhibitory effect of 
tetracaine on RyR-mediated Ca
2+
 release, an increase in fura-2 ratio was still 
measured in the presence of tetracaine. Figure 4.3.1.B indicated that, even though 
tetracaine was present during ryanodine stimulation, the rise in fura-2 ratio was still 
significantly higher than those vehicle-alone responses. This result suggests, when 
RyR-mediated Ca
2+
 release was blocked by tetracaine, an alternative mechanism was 
still functional to sustain the rise in [Ca
2+
]i in BeWo cells.  
In JEG-3 cells, tetracaine appeared to completely abolish ryanodine-induced 
rise in [Ca
2+
]i (Panel A, Figure 4.3.2). The rise in fura-2 ratio measured in the 
presence of tetracaine during ryanodine stimulation was 0.03 ± 0.006 (n = 6). This 
value was significantly smaller than that measured in response to ryanodine alone 
(0.18 ± 0.02, n = 9). This result was also similar to the response to vehicle alone 
(Figure 4.3.2.B), suggesting that tetracaine completed inhibited ryanodine-induced 
Ca
2+
 release in JEG-3 cells. 
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Figure 4.3.1 Changes in fura-2 ratio in BeWo cells in response to tetracaine and 
ryanodine. 
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Figure 4.3. Panel A. Representative traces (n = 8) of changes in fura-2 ratio in BeWo cells 
upon stimulation with 1 µM ryanodine (RYD) in the presence or absence of 100 µM tetracaine (TET). 
Black bars at the top represent stimulation periods of tetracaine and ryanodine; arrows below traces 
represent time points when drugs or vehicle were added; dark blue trace represents changes in fura-2 
ratio during stimulation; light blue trace represents changes in fura-2 ratio during application of 
vehicle that delivered TET and RYD. Panel B. Change in fura-2 ratio in BeWo cells in response to 
RyR agonist and antagonist. P = 0.04, RYD vs RYD plus TET (n = 11 vs 8);  P = 0.02, RYD plus 
TET vs vehicles (n = 8 vs 3); * = P < 0.05, two-tailed unpaired t test. 
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Figure 4.3.2 Changes in fura-2 ratio in JEG-3 cells in response to tetracaine and 
ryanodine. 
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Figure 4.3.2 Panel A. Representative traces (n = 6) of changes in fura-2 ratio in JEG-3 cells 
upon 1 µM ryanodine (RYD) stimulation in presence or absence of 100 µM tetracaine (TET). Black 
bars at the top represent stimulation periods of tetracaine and ryanodine; arrows below traces 
represent time points when drugs/vehicles were added; dark blue trace represents changes in fura-2 
ratio during stimulation; light blue trace represents changes in fura-2 ratio during application of 
vehicle that delivered TET and RYD. Panel B. Change in fura-2 ratio in JEG-3 cells in response to 
RyR agonist and antagonist. P < 0.0001, RYD vs RYD plus TET (n = 9 vs 6); *** = P < 0.0001, two-
tailed unpaired t test. 
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4.4 CmC-induced [Ca
2+
]i rise in BeWo and JEG-3 cells was unaffected by RyR 
antagonists  
           
To examine whether CmC-induced [Ca
2+
]i rise in fura-2 ratio in BeWo and 
JEG-3 cells can be suppressed by RyR antagonists, tetracaine or ryanodine at 
inhibitory concentration (100 µM) were used. In BeWo cells, similar increases were 
found during CmC stimulation, regardless of the presence and absence of 100 µM 
ryanodine (Figure 4.4.A). Likewise, CmC-induced rise in fura-2 ratio was unaffected 
by the presence of tetracaine. In addition, pre-incubation with neither tetracaine nor 
100 µM ryanodine were able to prevent the resultant lost of fluorescence detection 
that induced by CmC in these cells, as described previously in Section 4.1. These 
observations suggested that, in addition to activation of RyR-mediated Ca
2+
-release, 
CmC also triggers other pathways that are independent of RyR activation, which 
caused the apparent rapid and massive rise [Ca
2+
]i in BeWo cells.  
In JEG-3 cells, 100 µM ryanodine pre-incubation did not affect the rise in 
fura-2 ratio induced by CmC, and the increase in ratio was similar to that without 
ryanodine (100 µM) (Figure 4.4.B). Pre-incubation with 100 µM tetracaine slightly 
enhanced the rise in fura-2 ratio. In addition, the response traces (data not shown) in 
the presence of either one of the antagonists, were apparently similar to ones with 
CmC alone. These observations suggest that CmC induced non-RyR-mediated Ca
2+
-
elevation in JEG-3 cells, as indicated by increases in fura-2 ratio; and these rises 
were unaffected by the addition of tetracaine or ryanodine. 
In both BeWo and JEG-3 trophoblast-like cells, neither tetracaine nor 
ryanodine (100 µM) showed inhibitory effect upon CmC stimulation. In addition, the 
response traces and maximal increases in ratio were apparently similar, regardless of 
the presence or absence of RyR antagonists. These results indicate tha CmC induces 
other pathways that cause increases in [Ca
2+
]i. Since such rises in [Ca
2+
]i were 
independent of RyR activation, CmC could not be used as an RyR-specific activator 
in BeWo or JEG-3 cells in this study.   
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Figure 4.4. Changes in fura-2 ratio in BeWo and JEG-3 cells in response to 
agonists and antagonists. 
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Figure 4.4 CmC induced changes in mean fura-2 ratios in BeWo and JEG-3 cells. Panel A. 
BeWo cells in response to 500 µM CmC in the absence and presence of antagonists (100 µM 
tetracaine, TET; 100 µM ryanodine, RYD). ** P < 0.01, CmC, CmC+TET vs vehicle (n = 8, 3 vs 3); 
*** P < 0.001, CmC+RYD vs vehicles (n = 3 vs 3); two-tailed unpaired t test. Panel B. JEG-3 cells 
response to 500 µM CmC in the absence and presence of antagonists (100 µM tetracaine, TET; 100 
µM ryanodine, RYD). * P < 0.05, CmC+RYD vs vehicles (n = 8 vs 3); ** P < 0.01, CmC, CmC+TET 
vs vehicle (n = 16, 10 vs 3); two-tailed unpaired t test. 
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4.5 Physiologically relevant peptide hormones induce increases in [Ca
2+
]i in BeWo 
cells  
           
Angiotensin II (AGII), arginine vasopressin (AVP), and endothelin 1 (ET1) 
are peptides present in human placenta that are involved in various physiological 
functions (Punnonen et al.,1987; Ferré et al.,1993; Poisner,1998). AGII type 1 
receptors (AT1) are expressed in human placenta and are responsible for hormonal 
secretion and vasoregulation (Li et al.,1998). AVP is a peptide hormone produced in 
the pituitary gland that plays important roles not only in the regulation of 
vasoconstriction and water re-absorption in the collecting ducts of the kidney, but 
also in the regulation of amniotic fluid (Punnonen et al.,1987). ET1 is the 
predominant isoform of endothelin peptide that stimulates cell differentiation, 
proliferation and cell invasion (Yohn et al.,1994; Cervar & Desoye,1998). To 
determine whether these endogenous peptides are involved in the regulation of 
[Ca
2+
]i in trophoblast, AGII, AVP and ET1 were applied to both BeWo and JEG-3 
cells. All three peptides used were dissolved and stored in ddH2O. In the current 
study, there was no detectable change in mean fura-2 ratio observed in JEG-3 cells 
when selected endogenous peptides were applied. Therefore, experimental data 
obtained from BeWo cells are presented.  
Figure 4.5.1.A, Figure 4.5.2.A and Figure 4.5.3.A show representative traces 
from BeWo cells stimulated by addition of endogenous peptide hormones. Increases 
in mean fura-2 ratios were measured as 0.37 ± 0.06, 0.16 ± 0.03 and 0.23 ± 0.04, 
during application of 200 nM AGII (n = 9) (Li et al.,1998), 200 nM AVP (n = 6) 
(Omura et al.,1999; Belkacemi et al.,2008) and 1 nM ET1 (n = 6) (Giulumian et 
al.,2000), respectively. These values for increases in mean fura-2 ratio are also 
equivalent to the rises in percentage over the basal ratio measurement of 74 ± 15 %, 
33 ± 11 %, and 44 ± 9 %, for AGII, AVP and ET1 stimulation, respectively. All 
values are means ± SEM, P < 0.05 relative to cells stimulated with vehicle alone. 
Both AGII and ET1 stimulated a slow but steady increase of mean fura-2 ratio before 
reaching a plateau (Figure 4.5.1.A and Figure 4.5.3.A, respectively). In contrast, 
AVP stimulation of cells caused a transient increase in fura-2 ratio, followed by a 
return to the pre-stimulation level (Figure 4.5.2.A).  
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To determine which subtypes of GPCR that coupled to AGII, AVP or ET1, 
selective receptor antagonists were used. Since the AT1 receptor subtype mediates 
many of the known effects of AGII and this receptor is also predominantly expressed 
in BeWo cells (Ino et al.,2003; Ishimatsu et al.,2006), the AT1 seletive antagonist 
losartan (5 µM) was used. Figure 4.5.1.B shows a representative trace (n = 5) of the 
response to 200 nM AGII in BeWo cells in the presence of losartan. An inhibitory 
effect of this AT1 receptor antagonist was observed, as the change in mean fura-2 
ratio was decreased to 0.06 ± 0.02 (P > 0.05, LOS+AGII vs vehicle, Figure 4.5.4.A). 
This result indicates that losartan significantly inhibited the AGII-induced rise in 
[Ca
2+
]i in BeWo cells. 
Expression of AVP receptors in trophoblast-like/ choriocarcinoma cells has 
not been extensively investigated to date. However, high levels of expression of both 
mRNA and protein for V1a AVP receptor subtype has been reported in the maternal 
stroma of ovine placenta (Koukoulas et al.,2003), as well as in equine conceptuses 
(Budik et al.,2012). In addition, the seletive V1a receptor antagonist SR49059 has 
been demonstrated to inhibit vasopressin binding to their myometrial and decicual 
receptors (Thibonnier et al.,1999). Therefore, SR49059 was used to investigate the 
role of V1a receptors in coupling AVP to rises in [Ca
2+
]i in BeWo cells. As shown in 
Figure 4.5.2.B, the AVP-induced transient increase was abolished by the co-
application of SR49059 (*P < 0.05, AVP vs SR+AVP). This observation indicates 
the significant inhibitory effect of SR49059 on AVP receptors coupled to [Ca
2+
]i 
rises in BeWo cells. In addition, a representative trace (n = 4) of the response to 200 
nM AVP in the presence of 100 nM SR49059 displayed no significant difference to 
trace in response to vehicle alone (P > 0.05, SR+AVP vs vehicle, Figure 4.5.4.B), 
which further indicates a full inhibition of AVP receptors coupled to Ca
2+
 signalling 
in BeWo cells.  
Expression of slightly higher levels of ETA receptors than ETB receptors has 
been reported in BeWo cells (Mauschitz et al.,2000). Therefore, the ETA receptor 
selective antagonist BQ123 was chosen to study the effect of ET1 in BeWo cells. 
Similar to the impact of AT1 antagonist, the ETA receptor antagonist was also 
showed significant inhibitory effect on ET1-induced rise in [Ca
2+
]i in BeWo cells 
(**P < 0.01, ET1 vs BQ+ET1; Figure 4.5.4.C). A representative trace (n = 4) in 
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Figure 4.5.3.B shows there was no further rise in mean fura-2 ratio by ET1 in the 
presence of 100 nM BQ123.  
The increases in mean fura-2 ratios in experiments in which BeWo cells were 
stimulated by endogenously occurring peptide hormomes AGII, AVP and ET1, 
indicate all three peptides can stimulate rises in [Ca
2+
]i in BeWo cells. The 
corresponding receptor antagonists losartan, SR49059 and BQ123 showed significant 
inhibitory effect on the increase in fura-2 ratio, suggesting that these hormone 
induced rises in BeWo [Ca
2+
]i were mediated by the activation of AT1, V1a and ETA 
receptors, respectively.  
 156 
Figure 4.5.1. Increases in mean fura-2 ratio in BeWo cells stimulated by AGII in 
the absence or presence of losartan. 
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Figure 4.5.1. BeWo cell calcium responses to AGII in the presence or absence of losartan 
(LOS). Panel A. Representative trace (dark blue) of mean fura-2 ratio in cells stimulated by 200 nM 
AGII (n = 9). light blue trace represents fura-2 ratio during addition of 2.5 µl ddH2O (vehicle). Panel 
B. Representative trace (dark blue) of mean fura-2 ratio in cells stimulated by 5 µM LOS and 200 nM 
AGII (n = 5). light blue trace represents fura-2 ratio during application of vehicle. In both panels, 
black bars at the top represent stimulation period in cells; arrows below traces represent time points 
when drugs/vehicle were added. 
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Figure 4.5.2. Increases in mean fura-2 ratio in BeWo cells stimulated by AVP in 
the absence or presence of SR49059. 
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 Figure 4.5.2. BeWo cell calcium responses to AVP in the presence or absence SR49059. 
Panel A. Representative trace (dark blue) of mean fura-2 ratio in cells stimulated by 200 nM AVP (n 
= 6). light blue trace represents fura-2 ratio during addition of 2.5 µl ddH2O (vehicle). Panel B. 
Representative trace (dark blue) of mean fura-2 ratio in cells stimulated by 100 nM SR49059 and 200 
nM AVP (n = 4). light blue trace represents fura-2 ratio during application of vehicle. In both panels, 
black bars at the top represent stimulation period; arrows below traces represent time points when 
drugs/vehicle were added. 
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Figure 4.5.3 Increase in mean fura-2 ratio in BeWo cells stimulated by ET1 in 
the absence or presence of BQ123. 
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Figure 4.5.3. BeWo cell calcium responses to ET1 in the presence or absence of BQ123. 
Panel A. Representative trace (dark blue) of mean fura-2 ratio in cells stimulated by 1 nM ET1 (n = 6). 
light blue trace represents fura-2 ratio during addition of 2.5 µl ddH2O (vehicle). Panel B. 
Representative trace (dark blue) of mean fura-2 ratio in cells stimulated by 100 nM BQ123 and 1 nM 
ET1 (n = 4). light blue trace represents change in fura-2 ratio during application of vehicle. In both 
panels, black bars at the top represent the stimulation period; arrows below traces represent time 
points when drugs/vehicle were added. 
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Figure 4.5.4. Change in mean fura-2 ratio in BeWo cells upon stimulation with 
peptide hormones and their antagonists. 
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Figure 4.5.4. Changes in mean fura-2 ratio in BeWo cells in response to various  hormones 
in the presence or absence of receptor antagonists. Panel A. AGII and AT1 antagonist: 200 nM AGII 
alone (AGII), with 5 µM losartan (LOS+AGII), * P < 0.05, AGII vs LOS+AGII, (n = 9 vs 3), ** P < 
0.01, AGII vs vehicle (n = 9 vs 5); Panel B. AVP and V1a antagonist: 200 nM AVP alone (AVP), 
with 100 nM SR49059 (SR+AVP), * P < 0.05, AVP vs SR+AVP, vehicles (n = 6 vs 4, 5); Panel C. 
ET1 and ETAR antagonist: 1 nM ET1 alone (ET1), with 100 nM BQ123 (BQ+ET1), ** P < 0.01, ET1 
vs BQ+ET1, vehicles (n = 6 vs 4, 5); statistical difference in means determined using two-tailed 
unpaired t tests. 
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4.6 Role of RyRs in calcium responses to physiologically relevant peptide 
hormones  
           
To determine whether RyR-mediated Ca
2+
 release of from internal stores 
contributed to hormone induced rise in [Ca
2+
]i in BeWo cells, these trophoblasts were 
pre-incubated with the RyR antagonists tetracaine or ryanodine (100 µM), before the 
application of AGII, AVP or ET1. Figure 4.6.1.A, Figure 4.6.2.A and Figure 4.5.3.A 
show representative traces from BeWo cells treated with 100 µM tetracaine (TET) 
followed by addition of 200 nM AGII (n = 3), 200 nM AVP (n = 5) or 1 nM ET1 (n 
= 5), respectively. Tetracaine inhibited the rise in fura-2 ratio in response to AGII, 
AVP or ET1. Similarly, the presence of 100 µM ryanodine (RYD), significantly 
suppressed the AGII, AVP or ET1-induced rises in fura-2 ratio in BeWo cells (n = 7, 
5, 4, respectively), as indicated in the response traces in Figure 4.6.1.B, Figure 
4.6.2.B, and Figure 4.5.3.B. These observations indicated that RyR-mediated Ca
2+
 
release makes a major contribution to the rise elevation of [Ca
2+
]i in BeWo cells 
upon AGII, AVP or ET1 stimulation. 
In addition, to determine whether the Ca
2+
 influx of cells via L-type Ca
2+
 
channels from extracellular space contributed to the rise of [Ca
2+
]i in response to the 
stimulation of these endogenous peptides, BeWo cells were pre-incubated with 
nifedipine, a dihydropyridine calcium channel blocker. Figure 4.6.5 shows a 
representative traces of BeWo cells in response to AGII (n = 10), AVP (n = 8) or 
ET1 (n = 10) in the presence of 100 nM nifedipine. Unexpectedly, addition of 
nifedipine resulted in rise of mean fura-2 ratio, implying that the presence of this 
dihydropyridine either triggered Ca
2+
 release from the internal store or Ca
2+
 influx of 
cell plasma membrane. The subsequent application of AGII or ET1 appeared to 
induce further small increase in mean fura-2 ratio (Figure 4.6.5, Panels A and C, 
respectively). However, it was not clear if such rises in ratio were due to peptide 
alone or due to the combined effect with nifedipine. Traces of responses to AVP in 
presence of nifedipine shows tendency of return to pre-stimulation level, which was 
similar as response to AVP alone. These observations indicated nifidepine was not 
sufficient to demonstrate the involvement of Ca
2+
 influx upon stimulation of AGII, 
AVP or ET1 in BeWo cells. 
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Figure 4.6.1. Traces of mean fura-2 ratio in BeWo cells stimulated with AGII 
and RyR antagonists   
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Figure 4.6.1. BeWo cell calcium responses to AGII in the presence and absence of RyR 
antagonists. Panel A. Representative trace (dark blue) of mean fura-2 ratio in cells stimulated with 
100 µM TET and 200 nM AGII (n = 3). light blue trace represents change in fura-2 ratio during 
application of vehicle. Panel B. Representative trace (dark blue) of mean fura-2 ratio in cells 
stimulated with 100 µM RYD and 200 nM AGII (n = 7). light blue trace represents change in fura-2 
ratio during application of vehicle. In both panels, black bars at the top represent stimulation period; 
arrows below traces represent time points when drugs/vehicle were added.. 
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Figure 4.6.2 Traces of mean fura-2 ratio in BeWo cells stimulated with AVP and 
RyR antagonists   
A. 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 100 200 300 400 500
Time (s)
M
ea
n
 F
u
ra
-2
 R
a
ti
o
 (
3
4
0
:3
8
0
 n
m
)
TET+AVP
vehicles
TET 100µM (EtOH)
AVP 200nM (H2O)
 
 
B. 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 100 200 300 400 500
Time (s)
M
ea
n
 F
u
ra
-2
 R
a
ti
o
 (
3
4
0
:3
8
0
 n
m
)
RYD+AVP
vehicles
RYD 100µM  (DM SO)
AVP 200nM  (H2O)
 
 
Figure 4.6.2. BeWo cell calcium responses to AVP in the presence or absence of RyR 
antagonists. Panel A. Representative trace (dark blue) of mean fura-2 ratio in cells stimulated with 
100 µM TET and 200 nM AVP (n = 5). light blue trace represents change in fura-2 ratio during 
application of vehicle. Panel B. Representative trace (dark blue) of mean fura-2 ratio in cells 
stimulated with 100 µM RYD and 200 nM AVP (n = 5). light blue trace represents change in fura-2 
ratio during application of vehicle. In both panels, black bars at the top represent stimulation period; 
arrows below traces represent time points when drugs/vehicle were added. 
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Figure 4.6.3. Traces of mean fura-2 ratio in BeWo cells stimulated with ET1 and 
RyR antagonists   
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Figure 4.6.3. BeWo cell calcium response to ET1 and RyR antagonists. Panel A. 
Representative trace (dark blue) of mean fura-2 ratio in cells stimulated with 100 µM TET and 1 nM 
ET1 (n = 5). light blue trace represents change in fura-2 ratio during application of vehicle. Panel B. 
Representative trace (dark blue) of mean fura-2 ratio in cells stimulated with 100 µM RYD and 1 nM 
ET1 (n = 4). light blue trace represents change in fura-2 ratio during application of vehicle. In both 
panels, black bars at the top represent stimulation period; arrows below traces represent time points 
when drugs/vehicle were added. 
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Figure 4.6.4 Change in mean fura-2 ratio in BeWo cells upon stimulation with 
various hormones, their antagonists and RyR inhibitors 
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Figure 4.6.4 Changes in mean fura-2 ratio in BeWo cells in response to hormones in the 
presence or absence of RyR antagonists. Panel A. AGII group: cell calcium responses to 200 nM AGII 
alone (AGII), with 5 µM losartan pre-incubation (LOS+AGII), with 100 µM ryanodine pre-incubation 
(RYD+AGII), or with 100 µM tetracaine pre-incubation (TET+AGII). * P < 0.05, AGII vs 
LOS+AGII, TET+AGII (n = 9 vs 3, 3) ** P < 0.01, AGII vs vehicle (n = 9 vs 5); *** P < 0.001, AGII 
vs RYD+AGII (n = 9 vs 7); two-tailed unpaired t test. Panel B. AVP group: cells in response to 200 
nM AVP alone (AVP), with 100 nM SR49059 pre-incubation (SR+AVP), with 100 µM ryanodine 
pre-incubation (RYD+AVP), and with 100 µM tetracaine pre-incubation (TET+AVP). * P < 0.05, 
AVP vs SR+AVP, RYD+AVP, TET+AVP, vehicle (n = 6 vs 4, 5, 5, 5); two-tailed unpaired t test. 
Panel C. ET1 group: cells in response to 1 nM ET1 alone (ET1), with 100 nM BQ123 pre-incubation 
(BQ+ET1), with 100 µM ryanodine pre-incubation (RYD+ET1), and with 100 µM tetracaine pre-
incubation (TET+ET1). ** P < 0.01, ET1 vs BQ+ET1, RYD+ET1, TET+ET1, vehicle (n = 6 vs 4, 4, 
5, 5); two-tailed unpaired t test.  
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Figure 4.6.5. Traces of mean fura-2 ratio in BeWo cells stimulated with peptide 
hormones and nifedipine   
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Figure 4.6.5 BeWo cells in response to AGII, AVP and ET1 in the presence of nifedipine 
(NIF). Panel A. Representative trace (dark blue) of mean fura-2 ratio in cells stimulated by 100 nM 
NIF and 200 nM AGII (n = 10). Panel B. Representative trace (dark blue) of mean fura-2 ratio in cells 
stimulated by 100 nM NIF and 200 nM AVP (n = 8). Panel C. Representative trace (dark blue) of 
mean fura-2 ratio in cells stimulated by 100 nM NIF and 1 nM ET1 (n = 10). The light blue trace of 
each panel represents fura-2 ratio during application of vehicle. In each panel, black bars at the top 
represent stimulation period; arrows below traces represent time points when drugs/vehicle were 
added. 
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4.7 Effect of CmC and ryanodine on trophoblast cell-line viability  
           
To examine whether the changes in [Ca
2+
]i observed during direct 
pharmacological activation of RyRs in BeWo and JEG-3 trophoblasts were linked to 
cell viability, cytotoxicity or changes in metabolic activity, cells were incubated with 
CmC, ryanodine or etoposide in various concentrations for 20 hours before being 
labelled with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide (MTT), 
as described in Section 2.11. MTT assay is a colourimetric assay that reveals 
metabolic activity of viable cells. In this method, the tetrazolium salt MTT is used; 
and MTT can only be reduced to a coloured, water-insoluble formazan salt by viable 
cells; the formazan salt can be solubilised in a solubilisation solution and can be 
quantitated in a conventional ELISA plate reader. Therefore, the MTT assay is used 
to quantitate cell proliferation and cytotoxicity (Mosmann,1983). Etoposide is 
regarded as an anti-cancer agent that targets and stabilises on the DNA-
topoisomerase II complex, and causes cell cycle arrest at G2 phase. The prevention 
of cell cycle progression leads to DNA strands breakage, and eventually results at 
apoptosis (Marks & Fox,1991). The use of etoposide in this study was to contribute a 
viability control group for drug-induced cell death.  
The graphs in Figure 4.7.1 present the percentage of formazan formation over 
controls (non-stimulated) in BeWo cells. These values were plotted against various 
final concentration of drugs after a stimulation period of 20 hours (all values are 
means ± SEM, n = 3). Stimulation with CmC (500 µM) resulted in a decrease in 
formazan formation to 22 ± 17 % (P < 0.05, vs non-stimulated BeWo cells, one-way 
ANOVA with Tukey’s multiple comparison test), as indicated in graph A of Figure 
4.5.1. This rate was nearly half of the formazan production in cells treated with 100 
µM etoposide (graph C, Figure 4.5.1), which was 42 ± 21 % (P < 0.05, vs non-
stimulated BeWo cells, one-way ANOVA with Tukey’s multiple comparison test). 
These values suggest the presence of CmC (500 µM) or etoposide (100 µM) 
significantly decrease the production of formazan from MTT in BeWo cells; in other 
words, both compounds affect BeWo cell viability. 
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In contrast, the rate of formazan production measured after 20 hours 
incubation with 1 µM ryanodine was 103 ± 41 %. This value suggests that 1 µM 
ryanodine neither suppress nor significantly enhances convertion of formazan from 
MTT, ie. ryanodine at this concentration has little effect on BeWo cell viability. 
Formazan production by JEG-3 cells in response to these drugs was different 
from that in BeWo cells. Closer production rates were measured at the end treatment 
with 500 µM CmC and 1 µM ryanodine, which were 94 ± 13 % and 80 ± 18 %, 
respectively, as revealed in graph A and graph B of Figure 4.5.2 (all values are 
means ± SEM, n = 3). These values suggest treatment with 500 µM CmC or 1 µM 
ryanodine neither enhance nor significantly suppress the convertion of formazan salt 
from MTT, therefore, both drugs have little effect on JEG-3 cell viability. Graph C of 
Figure 4.5.2 displays JEG-3 cells that were incubated with etoposide for 20 hours. 
Treatment of 100 µM etoposide in JEG-3 cells resulted in a significant decrease in 
formazan production to 31 ± 15 % (P < 0.05, vs non-stimulated JEG-3 cells, one-way 
ANOVA with Tukey’s multiple comparison test). This figure does not significantly 
differ from the measurement obtained in BeWo cells (42 ± 21 %). 
Although these MTT assays were statistically insufficient, the preliminary 
data indicates that 1 µM ryanodine does not significantly affect the cell viability of 
either BeWo or JEG-3 cells; while 500 µM CmC has little effect on JEG-3 cells, it 
significantly suppressed formazan salt production, which implies the application of 
500 µM CmC affects BeWo cell viability. Treatment of cells with 100 µM etoposide 
resulted in a significant decrease on formazan conversion. These results provide 
positive evidence supporting the cytotoxic effect of etoposide (Marks & Fox,1991).    
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Figure 4.5.1 CmC or ryanodine concentration dependent effects on BeWo cell 
viability  
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Figure 4.5.1. BeWo cell MTT reduction (n = 3) after 20 hour stimulation of CmC, ryanodine 
or etoposide at various concentrations. Panel A, BeWo cells were stimulated with CmC at various 
concentrations (0, 5, 10, 50, 100, 200, *500 µM); Panel B, BeWo cells were stimulated with 
ryanodine at various concentrations (0, 0.1, 0.2, 0.5, 1 µM); Panel C, BeWo cells were stimulated with 
etoposide at various concentrations (0, 10, 25, 50, *100 µM). * P < 0.05, vs non-stimulated BeWo 
cells, one-way ANOVA with Tukey’s multiple comparison test. 
* 
* 
A 
B 
C 
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Figure 4.5.2 CmC or ryanodine concentration dependent effects on BeWo cell 
viability  
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Figure 4.5.2. JEG-3 cell MTT reduction (n = 3) after 20 hour stimulation of CmC, ryanodine 
or etoposide at various concentrations. Panel A, JEG-3 cells were stimulated with CmC at various 
concentrations (0, 5, 10, 50, 100, 200, 500 µM); Panel B, JEG-3 cells were stimulated with ryanodine 
at various concentrations (0, 0.1, 0.2, 0.5, 1 µM); Panel C, JEG-3 cells were stimulated with etoposide 
at various concentrations (0, 10, 25, 50, *100 µM). * P < 0.05, vs non-stimulated BeWo cells, one-
way ANOVA with Tukey’s multiple comparison test. 
* 
A 
B 
C 
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Chapter V.  Discussion 
 
In present study, the expression of RyRs has been investigated in both human 
trophoblast-like cells and human placental villous samples. Results presented in 
Chapter III demonstrated that 1) RyR1 is expressed in both BeWo and JEG-3 
trophoblastic cells (IF, RT-PCR and western blot); 2) RyR2 and RyR3 are co-
expressed with RyR1 in BeWo and JEG-3 cells, respectively (IF and RT-PCR); 3) 
human first trimester placental villi express RyR1 (IHC and RT-PCR), plus either or 
both RyR2 (RT-PCR) and RyR3 (IHC); 4) human term placental villi express RyR3 
(IHC and RT-PCR), plus either or both RyR1 (IHC) and RyR2 (RT-PCR); 5) both 
BeWo and JEG-3 cells express the RyR accessory proteins: CSQ and TRD (IF and 
western blot); 6) human first trimester placental villi express TRD (IHC and western 
blot), while CSQ was detected in human term placental villous tissue (western blot).  
The preliminary functional investigation carried out in BeWo and JEG-3 cells. 
The results presented in Chapter IV indicate: 1) both CmC and ryanodine (1 µM) 
induced a rise in [Ca
2+
]i in BeWo and JEG-3 cells; 2) application of 100 µM 
tetracaine suppressed ryanodine-induced [Ca
2+
]i rise in BeWo and JEG-3 cells, but 
had little effect on CmC-induced [Ca
2+
]i elevation, suggesting CmC also induces a 
non-RyR-mediated increase in [Ca
2+
]i in these cells; 3) AGII, AVP and ET1 were 
demonstrated to induce [Ca
2+
]i increases in BeWo cells, and such rise could be 
inhibited by losartan, SR49059 or BQ123, the corresponding antagonists of AGII, 
AVP and ET1; 4) both tetracaine and ryanodine (100 µM) inhibit AGII-, AVP- and 
ET1-induced rises in [Ca
2+
]i, suggesting RyR mediates peptide-stimulated signalling 
pathways in BeWo cells.  
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5.1 Differential Expression of RyRs in Human Trophoblast 
 
Expression of RyRs and selected accessory proteins of RyRs was 
demonstrated and confirmed for the first time by using RT-PCR, western blotting 
and IIF/IHC microscopy in both human trophoblastic cell lines and human placental 
villous tissues, as summarised in Table 5.1. In the current study, RyR1 was shown to 
express in human first trimester villous tissue and in the BeWo trophoblastic cell line 
(Section 3.1 and 3.2), by all methods employed (RT-PCR, western blotting and IIF 
microscopy /IHC); while RyR1 expression in JEG-3 was demonstrated by western 
blotting and IIF microscopy; in addition, RyR2 and RyR3 proteins were also detected 
by IIF microscopy in BeWo and JEG-3 cells (Figure 3.5.1 A and Figure 3.5.1 B).  
 
Table 5.1. RyR expression in trophoblast cell lines and human placental samples 
 
Method of 
detection 
BeWo JAR JEG-3 
1
st
 trimester 
samples 
Term 
samples 
RT-PCR 
RYR1, 
RYR2 
RYR1, 
RYR2 
**N/A 
RYR1, 
RYR2 
**N/A 
Western 
blot 
RyR1 N/A RyR1 +ve +ve 
IIF/IHC 
RyR1, 
RyR2, 
RyR3 
*RyR1, 
*RyR2, 
*RyR3 
RyR1, 
RyR2, 
RyR3 
RyR1, 
RyR3 
RyR1, 
RyR3 
* Data not shown; 
** PCR product nucleotide sequence displayed less than 99% identity to target DNA templates (JEG-
3 cells); or PCR products detected by electrophoresis but only partially sequenced (term samples). 
 
In human placental villous samples, PCR products derived from RYR1 (three 
out of four samples) and RYR2 (four out of four samples) were amplified from RNA 
extract of first trimester placental tissue. Sequencing analysis of RyR1 and RyR2 
PCR products by Eurofins (Eurofins MWG Operon, Germany) revealed 99% identity 
to both human RyR1 mRNA (NM_001042723.1; sequences 13997-14922; Appendix 
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XII) and RyR2 mRNA (NM_001035.2; sequences 13748-14703; Appendix XIII). 
Similarly, DNA sequencing indicated that the PCR products of RYR1 and RYR2 from 
BeWo and JAR cells displayed 99% to 100% identities to their corresponding Homo 
sapiens sequences. RYR1 and RYR2 from BeWo cells showed 99% identity to Homo 
sapiens RYR1 (NM_001042723.1; sequences 13979-14831; Appendix I) and Homo 
sapiens RYR2 (NM_001035.2; sequences 13750-14706; Appendix II), respectively; 
the product of RYR1 from JAR cells showed 100% identity to Homo sapiens RYR1 
(NM_001042723.1; sequences 13933-14908; Appendix III), while product of RYR2 
from the same cell line displayed 99% identity to Homo sapiens RYR2 
(NM_001035.2; sequences 13784-14628; Appendix IV). The product of RYR2 from 
human term placental villi displayed 100% identity to Homo sapiens RYR2 
(NM_001035.2; sequences 14239-14677; data not shown). Since less than half 
length (439 nucleotides) of expected PCR product was sequenced in current study, 
the presence of RyR2 mRNA in human term placental villous tissue was 
inconclusive. 
Selective PCR products of RYR3 of the expected size from JEG-3 and 
SGHPL-4 cells and human term placental villous samples (four out of five samples) 
were detected on agarose gels after electrophoresis (Figure 3.1.1.C and Figure 
3.1.3.C). However, DNA sequencing indicated that none of these products displayed 
greater than 99% identity to Homo sapiens RYR3 (NM_001036.3). Primer-BLAST 
(Ye et al.,2012) (available at: http://www.ncbi.nlm.nih.gov/tools/primer-blast/) 
results indicated that the primers used to target Homo sapiens RYR3 in current study 
were not completely matched to template sequence. Specifically, two mismatched 
nucleotides were identified in the forward primer, and one mismatch was found in 
the reverse primer (Panel III, Appendix XI). These mismatched nucleotides increase 
the chance of attaching to a sequence beyond the target, which could result in an 
unrelated PCR product. In contrast, primers targeting Homo sapiens RYR2 displayed 
completely matched alignment with the target sequence (Panel II, Appendix XI); 
whereas, one mismatched nucleotide was found in the common forward primer for 
Homo sapiens RYR1 sequence (Panel I, Appendix XI). These results indicate that the 
primers used in current study that targeted on Homo sapiens RYR2 and RYR1 
amplified products in expected size and sequence; whereas, PCR products produced 
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by primers targeted to RYR3 required further verification experiments, possibly using 
new primers and then analysing by restriction digestion or DNA sequencing (Sei et 
al.,1999).  
Western blot analyses demonstrated the protein expression of RyRs in 
trophoblast BeWo and JEG-3 cell lines and in human first and term placental villous 
tissue, as high molecular weight bands (>500 kDa) shown in Figure 3.2.1.A and 
Figure 3.2.2. Immunoblotting with isoform-specific antibodies for RyR1 further 
supported the presence of this receptor type in both BeWo and JEG-3 cells (Figure 
3.2.1.B). Despite the use of protease inhibitors and preparation of samples at 4 
o
C, 
multiple lower molecular weight bands were still detected along with the high 
molecular weight RyR band. This observation suggests RyR protein degradation had 
occurred as seen in other reports (Meissner et al.,1989; Junankar & Dulhunty,1994; 
Fitzsimmons et al.,2000; Pedrozo et al.,2010; Pedrozo et al.,2013). Such degradation 
can be caused by endogenous proteases (Lai et al.,1988). The calcium-dependent 
cysteine proteases calpains for instance, are known to be ubiquitously expressed in 
many cells including trophoblasts (Nicola et al.,2005b; Gauster et al.,2010); these 
proteases have also been demonstrated as a potential contributors to RyR degradation 
(Pedrozo et al.,2010). Other possible degradation pathways that present in 
trophoblast such as ubiquitin-proteasome system (Trausch et al.,1993; Yehia et 
al.,2001; Fu et al.,2010) and autophagy complex (Oh et al.,2008; Curtis et al.,2013),  
also participated in cellular protein degradation (Pedrozo et al.,2010). In current 
study, bands at ~300 kDa and ~160 kDa were consistently detected on immunoblots 
probing for RyRs in skeletal muscle (Figure 3.2.1.A, Figure 3.2.1.B and Figure 
3.2.2.B). These findings were in consistent with early studies, which suggested these 
proteolytic fragments were products of RyR degradation caused by endogenous 
proteases (Lai et al.,1988; Shoshan-Barmatz et al.,1994). 
In addition to susceptibility of degradation of RyR protein, large molecular 
weight and low expression level of these receptors in cells and tissues of interest also 
contributes to the difficulty of protein transfer and detection by western blot, as low 
intensity RyR bands of on immunoblots have also been reported in other studies 
(Saldaña et al.,2009). RyRs are also subject to post-translational modifications, such 
as oxidation, glycation, isomerization, deamidation, racemization, and cross-linking 
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(Ferrington et al.,1998). These factors may also contribute to the differential turnover 
of proteins (Ferrington et al.,1998). The RyR is one of the largest ion channel 
complexes, which is functionally modulated by multiple accessory proteins via 
different interaction motifs, as mentioned in Section 1.6. Such natural complexity 
contributes to the challenge on the investigation of RyR in cells and tissue with low 
abundance. 
Other antibody-dependent detection methods, such as IIF microscopy and 
IHC were used to support the limited detection of RyRs in trophoblasts by western 
blotting. Microscopy images indicated all isoforms of RyRs are expressed in both 
BeWo and JEG-3 trophoblast cell lines (Figure 3.5.1.A and Figure 3.5.1.B, 
respectively). In BeWo cells, the detection of RyR1 and RyR2 by IIF microscopy 
was consistent with RT-PCR assays, in which, RYR1 and RYR2 were amplified. The 
presence of RYR3 in trophoblasts was not determined by RT-PCR, likely due to the 
lack of specificity of primers, as discussed previously. The same explanation may be 
extended to the discovery of RyR3 protein by IHC and failure to detect the 
corresponding mRNAs by RT-PCR in human first and term villous samples. 
Interestingly, the use of the same RyR3-specific antibody (AB9082) revealed 
expression of type 3 RyR by IIF microscopy/IHC, but not in western blotting. These 
results imply that this antibody is more sensitive for RyR3 detection in fixed cells or 
tissues. In other words, this antibody may be less sensitive in western blotting assays, 
where proteins might be denatured and display fewer conformational epitopes.  
Another interesting finding was the detection of RyR1 and RyR3 by IHC in 
both human first trimester and term placental villous tissues, while staining of RyR2 
remained negative (Figure 3.4.1 and Figure 3.4.2, respectively). However, in one 
sample of human first trimester decidua basalis, positive RyR2 expression was 
demonstrated in both stroma cells and trophoblasts (likely extravillous trophoblasts) 
by IHC (Figure 3.4.3.A). The RyR2-specific antibody (HPA016697) used in current 
study, has been approved for IHC application by manufacturer (antibody validation 
information available at: ‘The Human Protein Atlas’, 
http://www.proteinatlas.org/ENSG00000198626/antibody); the same antibody also 
recognized the cardiac RyRs in the rat heart by western blotting (Figure 3.2.1.C). 
These findings indicated the reliability of this anti-RyR2 antibody. The 
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demonstration of RyR2 positive staining in an IHC section of first trimester decidua 
basalis, therefore, suggests that RyR2 expression in trophoblastic cells is transient 
and highly regulated. This preliminary result was consistent with other reports. 
Particularly, transient upregulation RYR2 mRNA level has been observed at day 4 
and/or day 6 in trophoblast lineage of human embryonic stem cells that 
differentitated in culture; RYR2 transient upregulation therefore, has been suggested 
to be associated with trophoblast differentiation and invasion (Marchand et al.,2011). 
The trophoblast phenotype possesses a sophisticated change from sessile to invasive 
during embryo implantation (Vićovac & Aplin,1996), followed by transformation 
back into non-invasive phenotypes and focus on nutritional and endocrinal functions 
of the mature placenta (Aplin,1991). Extravillous trophoblast in the decidua basalis, 
however, remains invasive in the mature placenta (Kaufmann & Castellucci,1997). In 
current study, both stroma cells and trophoblasts in decidua section were positive to 
RyR2 IHC detection, these stroma cells may contribute to the consistent detection of 
RYR2 mRNA in first trimester placental villi trophoblast. It is also possible that 
RyR2 protein expression is associated with invasion process and may be transiently 
upregulated; gene expression of RYR2 appeared to be down regulated or absent in 
trophoblast of term placenta, suggesting that RyR2 is involved in cell differentiation; 
protein expression of RyR1, RyR3 and TRD appeared to be constant in trophoblasts 
from first trimester and term placenta, suggesting that these proteins may be essential 
for trophoblastic cell function during pregnancy.  
Using differential-display RT-PCR, it has been demonstrated that there are a 
high number of genes that are expressed differentially between first trimester and 
term placental trophoblastic cells (Huch et al.,1998). For example, β1-intergrin 
shows a much higher expression in first trimester trophoblast than in term placental 
trophoblasts at both mRNA and protein levels, correlating with invasiveness 
(Damsky et al.,1994; Huch et al.,1998). In addition, PBK1 gene (which is also 
known as ribosomal L1 domain containing 1 (RSL1D1)) was initially identified 
exclusively in first trimester by Huch and colleagues; high expression levels of 
PBK1 were also discovered in JAR cells by the same group, the authors proposed 
PBK1 is involved in the regulation of trophoblastic invasiveness (Huch et al.,1998). 
The current study demonstrated that RYR2 mRNA is present in cytotrophoblast-like 
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cell lines of BeWo and JAR (in addition to RYR1), and in human first trimester 
villous trophoblasts (Figure 3.1.1 and Figure 3.1.2). These findings suggest that  of 
RyR2 expression correlates with the sessile-invasive transformation of human 
trophoblast.  
Phenotypically distinct trophoblastic cells distribute in different sites of the 
placenta. It has been demonstrated that the IHC staining intensities of EVT marker 
proteins CD9 and HLA-G were increased in where cells were found at near the 
maternal decidua, ie. trophoblastic cell column that differentiated into EVTs; in 
contrast, both SCTs and villous CTs of proximal CT cell columns (undifferentiated 
CTs) were negatively stained (Nagamatsu et al.,2004). In contrast, E-cadherin is 
down-regulated in EVTs as CT differentiates (Zhou et al.,1997). In the current study, 
IHC staining of RyR2 was positive in human decidua basalis of first trimester tissue 
sections. Similarly, IIF microscopy also shows RyR2 expression in both BeWo and 
JEG-3 cells. However, negative staining of E-cadherin is observed in malignant JEG-
3 trophoblastic cells (Appendix 0), but positive in CT-like BeWo cells (Figure 
3.5.1.A). These observations on human choriocarcinoma cell lines (BeWo and JEG-3 
cells) suggest 1) variations exist between BeWo and JEG-3 cells; 2) variation exists 
between these trophoblastic-like cells and normal trophoblastic cells from primary 
culture. Therefore, BeWo or JEG-3 may not respond to regulatory agents in the same 
way as normal trophoblasts. As reviewed in Section 1.11, EVTs are invasive 
trophoblastic cells differentiated from CTs. Although samples from human decidua 
section were limited, these preliminary data further imply that RyR2 expression is 
correlated with invasiveness of trophoblastic cells. Based on this observation, in vitro 
demonstration of this hypothesis may be possible. Nagamatsu and colleagues have 
shown purified CTs from human first trimester can acquire EVT phenotype in a low 
[Ca
2+
] culture medium (0.1 mM Ca
2+
, dKSFM medium) within 96 hour without 
syncytialisation (Nagamatsu et al.,2004). The same method may be adapted and 
RyR2 expression could be examined when the EVT phenotype appears. 
Cytotrophoblast-like BeWo cells have been demonstrated to respond to forskolin and 
differentiate into SCTs (Wice et al.,1990). Therefore, differentiated BeWo cells may 
be used to demonstrate the loss of expression of RyR2. However, as mentioned 
earlier, variations do exist between ‘trophoblastic-like’ and normal trophoblastic 
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cells. Expression levels of RyR2 could be hard to predict in BeWo cells, even their 
apparent phenotype may be altered by corresponding regulatory agents (such as 
forskolin). 
 
 
5.2 Impact of RyR Direct Pharmacological Stimulation on BeWo and JEG-3 Cells 
 
The functional characterisation of RyRs in trophoblasts was carried in both 
BeWo and JEG-3 cells. The RyR agonist ryanodine modulates all types of RyRs by 
an allosteric mechanism, as reviewed in Introduction Section 1.4. The use of 1 µM 
final concentration of ryanodine should promote RyR channels opening, as reviewed 
by Zissimopoulos and Lai (Zissimopoulos & Lai,2007). Addition of ryanodine (1 µM) 
induced rise in [Ca
2+
]i in both BeWo and JEG-3 cells (Figure 4.1.4). The ryanodine 
induced [Ca
2+
]i increase in JEG-3 cells appeared to be transient, while a sustained 
increase was observed in BeWo cells. The addition of the RyR antagonist tetracaine 
completely abolished the ryanodine-induced [Ca
2+
]i increase in JEG-3 cells (Figure 
4.3.2), indicating that JEG-3 cells express functional RyRs, sensitive to both 
ryanodine and tetracaine. In BeWo cells, tetracaine appeared to only partially inhibit 
the ryanodine-induced [Ca
2+
]i increase, as cell responses to ryanodine in the presence 
of tetracaine remained significant higher than to vehicle-alone (Figure 4.3.1.B). 
These observations suggest that teteracaine resulted in a delayed potentiation of 
spontaneous Ca
2+
 release in BeWo cells, as reported in an earlier studyon rat 
ventricular myocytes (Györke et al.,1997).   
CmC has been demonstrated as an effective RyR activator that specifically 
targets on skeletal muscle RyR1 and cardiac muscle RyR2 (Zorzato et al.,1993; 
Herrmann-Frank et al.,1996), The final CmC concentration (500 µM) initially used 
in this study was above the estimated EC50 (about 100 µM) for skeletal muscle RyR 
(Herrmann-Frank et al.,1996), in order to achieve a maximum response. The addition 
of CmC was demonstrated to induce rise in [Ca
2+
]i in both BeWo and JEG-3 cells. 
However, the presence of RyR antagonist (tetracaine or 100 µM ryanodine) did not 
inhibit this [Ca
2+
]i rise (Figure 4.4). These observations indicated that CmC induced 
[Ca
2+
]i increases in BeWo and JEG-3 cells via activation of other mechanisms, 
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independent of RyR gating. CmC not only induced rapid [Ca
2+
]i increase in BeWo 
cells, but apparently also caused memebrane damage, as loss of fluorescence was 
observed (Figure 4.1.1.B) This unexpected outcome from CmC stimulation indicated 
that this molecule activated other rather than non-RyR-mediated pathways that cause 
[Ca
2+
]i in BeWo cells, which leaded to membrane destruction. Such non-specific 
effect of CmC has also been reported to cause calcium flux and respiratory burst in 
human neutrophils (Hauser et al.,2005). Therefore, the use of CmC was not suitable 
for current study.  
Another unexpected observation was that dantrolene enduced 
autofluorescence in fura-2-loaded BeWo and JEG-3 cells. Dantrolene was originally 
used to examine the involvement of RyR subtype activation in cells, as this molecule 
is known as an RyR channel blocker that directly targets RyR1 and RyR3 (Fruen et 
al.,1997). Decreases in fura-2 ratios were observed in both BeWo and JEG-3 cells 
upon application of dantrolene. Examination in the duo fluorescence intensities at 
excitation wavelength of 340 nm and 380 nm indicated that such decreases in fura-2 
ratios were due to the rise in F380 unaccompanied by a change in F340 during 
dantrolene stimulation, rather than due to the decrease in the intracellular Ca
2+
 
content of cells (Figure 4.2.3). The interference in cell caused fluorescence by 
dantrolene was further examined in fura-2-free cells. As Figure 4.2.4 shows, the rise 
of F380 was observed in both BeWo and JEG-3 cells, while F340 remained steady, 
during dantrolene stimulation. Despite increase in F380, the ratios of fluorescence 
were relatively stable, by comparison to fura-2-loaded experiments. These 
obervations suggest that the cellular free Ca
2+
 indicator fura-2 and dantrolene co-
ordinately enhance the F380 fluorescence and suppress the F340/F380 ratio in BeWo 
and JEG-3 cells. Therefore, the use of dantrolene was not suitable as an RyR 
antagonist in fura-2 loaded BeWo and JEG-3 cells. 
.     
 
5.3 Impact of RyRs in BeWo Cell [Ca
2+
]i Responses to Peptide Hormones  
 
The channel activity of RyR can be regulated by various factors such as Ca
2+
 
and CaM, as reviewed in Introduction Section 1.5 and 1.6. The channel activity and 
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the subsequent RyR-mediated Ca
2+
 mobilisation can also be modified by 
phosphorylation on specific serine/threonine domains of the channel subunit, as 
reviewed in Introduction Section 1.7. The release of Ca
2+
 mediated by 
phosphorylated RyR channels is one of the consequences of GPCR activation that 
transmits extracellular stimuli to intracellular events. In current study, BeWo and 
JEG-3 trophoblast-like cells were used for the first time to demonstrate changes in 
[Ca
2+
]i in response to extracellular stimulation by endogenous peptides: AGII, AVP 
and ET1. In these experiments, JEG-3 cells displayed no overall change in fura-2 
ratio upon addition of any of the peptides; whereas increased fura-2 ratios were 
observed in BeWo cells, which indicated a net change in [Ca
2+
]i upon stimulation 
with these endogenously occuring peptides. As reported in Results Section 4.4, 
addition of AGII, AVP, or ET1 in BeWo cells, leads to a rise of over 30% in mean 
fura-2 ratio above the basal level. These hormonal peptide-induced rises in fura-2 
ratios were inhibited by the presence of the corresponding GPCR blockers (losartan, 
SR49059 or BQ123), suggesting that AGII type 1 receptor (AT1R), AVP V1a 
receptor, and ETA receptor are the respective mediators of AGII, AVP and ET1 
calcium signalling in BeWo cells. Such elevations in fura-2 ratio by AGII, AVP and 
ET1 were also abolished when BeWo cells were pre-incubated with tetracaine or 
ryanodine (100 µM). These experiments, therefore, demonstrated that functional 
RyRs in BeWo cells are involved in signal transduction initiated by AGII, AVP or 
ET1 via extracellular stimulation of GPCRs, ie. the activated RyRs are the mediators 
of subseqent Ca
2+
 mobilisation in BeWo cells in these events.  
Studies using radioactive ligand binding assays have indicated that the AGII 
type 1 receptor (AT1R) is the major AGII receptor of the placenta; whereas there is 
only 0 to 10% of AGII receptors were identified as the type 2 (AT2R) subtype in the 
human placenta (Jiménez et al.,1996; Kalenga et al.,1996). Recently, expression of 
AT4R, a specific receptor for angiotensin (3-8) (AngIV) has been identified in human 
placenta, along with AT1R and AT2R throughout both normal pregnancy and pre-
eclampsia (Williams et al.,2010). Location of AT1R in EVTs suggests the role of 
AGII in trophoblastic invasion and vaso-remodelling (Pringle et al.,2011). It has 
been demonstrated that BeWo choriocarcinoma cells express AT1R that activates 
PKC-mediated ERK signalling pathways and phosphatidylinositol 3-kinase (PI3K) 
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pathways (Ino et al.,2003; Ishimatsu et al.,2006). The activation of RyRs by CaMKII 
phosphorylation therefore, is expected as a consequence of AT1R activation by AGII 
via PKC-activation in BeWo cells, as illustrated in Figure 1.8. JEG-3 cells do not 
express the endogenous angiotensinogen mRNA (Brasier et al.,1989). However, the 
expression of angiotensin receptor protein is controversial in JEG-3 cells, as the 
presence of mRNA and protein of both AT1R and AT2R was demonstrated (Lanz et 
al.,2003). In current study, there was no increase in fura-2 ratio observed during 
AGII stimulation in JEG-3 cells. Such absence of response may due to absence of 
AT1R-mediated signalling, or due to the activation of AT2R in the membrane that 
inhibits cAMP-mediated pathways. The Gi/o-coupled GPCR AT2R is distinct from 
that linked to AT1R. The activation of AT2R by AGII induces opposing actions of 
AT1R, such as vasodilation, inhibition of cell proliferation and induction of 
programmed cell death (Horiuchi et al.,1999; de Gasparo et al.,2000). One 
consequence of such growth-inhibitory effects of AT2R is the subsequent activation 
of a variety of phosphatases that protentially dephosphorylate RyRs and result in 
inhibition of Ca
2+
 release from the receptor channel, as reviewed in Introduction 
Section 1.8.  
There are two subtypes of GPCRs that mediate the action of endothelins (ET1, 
ET2 and ET3). Of these, ETAR has a higher affinity for ET1 than ET3, while ETBR 
display similar binding affinity for both ET1 and ET3 (Sakurai et al.,1990). The 
effect of ET1 is primarily through the activation of ETAR that subsequently triggers 
various subcellular events via different G protein-mediated signaling pathways, as 
reviewed by Bagnato and Rosanò (Bagnato & Rosanò,2008). Ligand binding studies 
using 
125
I-labeled ET1 identified the expression of ETAR and ETBR in the 
microvillous membrane of early gestation placental microvilli, while only ETBR was 
found in term placental microvilli (Rutherford et al.,1993; Mondon et al.,1998). In 
other words, the receptor ETBR has been detected in trophoblastic cells throughout 
gestation (Kilpatrick et al.,1993), in contrast to the differential expression pattern of 
ETAR during the developing placenta (Cervar et al.,2000). The expression of ETAR 
and ETBR has also been demonstrated in both BeWo and JEG-3 cells (Mauschitz et 
al.,2000), although the mRNA levels of both ET receptors in these chriocarcinoma 
cell lines were lower than in their nonmalignant tissue of origin (the trophoblast) 
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(Bilban et al.,2000). Moreover, both BeWo and JEG-3 cell lines secrete ET1 
(Mauschitz et al.,2000). The presence of both ET receptors and ET1 secretion has 
been linked to the auto-/paracrine action and growth promotion effect of ET1 in 
human cancer cell lines (Shichiri et al.,1991; Bagnato et al.,1997). 
Both AT1R and ETAR are GPCRs coupled to Gαq; PLC is one of the effector 
proteins that mediate Gαq-coupled GPCR responses (de Gasparo et al.,2000). 
Therefore, activation of AT1R and ETAR can lead to intracellular Ca
2+
 mobilisation 
and activation of PKC signaling cascade, as reviewed in Introduction Section 1.8. To 
investigate whether inhibition of PLC could also block [Ca
2+
]i increase, the well 
known PLC inhibitor U73122 (1 µM) was initially used coupled to peptide 
stimulation. However, U73122 induced rise in fura-2 ratio in its own right, indicated 
by an increase in [Ca
2+
]i (data not shown), as similarly seen in other reports (Klein et 
al.,2011). Therefore, the PLC-mediated downstream signaling cascade could not be 
examined by using U73122. Interestingly, AGII and ET1 stimulation in BeWo cells 
induced similar [Ca
2+
]i responses, as slow and prolonged elevations in [Ca
2+
]i took 
place when AGII and ET1 were added. These observations might suggest that 
common signaling pathways may be shared by different extracellular stimulating 
agents. According to the Ca
2+
 concentration gradients across membrane and cellular 
compartments (as reviewed in Introduction), it is possible that both intracellular 
stores and the extracellular space are sources for intracellular Ca
2+
 increases in 
response to these hormones. As illustrated in Figure 1.8, there are two pathways 
leading to Ca
2+
 mobilisation initiated by Gαq-mediated GPCR activation: 1) Ca
2+
 
influx via activation of either or both TRPC and L-type calcium channel (LTCC) on 
the plasma membrane; 2) Ca
2+
 release from internal stores via activation of either or 
both IP3Rs and RyRs. To verify the source(s) of such Ca
2+
 increases, channel 
blockers were co-applied with stimulating agents. Blockade of LTCC-mediated Ca
2+
 
influx with nifedipine pre-incubation caused little reduction on either AGII- or ET1-
induced [Ca
2+
]i elevation, suggesting that LTCC-mediated Ca
2+
 influx contributes 
little to the rise of [Ca
2+
]i upon AGII or ET1 stimulation in BeWo cells. The 
commonly used IP3R blocker 2-aminoethoxydiphenyl borate (2-APB) was initially 
used to examine the contribution of the IP3R-mediated pathway in trophoblast 
peptide hormone induced calcium signals. However, an unexpected rise in [Ca
2+
]i 
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was observed in response to this molecule (data not shown), as reported by other 
groups (Bootman et al.,2002; Lefièvre et al.,2012).  As both AGII- and ET1-induced 
[Ca
2+
]i elevations were completely abolished in cells pre-incubated with tetracaine or 
ryanodine (100 µM), these results suggesting that RyR-mediated Ca
2+
 release makes 
a major contribution to Ca
2+
 rises in these cells. This finding is consistent with the 
cytofluorimetric analysis by Niger and colleagues, in which nifedipine (10
-6
 M) did 
not reduce ET1-induced Ca
2+
 entry in cultured human trophoblastic cells (Niger et 
al.,2004). Two mechanisms of RyR activation may be possible during the alteration 
of Ca
2+
 homeostasis following by GPCR activation: 1) CICR induced by the initial 
rise of [Ca
2+
]i from the activation of IP3R and/or Ca
2+
 entry via membrane Ca
2+
 
channels; 2) phosphorylation of RyRs by activated CaMII, PKC and/or PKA (via AC 
activation via Gαs-GPCR), as reviewed in Introduction Section 1.8. Collectively, 
these observations in BeWo cells upon AGII or ET1 stimulation suggest that RyRs 
contribute the cellular Ca
2+
 mobilisation; this Ca
2+
 release function of RyR may 
participate in the signal transduction of AGII and ET1, with an impact on 
trophoblastic invasion, vaso-remodeling, hormonal secretion and growth promotion 
(Cervar & Desoye,1998; Pringle et al.,2011).  
Although Ca
2+
 release via RyR activation contribute to both AGII- and ET1-
induced Ca
2+
 elevation, the possibility of Ca
2+
 entry via other mediators on the cell 
membrane cannot be excluded. Possible candidates that mediate the Ca
2+
 entry 
include the voltage-independent Ca
2+
 channels. For instance, both store-operated 
Ca
2+
 channel (SOCC, eg. TRPC) and non-seletive cation channel (NSCC) mediated 
Ca
2+
 entry may contribute the Ca
2+
 current, together with LTCC during AGII/ET1 
stimulation, as both SOCC and NSCC have been demonstrated to mediate Ca
2+
 entry 
in human placental trophoblastic cells (Clarson et al.,2003; Niger et al.,2004). The 
current study did not investigate the connection between peptide hormone-evoked 
Ca
2+
 current and membrane Ca
2+
 entry pathways in trophoblast. To identify whether 
extracellular Ca
2+
 entry is involved in the rise of [Ca
2+
]i in response to  AGII or ET1 
stimulation of BeWo cells, the Ca
2+
 chelator ethylene glycol tetraacetic acid (EGTA) 
may be applied to remove extracellular Ca
2+
. Further investigation may also use of 
specific blockers/inhibitors of SOCC and NSCC. 
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AVP-evoked Ca
2+
 elevations displayed distinct profiles from those of AGII 
or ET1 in BeWo cells. Instead of a slow prolonged [Ca
2+
]i increase, a transient 
[Ca
2+
]i rise occurred upon AVP stimulation, as indicated by a transient increase in 
fura-2 signal before a return to resting levels (Figure 4.6.2.). Among AVP receptors, 
both V1a and V1b are GPCRs couple to Gαq, whereas V2 is a Gαs-coupled GPCR. In 
the current study, transient [Ca
2+
]i elevation in response to AVP stimulation were 
observed in trophoblast-like cells, the BeWo cells. The absence of response in the 
presence of V1a blocker (SR49059) suggests that the V1a receptor mediates 
subsequent signalling. The co-application of AVP in the presence of the RyR 
antagonist (tetracaine or 100 µM ryanodine) abolished the fura-2 ratio. This 
observation implicates the involvement of RyR-mediated Ca
2+
 mobilisation in AVP-
stimulated signaling events; this finding is also consistent with the study by Chou 
and colleagues. The authors reported that RyR-mediated Ca
2+
 cellular mobilization 
(together with CaM) is crucial for AVP-induced aquaporin 2 (AQP2)-contained 
vesicles trafficking in primary cultures of inner medullary collecting duct cells, as 
ryanodine at 100 µM concentration blocked the process (Chou et al.,2000). These 
authors have also demonstrated that neither IP3R-mediated Ca
2+
 release nor 
extracellular Ca
2+
 are involved in the process of AVP-stimulated Ca
2+
 mobilization 
pathway in the renal collecting duct (Chou et al.,1998; Chou et al.,2000).  
Although there are no detailed studies reporting the expression of AVP 
receptors in the human placenta, mRNAs encoding both V1a and V2 were detected 
in the developing ewe placenta (Koukoulas et al.,2003). In addition, an in vitro study 
demonstrated that expression of AQP1 gene in JEG-3 cells is up-regulated by AVP 
in a cAMP-dependent pathway, suggested that AVP regulated AQP1 expression is 
mediated by the activation of Gαs-coupled GPCR (ie. via V2 receptor) in JEG-3 
trophoblast-like cells (Belkacemi et al.,2008). Such a cAMP-dependent AQP 
expression pathway has also been demonstrated in the apical membrane of human 
SCT explants, where hCG enhances the expression and function of AQP9 via the 
cAMP pathways (Marino et al.,2010). These studies suggest that the cAMP-mediated 
cascades in trophoblast can be triggered by various stimulating agents via Gαs-
mediated GPCR. Such Gαs-mediated GPCR processes lead to AC activation and 
cAMP elevation. Both PKA and EPAC are cAMP effector proteins that 
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independently conduct cAMP-sensitive downstream signaling cascades. In inner 
medullary collecting duct cells, the process of AQP2 exocytosis is EPAC-mediated, 
inducing Ca
2+
 mobilisation via RyR activation (Yip,2006). In cardiac myocytes, the 
EPAC-PLCξ-PKCξ-CaMKII cascade has been established as a cellular Ca
2+
 handling 
pathway that enhances RyR2 opening (Oestreich et al.,2007). This Gαs-initiated 
EPAC-mediated signaling cascade has been demonstrated to result in 
phosphorylation of PLN, which subsequently relieves the inhibitory effect on 
SERCA, ie. enhances Ca
2+
 reuptake (Oestreich et al.,2007).  
In the current study, there was no change in fura-2 ratio observed upon 
addition of AGII, ET1 or AVP in JEG-3 cells. These observation may reflect a 
dynamic balance of [Ca
2+
]i in JEG-3 cells upon activation of different GPCRs. In 
other words, the signals lead to [Ca
2+
]i increase via activations of Gαq-PLC-PKC and 
Gαs-cAMP-PKA pathways, might be compensated by signals that lead to [Ca
2+
]i 
decrease via suppression of cAMP production. Particularly, as reviewed by Tanfin et 
al. (Tanfin et al.,2011), the activation of Gαi/o-coupled ETAR leads to the inhibition 
of cAMP production. During the stimulation of ET1 in JEG-3 cells, the possible 
activation of Gαi/o-coupled to ET1-ETA/BR results in decrease of cAMP production 
that directly affects PKA-mediated signaling pathways acting on phosphorylation of 
RyR, CaMKII and LTCC. The signaling events initiated by AVP possibly involve 
activation of Gαs-coupled GPCR, and the subsequent activation may involve 
phosphorylation of RyR, PLN and LTCC. All these downstream signaling pathways 
exert complex effects on global [Ca
2+
]i, hence, changes in fura-2 ratio. On the other 
hand, the intracellular buffering effect of fura-2 may also result in no detection of 
change in ratio. As fura-2 is a high-affinity Ca
2+
 indicator (Kd ≈ 224 nM), small 
changes in [Ca
2+
] in dye-loaded cells may be buffered (Hofer & Machen,1994). 
Moreover, other studies indicate that Ca
2+
-buffering capacity of fura-2 at commonly 
used concentrations is 10-20% of the intrinsic buffering power of the cytosol in 
smooth muscle cells (Becker et al.,1988). Therefore, if the change in [Ca
2+
]i is too 
small, too local and/or too transient in JEG-3 cells upon stimulation by endogenous 
peptides (AGII, AVP and ET1), Ca
2+
 indicator with lower affinity may be use in 
such conditions. 
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5.4 Other Possible Mechanism of RyR-mediated Ca
2+
 Mobilisation 
 
The endogenous production of NO is involved in multiple functional 
regulation in the placenta, including vascular tone maintainance (Poston,1997; 
Lopez-Jaramillo et al.,2008), EVT invasion (Lyall et al.,1999); hormonal release (Ni 
et al.,1997; Rossmanith et al.,1999); and placental glucose uptake (Acevedo et 
al.,2005). Therefore, dysregulated NO-related signals are thought to be associated 
with pathlogical conditions in pregnancy, such as PE (Gilbert et al.,2008). NO-
induced signals have been shown to couple to Ca
2+
 mobilisation, as stated in 
Introduction Section 1.9. Briefly, as summarised in Figure 1.9: NO initiates GC 
activation and cGMP production which activates PKG that in turn triggers the 
synthesis of two Ca
2+
 mobilising molecules NAADP and cADPR. Both NAADP and 
cADPR are potent Ca
2+
 mobilising inducers, and their subsequent actions can also 
indirectly result in RyR-mediated Ca
2+
 release from the ER (Figure 5.4, cream zone). 
Therefore, the potential contribution of both NAADP and cADPR to the modulation 
of global Ca
2+
 dynamics cannot be ignored. Particularly, synthesis of cADPR is 
favoured at physiological pH (Lee,1997).  
The ADPR cyclase homolog CD38 is present on the surface of many human 
cells, including decidual granulated lymphocytes (Bulmer et al.,1988; Fernàndez et 
al.,1998). CD38 is a multi-functional enzyme that not only catalyses the production 
of cADPR but also serves as a permeating channel for cADPR, as reviewed by Lee 
(Lee,2000a). Therefore, cADPR could be available in placental trophoblast by either 
or both endogenous synthesis and transport via cADPR channels. In BeWo CT-like 
cells, self-production of NO has been described (Sooranna & Das,1995); inhibited 
Ca
2+
/CaM-dependent NOS activity has been reported in the presence of L-arginine 
analog in these cells (Myat-Thanda et al.,1996). Collectively, these observations 
suggest NO-induced/cADPR-activated signals contribute to global Ca
2+
 mobilisation 
in BeWo cells. 
Although the activation of the NO-induced cGMP-mediated pathway is 
independent to the GPCR-coupled pathways, such as the Gαq-PLC-PKC and Gαs-
cAMP-PKA pathways mentioned in previous section; downstream signalling 
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regulation can be modified by cross-pathway interactions (Figure 5.4). For example, 
prostaglandin E2-induced angiogenesis involves activation of NO-cGMP pathway 
through PKA/PI3K/Akt (PKB)-dependent increase in eNOS activity (Namkoong et 
al.,2005; Hashimoto et al.,2006); in human umbilical vein endothelial cells, 
independent of the PI3K-Akt pathway, activation of 5’-AMP-activated protein kinase 
(AMPK) results in eNOS phosphorylation, hence activation of NO-cGMP pathway 
(Thors et al.,2004); these studies suggest that PKA signalling converges on the 
activation of eNOS and NO-induced cascade through the activation of other 
pathways (eg. Akt and AMPK), as reviewed by Bir et al. (Bir et al.,2012) (Figure 5.4, 
pink zone). It has been demonstrated that both PLC-β2 and PLC-β3 are directly 
phophorylated by PKG in vitro by purified proteins and in vivo with metabolic 
labelling; the phosphorylation of PLC by PKG therefore, blocks the activation of 
Gαq-PLC-PKC pathway and results in inhibition of IP3-dependent Ca
2+
 release (Xia 
et al.,2001). Although the cGMP-mediated pathway is in parallel to the cAMP-
mediated pathway, the activation of either could trigger the ERK1/2 cascade (Figure 
5.4, cream zone and blue zone, respectively). NO-induced cGMP-mediated signalling 
has been shown to stimulate the phosphorylation of ERK1/2 that results in cell 
migration in rat mammary tumours C3L5 cells and in human lung carcinoma A549 
cells (Jadeski et al.,2003; Punathil & Katiyar,2009). Moreover, communication 
between downstream mediators that correspond to cAMP- or cGMP- mediated 
pathways has also been demonstrated. In cardiomyocytes, phosphodiesterases (PDEs) 
modulate crosstalk and feedback signalling through cAMP, cGMP and their 
associated protein kinases PKA and PKG, resepectively; these signalling mediators 
modify calcium transient and cardiac contractility by subsequent modulation of their 
downstream regulators including VGCC, RyR, SERCA and PLN, as reviewed by 
Rao and Xi (Rao & Xi,2009). Therefore, the experimental measurement of change in 
[Ca
2+
]i reflect the end result of global Ca
2+
 mobilisation via independently activated 
but converging pathways.   
 In the current study, although there was no direct demonstration of activation 
of AVP-stimulated Gαs-coupled pathway, changes in fura-2 ratio observed could 
result from the complexity of signalling crosstalk. A transient increase followed by 
the recovery to near initial fura-2 ratio was observed in during AVP stimulation. This 
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observation was different from that in AGII or ET1 stimulation in BeWo cells where 
no recovery of signal was observed. The initial rise of ratio may be due to the 
activation of Gαs-cAMP-PKA pathway leading to the activation of RyR channel and 
release of ER Ca
2+
; the drop of ratio may be due to the Ca
2+
 reuptake via subsequent 
PLN phosphoryaltion and SERCA activation (Figure 5.4, pink zone). Since BeWo 
cells are capable of NO production by eNOS (Kiss et al.,1998; Cha et al.,2001), 
signals converging on the activation of eNOS is possible in these cells (Figure 5.4 
cream zone). The activation of PKG-mediated pathway results in subsequent 
inhibition of PLC-PKC pathway may also contribute to current observation (Figure 
5.4 blue zone). Collectively, upon AVP stimulation in BeWo cells, activation of 
GPCRs could initially split into two pathways: 1) stimulation of V1a/b results 
activation of Gαq-PLC-PKC pathway, in which, PLC results IP3R-mediated Ca
2+
 
release and possibly CICR via RyR; while PKC phosphorylates CaMKII resulting in 
RyR-mediated Ca
2+
 release; 2) PKC may also activate EPAC, results in PLN 
phosphorylation and Ca
2+
 reuptake via SERCA; while PKA activates CaMKII and 
promotes RyR-mediated Ca
2+
 release; it also activates eNOS and promotes NO-
induced pathway via activation of PKG. The PKG-mediated pathway involves 
activation of cADPR-induced Ca
2+
 release via RyR and inhibition of PLC-PKC 
pathway that result in inhibitory IP3R-mediated Ca
2+
 release. Therefore, further 
suppression of fura-2 ratio in AVP-treated dantrolene-preincubated BeWo cells 
suggesting that Ca
2+
 reuptake was promoted upon stimulation of GPCRs in these 
cells with RyRs blocked by dantrolene. The mechanism of enhancement of Ca
2+
 
reuptake probably involves activation of the Gαs-cAMP-PKA-EPAC-PKC-PLN 
pathway, while inhibitory mechanisn of Ca
2+
 release probably involves NO-induced 
PKG-meidated inhibition on PLC-PKC pathway, via PKA stimulated eNOS 
activation. Taken together, the observation of change in fura-2 ratio in BeWo cells 
upon AVP stimulation implicate a potential role of RyR in participation of gene 
expression and water homeostasis in trophoblast during gestation in response to AVP 
(Belkacemi et al.,2008).    
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Figure 5.4. Putative mechanisms triggering RyR-mediated Ca
2+
 mobilisation in 
trophoblasts.  
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Figure 5.4. Possible Ca
2+
 mobilisation initiated by activation of GPCRs. Stimulation of 
Gαs-coupled receptors, such as βAR and V2, leads to the activation of AC. The subsequent elevation 
of cAMP results in various cellular events via different signalling pathways (left, pink zone): 1) 
Augmentation of cAMP causes PKA phosphorylation; activated PKA leads to phosphorylation of 
RyRs and ER Ca
2+
 release; PKA can also converge on the activation of eNOS, as reviewed by Bir et 
al. (Bir et al.,2012); 2) Independent of PKA activation, cAMP also activates EPAC, mediates CICR 
from RyR via activation of PKC and CaMKII; another downstream effector of EPAC is PLN; 
phosphorylated PLN promotes SERCA activation and Ca
2+
 re-uptake. The nitric oxide (NO)-induced 
signalling pathways (middle, cream zone), catalysed by nitric oxide synthase (NOS) which is 
acitivated through the PKA pathway; NO activates soluble guanylate cyclase (GC) and produces 
intracellular cyclic guanosine monophosphate (cGMP) (Murad,1994). Elevated cGMP activates 
cGMP-dependent kinase (PKG); 1) PKG phosphorylates ADP-ribosyl cyclase (ADPR cyclase); 
activated ADPR cyclase in turn produces cyclic ADP-ribose (cADPR) and/or nicotinic acid adenine 
dinucleotide phosphate (NAADP) (Lee et al.,1989). NAADP targets on lysosmal two-pore channel 
(TPC) to release Ca
2+
, which subsequently results in CICR possibly via endoplasmic RyR and/or IP3R 
(Lee,1997). cADPR targets on the ER Ca
2+
 release channel RyR; 2) PKG also could trigger ERK1/2 
cascade, and 3) mediate inhibition of PLC-PKC pathway. Signalling pathways initiated by activation 
of Gαq-coupled receptors, such as αAR, AT1R, ETAR and V1, are mediated through PLC activation 
(right, blue zone): the activation of PLC leads to the production of DAG and IP3. 1) IP3 activates IP3R 
channel and mediates Ca
2+
 mobilisation; Ca
2+
 can stimulate RyR channel directly through the CICR 
mechanism; 2) DAG activates PKC, leading to CaMKII activation, which subsequently 
phosphorylates RyR in the presence of Ca
2+
; PKC also triggers ERK1/2 signalling cascade; the 
activation of both CaMKII and ERK1/2 leads to gene transcription.  
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Chapter VI.  Conclusion 
 
In summary, the major findings in present study are 1) BeWo and JEG-3 
trophoblastic cells express functional RyRs that respond to several pharmacological 
agents; 2) in BeWo cells, the activation of RyRs was demonstrated to contribute to the 
rise of [Ca
2+
]i induced by endogenously occuring peptides AGII, AVP and ET1; 
mechanisms contributing to the increase of [Ca
2+
]i possibly involve GPCR-activated 
and NO-induced signaling cascades 3) both BeWo and JEG-3 cells express the RyR 
accessory proteins: CSQ and TRD; 4) human first trimester and term placental villi 
express RyR1 and RyR3, while RyR2 might be transiently expressed and highly 
associated with trophoblast differentiation; 5) human first trimester and term placental 
villous tissues were demonstrated to express TRD by IHC, while CSQ was detected in 
human term placental villi samples by western blotting.  
Taken together, observations from the current study suggest that RyR are 
actively involved in human trophoblast Ca
2+
 mobilisation. Extracellular stimulating 
agents such as hCG, AGII, AVP, and ET1 are possible endogenous triggers of such 
RyR-mediated trophoblastic Ca
2+
 mobilisation.This is the first study provides direct 
evidence of RyR expression at both mRNA and protein levels in human trophoblast-
like cells. The experimental results have shown that RyRs are capable of Ca
2+
 release 
upon direct pharmacological stimulation of the channel. The preliminary results also 
demonstrated RyR-mediated Ca
2+
 releasing in response to indirect stimulation via 
GPCR activation. However, the exact mechanism of interaction between RyR and 
GPCR is unknown; also, the possible participation of NO-induced cADPR-stimulated 
Ca
2+
 release via RyR has not been examined. Further investigation is required for the 
identification of downstream signaling mediators. For instance, cAMP-dependent 
Gαs-mediated pathway splits into two sub-pathways: the PKA- and EPAC- dependent 
pathways; and the activation of PKA may also induce PKG-mediated cADPR-induced 
Ca
2+
 mobilisation and PKG-induced inhibition of PLC-PKC pathway. Therefore, 
specific inhibitors of PKA, EPAC, PKG and cADPR analogs may be induced to 
identify the exact cascade leads to RyR-sensitive Ca
2+
 releasing. In the current study, 
it has been demonstrated that LTCC is not involved in such process in BeWo cells; 
studies in cultured primary human trophoblastic cells also indicate that LTCC do not 
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participate in ET1-induced Ca
2+
 entry (Niger et al.,2004). As both voltage-
independent Ca
2+
 channels such as SOCC and NSCC have been demonstrated to 
mediate Ca
2+
 entry in human placental trophoblastic cells (Clarson et al.,2003; Niger 
et al.,2004), the possible involvement of SOCC and NSCC in connection with GPCR-
induced RyR-mediated Ca
2+
 release may be a worthy subject for further investigation 
to complete the Ca
2+
 trans-trophoblastic mobilisation theory. Furthermore, the 
mechanism of Ca
2+
 extrusion at the basal membrane in contact with fetal circulation 
has not been fully established. Although the involvement of PMCA and NCX has 
been proposed, and PMCA has been demonstrated to play a major role (Moreau et 
al.,2003a; Moreau et al.,2003b), the exact mechanism of how PMCA cooperate with 
Ca
2+
 binding proteins is unknown. In addition to the RyR-mediated Ca
2+
 mobilisation 
pathway as proposed in previous paragraph, evidence of co-localisation of RyRs and 
PMCA are essential to fulfill the proposal.  
The predominant Ca
2+
 trans-trophoblastic transport theory is in favour of the 
Ca
2+
 binding and shuttling pathway, due to the high expression levels of different 
Ca
2+
 binding proteins in human trophoblast (Belkacemi et al.,2002), as reviewed by 
Belkacemi and colleagues (Belkacemi et al.,2005). The current study provided 
evidence of the possible involvement of RyR in an alternative pathway, ie. the RyR-
mediated Ca
2+
 transport pathway, in additional to the ‘binding and shuttling’ pathway 
for Ca
2+
 trans-trophoblastic transport. The current study is still at preliminary stage of 
this proposal. However, the demonstration of RyR involvement in trophoblastic cell 
Ca
2+
 mobilisation suggests these calcium channels participate in maternal-fetal Ca
2+
 
transport. Examination of RyRs and/or RyR accessory proteins in primary trophoblast 
cells may provide better understanding on IUGR, and/or other pregnancy-related 
diseases such as maternal diabetes that linked to fetal hypocalcaemia (Strid et 
al.,2003). The Ca
2+
 release channel RyR is regulated and targeted by multiple 
molecules. Therefore, RyR could be a multiple participant in the regulation of 
trophoblastic cell function. As discussed in previous section, RyR may be involved in 
trophoblastic invasion, hormonal secretion, gene expression and growth promotion. 
Such outcomes of RyR activation should also be considered in future studies and 
experimental design.    
In conclusion, the current study demonstrated that functional RyRs are 
expressed in human trophoblast, and these Ca
2+
 release channels are sensitive to RyR 
agonists and antagonists in both BeWo and JEG-3 cells; RyR-mediated Ca
2+
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mobilisation was also demonstrated in BeWo cells in response to endogenously 
occurring peptides (AGII, AVP and ET1), suggesting that RyRs contribute not only in 
trophoblastic cellular Ca
2+
 homeostasis, but also in cell function in connection with 
these hormonal induced events.  
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Appendix 0. IF Microscopy in JEG-3 Cells 
 
Appendix 0.. The IF microscopy in JEG-cells. Panel A, cells were stained with anti-RyR2 
antiserum (AB9080) as primary antibody; Panel B, cells were stained with anti-E-cadherin (ab1416) as 
primary antibody; Panel D and E, negative controls: no primary antibodies used; Panel C and F, merge 
images. Scale bar: 10 µm. 
C. Merge in DAPI 
A. RyR2/Cy2 
B. E-cadherin/Cy3 
D. -/Cy2 
E. -/Cy3 
F. Merge in DAPI 
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Appendix I. 
 
Sequences alignment of human skeletal RYR1 (NM_001042723) and PCR 
product obtained from BeWo cell RNA (query). The PCR product of RYR1 was 
amplified by using downstream primer (5′-dCAGATGAAGCATTTGGTCTCCAT-3′) 
pairs to the upstream primers JBR1 (5′-dGACATGGAAGGCTCAGCTGCT-3′). 
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Appendix II. 
 
Sequences alignment of human cardiac RYR2 (NM_001035.2) and PCR 
product obtained from BeWo cell RNA (query). The PCR product of RYR2 was 
amplified by using downstream primer (5′-dCAGATGAAGCATTTGGTCTCCAT-3′) 
pairs to the upstream primers JBR2 (5′-dAAGGAGCTCCCCACGAGAAGT-3′). 
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Appendix III. 
 
Sequences alignment of human skeletal RYR1 (NM_001042723) and PCR 
product obtained from JAR cell RNA (query). The PCR product of RYR1 was 
amplified by using downstream primer (5′-dCAGATGAAGCATTTGGTCTCCAT-3′) 
pairs to the upstream primers JBR1 (5′-dGACATGGAAGGCTCAGCTGCT-3′). 
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Appendix IV. 
 
Sequences alignment of human cardiac RYR2 (NM_001035.2) and PCR 
product obtained from JAR cell RNA (query). The PCR product of RYR2 was 
amplified by using downstream primer (5′-dCAGATGAAGCATTTGGTCTCCAT-3′) 
pairs to the upstream primers JBR2 (5′-dAAGGAGCTCCCCACGAGAAGT-3′). 
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Appendix V. 
 
Sequences alignment between RYR1 PCR products obtained from RNA extract 
of BeWo (query) and JAR cells. Both PCR products obtained from BeWo and JAR 
cells were amplified by using downstream primer (5′-
dCAGATGAAGCATTTGGTCTCCAT-3′) pairs to the upstream primers JBR1 (5′-
dGACATGGAAGGCTCAGCTGCT-3′). 
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Appendix VI. 
 
Sequences alignment between RYR2 PCR products obtained from RNA extract 
of BeWo (query) and JAR cells. Both PCR products obtained from BeWo and JAR 
cells were amplified by using downstream primer (5′-
dCAGATGAAGCATTTGGTCTCCAT-3′) pairs to the upstream primers JBR2 (5′-
dAAGGAGCTCCCCACGAGAAGT-3′). 
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Appendix VII. 
 
Sequences alignment of human skeletal RYR1 (NM_001042723) and PCR 
product obtained from RNA extract of human first trimester villi sample (E66) 
(query). The PCR product of RYR1 was amplified by using downstream primer (5′-
dCAGATGAAGCATTTGGTCTCCAT-3′) pairs to the upstream primers JBR1 (5′-
dGACATGGAAGGCTCAGCTGCT-3′). 
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Appendix VIII. 
 
Sequences alignment of human cardiac RYR2 (NM_001035.2) and PCR 
product obtained from RNA extract of human first trimester villi sample (E66) 
(query). The PCR product of RYR2 was amplified by using downstream primer (5′-
dCAGATGAAGCATTTGGTCTCCAT-3′) pairs to the upstream primers JBR2 (5′-
dAAGGAGCTCCCCACGAGAAGT-3′). 
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Appendix IX. 
 
Sequences alignment between RYR1 PCR products obtained from RNA extract 
of BeWo (query) and human first trimester villi sample (E66). Both PCR products 
obtained from BeWo and sample E66 were amplified by using downstream primer 
(5′-dCAGATGAAGCATTTGGTCTCCAT-3′) pairs to the upstream primers JBR1 
(5′-dGACATGGAAGGCTCAGCTGCT-3′). 
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Appendix X. 
 
Sequences alignment between RYR2 PCR products obtained from RNA extract 
of BeWo (query) and human first trimester villi sample (E66). Both PCR products 
obtained from BeWo and sample E66 were amplified by using downstream primer 
(5′-dCAGATGAAGCATTTGGTCTCCAT-3′) pairs to the upstream primers JBR2 
(5′-dAAGGAGCTCCCCACGAGAAGT-3′). 
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Appendix XI. 
 
Sequences alignment between primers and human RyR1, RyR2 and RyR3 
mRNA by Primer-BLAST The PCR product of RYR1, RYR2 and RYR3 was amplified 
by using the same forward primer (5′-dCAGATGAAGCATTTGGTCTCCAT-3′) 
pairs to the corresponding reverse primers: Panel I. JBR1 (5’- 
GACATGGAAGGCTCAGCTGCT-3’), Panel II. JBR2 (5'-
dAAGGAGCTCCCCACGAGAAGT-3') and Panel III. JBR3 (5′-
dGAGGAAGAAGCGATGGTGTT-3′). 
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